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ABSTRACT 
Background 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a cause of sudden cardiac 
death (SCD) in young people due to ventricular tachyarrhythmias. One autosomal 
dominant genetic subtype of ARVC in Newfoundland, linked to a founder haplotype at 
3p25 (ARVD5) provided a genetically homogenous population in which to define the 
epidemiology of ARVD5 and find the causative gene using a retrospective and 
prospective familial cohort. 
Methods 
The final sample comprised 496 well ascertained subjects from 15 families (270 men, 
226 women) born at an a priori 50% risk of ARVD5. Subjects were 'affected ' if they i) 
had the founder haplotype OR the causative mutation, ii) were an obligate carrier, iii) had 
SCD or cardioversion for ventricular arrhythmia under age 50 years. 'Unaffected ' 
subjects' did not have the founder haplotype/ mutation and formed a comparison group. 
Genetic information was used to determine ARVD5 penetrance. Incident and prevalent 
clinical events, symptoms, hospitalization and death were compared between affected and 
unaffected subjects. Affected subjects with an implantable cardioverter defibrillator 
(lCD) were matched to affected controls to assess treatment efficacy. 
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Results 
The causative gene for ARVD5 was TMEM43 , a transmembrane protein of unknown 
function. ARVD5 was 100% penetrant for signs and symptoms over the lifespan. Novel 
clinical findings were poor R wave progression, and dilated cardiomyopathy. All 
abnormal test results occurred significantly earlier in affected men and women compared 
with their unaffected same-sex relatives. Survival was decreased in affected subjects 
where 50% of men and 5% of women were dead by age 40 years: a relative risk of death 
between affected men and women of 5.1 (95% CI 3-8.5). The time course of disease was 
prolonged in affected women by 1-2 decades, who were four times less likely to be 
hospitalized than affected men. Heart failure eventually occurred in those who did not 
experience SCD. Holter monitoring for ectopy was diagnostically useful (likelihood ratio 
> I 0). In men, the five year mortality rate post lCD was zero compared with 28% in the 
comparison group (p=0.009). The issues of overlap between genetic research and clinical 
genetics, privacy and duty to warn are addressed. 
Conclusions 
ARVD5 is caused by a 100% penetrant novel gene for ARVC. It is lethal in men, who are 
significantly more affected at all stages of the disease than women. lCD provides 
effective treatment. Clinical genetic and research practice should not be differentiated for 
severe conditions. 
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PROLOGUE 
"I am the family face; 
Flesh perishes, I live on, 
Projecting trait and trace 
Through time to times anon, 
And leaping from place to place 
Over oblivion 
The years-heiredfeature that can 
In curve and voice and eye 
Despise the human span 
Of durance- that is I; 
The eternal thing in man, 
That heeds no call to die. " 
Heredity 
Thomas Hardy 
This poem captures the juxtaposition of history and biology, where inherited traits link 
individuals across time. This is an awesome concept: that genes, which make each 
individual unique, are conserved across generations: that a single gene which gives ones 
family a 'distinctive nose ' has been inherited by individuals lost in the centuries prior to 
one's birth, and will do so by unknown descendants. This biological link is true 
immortality for genes: an immortality that sometimes comes at the expense of human 
mortality. This truth is the impetus behind the story ofthis piece ofwork: the story of one 
gene, passed across multiple generations on the island of Newfoundland in Canada, "the 
family face ... that heeds no call to die". This gene has caused the deaths of many young 
men, some named and remembered, some forgotten; the gravestones of whom can be 
found in isolated communities across this temperamental island. This is the burden that 
has been faced by Newfoundland families with this "eternal" gene. These people and 
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their stoicism in the face of tragedy have provided the material that allowed this thesis to 
be written. 
This piece of work tells a story in which my role began in 1996. Several families had 
arrhythmogenic right ventricular cardiomyopathy, with striking histories of sudden death 
in young individuals. The following five years were spent meeting with these fan1ilies, 
extending their genealogy, listening to their stories and collecting all available data on 
both alive and deceased family members with and without disease. In 2002, I embarked 
on a Ph.D. and with the collection of more data I began the journey to determine the 
clinical and genetic epidemiology of this lethal disorder. All work of this nature requires 
the concerted effort of a team of people: this was a journey therefore taken alongside my 
clinical and academic colleagues and teachers. 
This piece of work was far more than just a thesis. Genetic research of this type becomes 
almost a crusade, revealing as it does the inequalities inherent in a health care system 
struggling to provide care in rural de-populated areas, and defines a desire to help 
individuals reluctant sometimes to face the inevitability of inheritance. Health care can be 
proactive, and preventative, but only if the full spectrum of a disease is known. 
Comparing those with disease (including those who are asymptomatic and those who die 
before seeing a health worker), and those without disease, (including those who may look 
as if they have the disease but in actuality do not), one can determine disease related 
features; how to diagnose appropriately, and how to treat. This should be the aim of this 
type of health research: to effect change in the lives of the people affected with and at 
risk of disease, by the acquisition of knowledge. 
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"No man is an Island, entire of itself; every man is a piece of the Continent, a part of the 
main,· if a clod be washed away by the sea, Europe is the less, as well as if a promontory 
were, as well as if a manor of thy friends or of thine own were; any man's death 
diminishes me, because I am involved in Mankind; And therefore never send to know for 
whom the bell tolls; It tolls for thee. " 
John Donne 
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1 INTRODUCTION 
"You see only what you look for; you recognize only what you know " (l) 
M.C. Sosman 
"We sometimes forget that diseases have no intrinsic being; that their names represent 
only convenient rubrics, classes that have logistic uses but no precise conceptual content 
particularly as to cause " (2) 
Childs and Motulsky 
1.1.1 Thesis history and organization 
This research project, and by definition this thesis, has a long history. It may be helpful to 
understand this history, and my role in the process. The introduction therefore starts with 
an explanation of how and why events unfolded as they did, and provides a temporal 
sequence. One can, however, begin reading from the literature review page 25 section 1.2 
and skip this 'introduction to the introduction' if desired. 
This is a body of work that focused on an eventual sample of 15 Newfoundland and 
Labrador families with arrhythmogenic right ventricular cardiomyopathy (ARVC) linked 
to a genetic locus at 3p25 (ARVD5). The sample comprised a familial cohort defined in a 
retrospective and prospective manner. Subjects were defined as those born at an a priori 
50% risk of inheriting the ARVD5 gene, alive or dead. This included all affected subjects 
(as they, by default, had to be born at an a priori 50% risk) and all those born to affected 
subjects. Data from all generations in the family pedigree were included (in some cases 
up to nine generations). Current generations were enrolled into the study and followed 
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clinically in a prospective manner resulting in a final sample size of 496 subjects (270 
males, 226 females). 
This is a cohort (from the Latin word for one of the 10 divisions of an ancient Roman 
legion) study: the non-experimental observational analytical analogue of the randomised 
control trial (RCT). A classic cohort study assigns two groups free of disease who differ 
according to an exposure and followed over time for an outcome (usually disease). A 
historical cohort study accesses past records to classify individuals and then follows the 
cohort forward through time, a longitudinal study from past to present rather than present 
to future. This study uses both approaches. A retrospective and prospective analysis of a 
cohort, divided by their 'exposure' (gene mutation positive or gene mutation negative), 
assessed for signs and symptoms of disease. 
In 1996 I became a Memorial University research associate funded by the Canadian 
Genetic Diseases Network. I recruited families with sudden cardiac death (SCD) and 
cardiomyopathy (CM) starting with those originally ascertained through the 
Newfoundland and Labrador Medical Genetics Program. Extended pedigrees were drawn 
and computerized, a unique identifier for all subjects was created, all current and past 
cardiac medical records were obtained and genetic counselling was provided for all 
subjects. This included summary letters to participants, general practitioners and other 
health care providers. 
One large family (Figure 8 page 79) was shown to have ARVC in the 1980' s (3) and 
family members were recruited to a research study based out of Baylor University, Texas 
in the early 1990' s. In 1998, linkage to the short arm of chromosome three (3p23: 
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ARVD5) was published by these researchers (4). Concurrently, Dr. Ludwig Thierfelder, a 
German cardiologist and molecular geneticist, requested collaboration with 
Newfoundland and Labrador aimed at finding the underlying ARVD5 gene. Thus, in 
1998, a Canadian/European research group was convened which included Dr. William 
McKenna, a senior cardiologist from London, England. Subjects were assessed and 
consented to the research project. In the absence of a formal clinic, their cardiology 
follow up was handled by the research team, which now included Dr. Sean Connors, an 
electrophysiological cardiologist. With Dr. Connors' recruitment, Newfoundland and 
Labrador could provide implantable cardioverter defibrillator (lCD) treatment. Prior to 
this, patients were referred to mainland Canada. 
Five additional unrelated ARVC families were ascertained, and linked by Dr. 
Thierfelder' s group to ARVD5 (4). At this time, the locus was repositioned by Dr. 
Thierfelders group to 3p25. All affected subjects in all six families were shown to have 
an identical DNA haplotype on 3p25 (a series of concurrent DNA markers inherited as a 
linear block across generations). This indicated that they all shared the same mutation-
carrying ancestor (founder). Thus presymptomatic diagnosis of ARVD5 in at-risk 
relatives in these six families could occur: if the haplotype associated with disease was 
present, it was likely that the ARVC gene mutation was also present. This was imp01tant 
for a clinically difficult to diagnose condition. I coordinated the research and clinical 
work relating to this endeavour, and discussed all research results with participating 
subjects. 
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In 2002 my part-time PhD formally began. Its remit was to determine the genetic 
epidemiology of ARVDS in Newfoundland and Labrador, the natural history, phenotype 
and efficacy of treatment. A secondary outcome was to find the causative gene. Initially 
the six already ascertained families were used. Abstraction forms were designed for aJl 
genetic and cardiac data. This data was input to a statistical package for social sciences 
(SPSS, Versions 11 and 15) dataset comprising over 1000 variables (Appendix A page 
255). This dataset was the basis for all statistical analyses. Informed consent in 
compliance with the requirements of Memorial University and Eastern Health was 
obtained from all subjects or appropriate surrogates. This included permission for access 
to medical records and for a blood sample for DNA extraction. Progress repmis were 
compiled, and a research website was created (http://www.med.mun.ca/arvc/). 
Information was provided for at- risk families living in other parts of Canada and the 
USA, including the referral of family members to local genetic and cardiology 
practitioners. An information sheet about ARVDS was produced for the use of health care 
professionals, and one for the use of patients. 
Information from this project provided the data central to the creation of a genetics-
cardiomyopathy clinic within Eastern Health. This clinic began in February 2004 and 
took direct referrals of patients with familial cardiomyopathies and arrhythmias. The 
main clinical diagnoses referred to the clinic were ARVC, SCD not otherwise specified 
(NOS), dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), 
Cardiomyopathy NOS, arrhythmias NOS and Long QT syndrome (LQTS). In September 
2004, the Canadian Institutes for Health Research (CIHR) funded a larger 
epidemiological study to define the molecular genetic etiology and epidemiology of 
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inherited cardiomyopathy in Newfoundland and Labrador. All family members referred 
to the genetics-cardiomyopathy clinic were asked if they wished to participate in this 
study. In this manner, nine subsequent families with ARVD5 were found. Thus the 15 
families which form the final sample for this thesis are a subset of an extensive 
epidemiological sample of cardiomyopathy families in Newfoundland and Labrador. 
In 2004, a new molecular genetic collaborator joined the ARVC team. Dr. Terry-Lynn 
Young returned to Newfoundland and Labrador after her post doctoral training in Seattle. 
With CIHR funding Dr. Young's molecular genetics laboratory recapitulated Dr. 
Thierfelder' s linkage analysis and worked towards finding the causative gene. In 2006, 
Dr. Young headed the Atlantic Medical Genetics and Genomics Initiative; (AMGGI) 
receiving a nine million dollar award from Genome Canada via Genome Atlantic. The 
primary aim of AMGGI was to find novel genes within the Atlantic Provinces: the 
ARVD5 study formed a major part of this initiative. 
This thesis details the genetic epidemiology of ARVD5 in Newfoundland Labrador and is 
organised in manuscript format. The manuscripts form a cohesive body of work produced 
since 2002. The number of families and the number of subjects vary across chapters as 
the ascertainment of new families (and family members within already ascertained 
families) continued throughout the study period (Table 1 page 24). 
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Table 1: Number of subjects and families represented in each chapter 
Chapter Number of Affected subjects (N) Unaffected subjects (N) 
families with 
ARVDS 
Male Female Male Female 
2 15 148 109 77 74 
3 15 148 109 77 77 
4 11 123 74 46 46 
I describe the discovery of the causative gene, provide a description of the natural history, 
the phenotype, the efficacy of treatment, methods of managing ARVD5 and several 
ethical issues. Appendix B details the academic and lay sequelae to this project. The 
chapters are presented in a pathophysiologically logical manner, not in the order in which 
they were written. Thus Chapter 2 defines the finding of the ARVD5 causative gene and 
mutation and its penetrance. Chapter 3 describes the phenotype and natural history. 
Chapter 4 analyses the efficacy of ICD treatment. The authorship of chapters 2-4 
represent the clinical and laboratory personnel involved in the multidisciplinary nature of 
the extended research project, including my supervisors. My position as first author 
represents the lead role in writing the manuscripts, designing each clinical 
epidemiological sub-study, and ascertaining and analyzing the clinical epidemiology 
data. Ethical issues that arose from my work in chapters 2-4 culminated in research 
collaboration with Daryl Pullman, a bioethicist. All ethics related issues are contained in 
chapters 5-6. The discussion (chapter 7) provides broad conclusions and suggests future 
research directions. 
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1.2 LITERATURE REVIEW 
ARVC is a cause of SCD in young people, due to ventricular tachyarrhythmias, caused 
by fat and fibrous tissue within the myocardium. ARVC is genetically heterogeneous, 
with many different genes, mutations and loci implicated in causation. One autosomal 
dominant (a 50% risk to first degree relatives of inheriting the mutated gene) form of 
ARVC is prevalent in Newfoundland and Labrador (ARVD5). This genetic subtype is the 
focus of this thesis. This introduction serves as a literature survey of ARVC in general 
and is organized in parallel structure to the order of the thesis chapters. 
A short history of ARVC 
It is likely that ARVC has been present throughout human history, but death at young 
ages in previous eras would be common and less noteworthy. ARVC may share a history 
with adipositas cordis (5) a myocardial condition characterized by fatty infiltration of the 
myocardium. Whether this was the disease to which Dr. Lydgate referred in George 
Eliot' s Middlemarch ( 1872) ( 6, 7) when he said: " ... you are suffering from what is called 
fatty degeneration of the heart ... it is my duty to tell you that death from this disease is 
often sudden .. . " or whether it was ARVC is unclear. However, 191h century pathology 
text books clearly describe adipositas cordis, considered within the differential diagnosis 
for ARVC (8), and thus may be mistaken for ARVC. Conversely, the fictional Dr. 
Lydgate may have been talking about deposition of cholesterol in coronary arteries. For 
the purposes of this thesis, I would like to think that it was ARVC. 
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Convention credits the recognition of ARVC as an arrhythmic disorder to a French team 
(9) . Earlier case reports do exist describing probable ARVC (1 0), including one of four 
patients, three with SCD, all with patchy fatty infiltration of the right ventricle (RV), and 
T wave inversion on ECG (11). However, Frank Marcus is credited as being the first to 
systematically describe the disease in 1982 (12). ARVC has undergone several name 
changes. It was initially known as a pre-excitation syndrome (9), it then became a 
dysplastic (where cells, tissues or organs abnormally develop or grow) disorder (13), it 
expanded to include an arrhythmic portion to become arrythmogenic right ventricular 
dysplasia (ARVD) (14), and is currently considered to be a cardiomyopathy (ARVC) 
(15). 
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1.3 THE GENETICS OF ARVC 
Table 2 Known loci and genes for ARVC 
Locus Gene Protein Chromosomal MOl Disease(s) location * 
ARVDl TGFJB Transforming 14q23-q24 AD ARVC 
growth factor 
133 
ARVD2 RYR2 Ryanodine lq41.2-q43 AD 1) ARVC 
receptor-2 2) Catecholiminergic 
polymorphic VT 
ARVD3 ? ? 14q12-q22 AD ARVC 
ARVD4 ? ? 2q32.1-q32.3 AD ARVC 
ARVDS See See thesis 3p25 AD ARVC + left ventricular 
thesis involvement (LVI) 
ARVD6 ? ? 10p14-p12 AD ARVC 
ARVD7 ? ? 10q22.3 AD ARVC 
ARVD8 DSP Desmoplak:in 6p24 AD 1) ARVC 
2) DCM with woolly hair 
syndrome. 
3) Epidermolysis bullosa 
(lethal acantholytic) 
ARVD9 PKP2 Plak:ophylin2 12pll AD ARVC 
ARVDlO DSG2 Desmoglein2 18q12.1-1 2.2 ?AD ARVC+LVI 
ARVDll DSC2 Desmocollin 18q12.1 ?AD ARVC + LVI 
ARVD12 PKGB Plak:oglobin 17q21 AD ARVC 
NAXOS PKGB Plak:oglobin 17q21 AR ARVC with woolly hair 
and keratoderma 
* MOl: Mode of Inheritance, AD: autosomal dominant, AR: autosomal recessive 
Early reports supported the case that ARVC was usually inherited as an autosomal 
dominant disorder, before the search for the underlying genes began in the early 1990's 
(16-23). Familial cases were present in the 1982 systematic description by Marcus (12) 
and many have suggested that about 30% of ARVC cases are fami lial (24, 25). As the 
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definition of ' familial' requires a comprehensive assessment of extended family trees to 
define variability of expression, it is likely to be an underestimate, as such family 
histories are rarely documented (12). A more realistic estimate may be that >90% is 
familial (26). Despite the preponderance of dominant families, the first gene to be cloned 
was, somewhat surprisingly, a recessive syndromic form of the disease, found at high 
prevalence on the Greek island ofNaxos. 
1.3.1 Autosomal recessive ARVC 
N axos Disease 
Naxos disease, described clinically in 1986 (27) presents at birth with 'woolly hair' 
(described as being like 'steel wire' ), erythema of the palms of the hands (redness of the 
skin caused by capillary congestion), leading to keratoderma ('horny' skin). Cardiac 
arrhythmias follow, causing SCD in late adolescence or early adulthood due to 
ventricular tachyarryhthmias (28). Four fami lies contributing nine affected subjects were 
originally described with ARVC-like features, three of the cases with left ventricular 
(LV) involvement. The disease occurs on many Hellenic islands, in addition to Naxos. 
The extracardiac congenital manifestations can be considered 'markers' for Naxos 
disease, and are thus a form of presymptomatic diagnosis (the diagnosis of a serious 
disorder before major clinical symptoms become apparent). 
Naxos disease was mapped to the long arm of chromosome 17 (17q21) in the late 1990s 
(29) and because of the defect in epidermal cells, investigators focused on the region of 
17q where keratin genes had been mapped. The gene for plakoglobin (PKGB), a 
desmosomal protein was located within this region. PKBG occurs in two isoforms, the 
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first with 15 exons (NM_021991), the second with 14 exons (NM_002230), both coding 
for 745 amino acids. Screening of PKGB in the subjects with Naxos disease showed a 
two nucleotide deletion (2157 del 2TG) in affected individuals resulting in a frame shift, 
predicting a stop codon in the protein (30). 
Autosomal dominant ARVC 
In less than a decade, twelve autosomal dominant forms of ARVC were linked to 
chromosomal regions, numbered sequentially in order of discovery: ARVD1-ARVD12. 
ARVDl (MIM # 107970) 
The first locus assignment for ARVC was described by an Italian group. Linkage studies 
in two large families (the largest with 19 affected subjects over four generations), 
determined a maximum LOD (log. of the odds ratio) score of 6.04 .(9 = 0.0) with marker 
D 14S42, at 14q23-q24 (31 ). Another four generation family was linked to this locus in 
2003 (32) with maximum LOD scores of 4.41 and 4.06 with markers D14S254 and 
D14S983 respectively. A family from Southern Germany in this latter publication was 
also said to be linked despite a) being small, b) several recombination events c) a 
maximum LOD score of 1.15 at marker D14S59 and d) a different background haplotype 
from the other two families (32). The authors screened the exonic sequences of four 
positional candidate genes expressed in cardiac tissue (POMT2, TGF/33, KIAA1036, and 
KIAA07591). However, no mutations were found (32). 
The gene, transforming growth factor beta 3 (TGF/33) compnses seven exons 
(NM_003239) and codes for 412 ammo acids. In 2005, a mutation in the 5-prime 
1 OMIM: http://www.ncbi.nlm.nih.gov/omim/ 
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untranslated region (UTR) of the TGF/33 gene was found in nine affected and three 
unaffected members of the four-generation Italian family initially described in 2003 (32, 
33). Thirty unrelated probands were screened, and an additional mutation in the 3-prime 
UTR ofthe TGF/33 gene was found in one patient. Of interest (and. unexplained) was the 
lack of mutations detected in the other large family originally described in 1994 which 
was said to link to the same locus (31) and in the family from Southern Germany (32). 
ARVD2 (MIM # 600996) 
Three further families were reported from the Italian group, one from Switzerland and 
two from northern Italy. One northern Italian family, previously described in 1988, 
presented with effort-induced polymorphic ventricular tachycardia (VT), despite a normal 
12 lead ECG and functional studies (22). Four juvenile SCDs had occurred in the family 
and autopsy showed grossly normal hearts with large areas of fatty-fibrous replacement 
(34). Linkage to 1q42-q43 was demonstrated with a lod score of 4.02 ate = 0.0, using 
95% penetrance. The two other families (from northern Italy and S'Yitzerland) showed no 
linkage to either chromosome 14 or chromosome 1. In 2000, another Italian family with 
polymorphic VT was described, and the original family from 1988 (22) was updated (35). 
In 2001 , two further Italian families with a similar type of · ARVC (manifesting 
polymorphic VT) were reported. These were used along with the families previously 
described in 2000 (35) to refine the 1q42 physical map (36). Four missense mutations 
were identified in the ryanadine receptor-2 gene (RYR2: a calcium channel) in two 
highly conserved regions of the protein. One mutation was found in two separate 
families, and in one family, two RYR2 mutations were found to co-segregate with disease 
(as a compound heterozygote) (36). The mechanism of different RYR2 mutations is thus 
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unknown (37). It may be that RYR2 mutations are dominant with reduced penetrance, or 
that some mutations require an additional RYR2 mutation in the opposite allele to 
become penetant, as with recessive mutations. RYR2 is the cardiac counterpart to the 
skeletal muscle protein RYRl. Mutations in analogous regions in the RYRJ skeletal 
muscle gene cause malignant hyperthermia susceptibility (a disorder of calcium 
regulation resulting in uncontrolled skeletal muscle hyper-metabolism), or central core 
disease (variable skeletal muscle weakness associated with a high risk of malignant 
hyperthermia). RYR2 is one of the largest human genes with 105 exons (NM_0010352) 
encoding 4967 amino acids. 
ARVD3 (MIM # 602086) 
A locus for ARVD was described (14q12-q22) proximal to the chromosome 14 locus of 
ARVDl (14q23-q24) in three small families from Italy, Slovenia and Belgium (38). 
Following a multipoint linkage analysis, a maximal cumulative LOD of 4.7 between 
D14S252 and D14S257 was found. This locus, 30cM nearer the centromere than 
ARVD1, was called ARVD2, later changed to ARVD3 (as ARVD2 on chromosome 1 
had been published between acceptance of the Severini et al manuscript and the proofs). 
ARVD4 (MIM # 602087) 
With two Italian families, and a family from the USA (with European ancestry) (39), a 
locus at 2q32.1-q32 was reported (40). Two ofthe families showed LV involvement, yet 
family sizes were small and there were no details on the unaffected or unknown family 
members. The two families previously reported by this research group and found not to 
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be linked to chromosomes 1 and 14 (34), were also found not to be linked to this 
chromosome 2 locus. 
ARVDS (MIM # 604400) 
This genetic subtype, prevalent in Newfoundland, is the focus of this thesis. It was 
recognised in the 1970's that a disorder caused SCD in young Newfoundland males, 
many of whom were distantly related ( 41 ). This family (now known as family AR1) was 
the focus of a research project in the early 1980s headed by Drs. Patrick Ko (cardiologist) 
and William Marshall (immunologist). At this time the diagnosis of ARVD was made, 
and at least one patient from this family was treated for ARVD in Ontario (41). The remit 
of this research was to determine if AR VD was associated with specific HLA types, 
following several reports in the literature implicating linkage between HLA and other 
cardiomyopathies ( 42, 43). Many subjects from AR1 were as~ertained, and blood 
samples taken. A letter describing the family was published in the late 1980's (3) 
following a comprehensive ARVD clinical publication by the Italian group (44). 
Unfortunately, prior to 1995, the biological samples from this study were destroyed due 
to a lack of storage space ( 45). As several of the early subjects were now deceased, this 
loss was irreplaceable. This is not a criticism of an event that occurs regularly when 
research grants end and storage space is at a premium. It does however emphasise the 
serious issue of amalgamating genetic research on diseases with a high morbidity and 
mortality with clinical care (Chapter 6 page 173). Linkage to a region on the short arm of 
chromosome 3 was published in 1998 (4), and the underlying gene mutation described in 
2008 (46) (Chapter 2) 
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ARVD6 (MIM # 604401) 
In a large North American Caucasian family, with 40 extant individuals over five 
generations, the first five ARVD loci were excluded by microsatetlite marker analysis, 
with a LOD score of < -2 for each locus (47). This ARVC phenotype was highly 
penetrant and malignant, with diagnoses in young children. A genome wide scan 
identified a novel locus at 10p14-p12, with a peak 2-point LOD score of 3.92 with 
marker D10S1664 on a shared haplotype of 10.6 eM between markers D10S547 and 
D10S1653. This region has been reduced to 2.9 eM in a South African family with 13 
affected individuals ( 48). 
ARVD7 (MIM # 609160) 
The locus for ARVD7 was mapped in a Swedish family with autosomal dominant 
myofibrillar myopathy (MFM) and cardiomyopathy ( 49). Myopathic changes (rimmed 
vacuoles, and the accumulation of desmin, dystrophin, and othet: proteins) on muscle 
biopsy and disorganization of myofibrils on electron microscopy were seen. Severity was 
variable, with an onset between the third and sixth decades. One deceased patient had RV 
dilatation on autopsy, with fibrofatty replacement of the myocardium, and mild changes 
in the LV. Three males were defined as having ARVC with non-sustained (ns) VT, atrial 
flutter, and RV dilatation. A multipoint peak lod score of3.06 between markers D10S605 
and D10S215 suggested linkage to 10q22.3 (49). Mutations in the ZASP (z-band 
alternatively spliced PDZ motif-containing protein) gene (1 Oq22.3) have been identified 
in myofibrillar myopathy patients (50), some of whom had cardiac involvement. ZASP is 
a lim domain binding protein (LDB3), comprising 16 exons and spanning 70 kb. LIM 
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domain binding proteins bind other LIM domain proteins. This brings together various 
transcription factors to form activation complexes or to block formation of such 
complexes (thus they act as either an enhancer or a repressor of transcription). PDZ 
proteins (fundamental building blocks in protein organization) iiiteract in cytoskeletal 
assembly. The PDZ domain of ZASP therefore interacts with the C terminus of alpha-
actinin-2 (51), whose isoform, localized to the Z-disc, anchors myofibrillar actin 
filaments in cardiac muscle. Although this seems a reasonable candidate for ARVD7 in 
these patients, to date, there have been no reports of mutations in ZASP causing ARVC. 
ARVD8 (MIM # 607450) 
The Rampazzo group described an Italian family comprising 26 individuals over four 
generations, ascertained via an 18 year old proband with ventricular fibrillation (VF) 
(52). After excluding the known loci, a ScM 700 rnicrosatelite genome wide scan 
produced a maximum LOD score of 4.32 for marker D6S309 at 6p24 and revealed a 
disease associated haplotype. This paper presented both the linked locus and the 
causative mutation in desmoplakin (DSP) (52). The DSP gene was considered an 
excellent functional candidate within this critical region because the authors recognised 
that Carvajal syndrome (manifesting DCM as part of the phenotype) (53) was caused by 
homozygosity for a mutation in DSP (54) at 6p24. The mutation caused a premature stop 
codon (7901 del G), resulting in a truncated protein with absence of the C domain. 
Carvajal syndrome is an autosomal recessive Ecuadorian disorder· initially described in 
1998 (53). Eighteen patients were originally described with epidermolytic (of the skin) 
palmoplantar (on the palms of the hands or soles of the feet) keratoderma (as found in 
Naxos disease), woolly hair, and DCM. Additionally they had altered cardiac 
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contractility, leading occasionally to heart failure and death in the second and third 
decade. In ARVD8, the resulting heterozygous mutation in DSP was a missense mutation 
(S299R). The DSP gene spans 45 kb and comes in 2 isoforms, DSP I (NM_004415) and 
DSP II (NM_001008844), each with 24 exons (2871 and 2272 amino acids respectively). 
ARVD9 (MIM # 609040) 
At the Max Delbruck centre in Germany, a plakophillin 2 (PKP2) null mouse was created 
which exhibited changes in cardiac morphogenesis (55). The absence of PKP2 disrupted 
the desmosome by dissociating DSP from the adherens junctions. Human PKP2 is found 
in 2 isoforms, PKP2a (NM_001005242) and PKP2b (NM_004572). PKP2a has 13 exons 
coding for 837 AAs and PKP2b has 14 exons coding for 881 amino acids. Dr' s. Gerull 
and Thierfelder shared a research floor with the PKP2 null mouse research team and 
recognised that this might have relevance to human ARVC (56) so they assessed 120 
unrelated ARVC probands of Western European descent (101 male~ and 19 females). All 
14 P KP2 exons, including flanking intronic splice sequences, were sequenced and 25 
different heterozygous mutations were found in 32 (27 male, 5 female) /120 probands 
(27%). In a cohort from Johns Hopkins University (57), nine families with eight PKP2 
mutations between them were assessed. Wide intra-familial variability was noted with 
male PKP2 carriers exhibiting more phenotypic features. The families were small and the 
ages at which subjects were tested varied across the lifespan thus firm conclusions about 
the penetrance or presentation of each P KP 2 mutation remains to be defmed. 
Page 35 of292 
ARVD10 (MIM # 610193) 
The Johns Hopkins team found no mutations in PKP2 (ARVD 9) and DSP (ARVD 8) in 
33 probands. They then chose to look at other desmosomal proteins (as functional 
candidates). They screened desmoglein2 (DSG2), a desmoso~al cadherin protein, 
mapped in 1992 (58), and found four ARVC probands with DSG2 mutations that were 
not present in 120 control individuals (59). DSG2 is a 15 exon gene (NM_001943) 
coding for 1118 amino acids. Three of the mutations (in exons· 3, 11 and 15) were 
heterozygous missense, highly conserved amino acid changes in functional domains of 
the protein; the fourth was a nonsense mutation in exon 8. The segregation of these 
mutations in the families, and whether they were all pathogenic was unclear. The families 
presented were small and it was not clear whether there were other relatives potentially 
available to screen. 
The Italian group (60) looked at 80 unrelated probands for known ARVC mutations, 26 
of whom had mutations in either DSP (ARVD8), PKP2 (ARVD9), or TGF./33 (ARVD1). 
Nine DSG2 (ARVD10) mutations (five missense, two insertion-deletions, one nonsense, 
and one splice site mutation) were found in 8 probands (five males and three females): 
none were found in 560 unrelated chromosomes from 280 controls. As with the Johns 
Hopkins team, the segregation involved combinations of mutations in affected and 
unaffected family members. The families were small, and it was again unclear whether 
there were more relatives available to determine whether two mutations were required for 
phenotypic expression. The authors argued that all the missense mutations were 
pathogenic. A high penetrance for DSG mutations (in 9 pro bands) has been described 
(61). 
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ARVDll (MIM # 610476) 
The McKenna London team screened 77 unrelated ARVC probands for mutations within 
desmocollin-2 (DSC2); the one major desmosomal protein remaining as a possible 
candidate for ARVC. They found two heterozygous mutations in affected members of 
four unrelated families in the DSC2 gene, resulting in frame shifts and premature 
truncation of the DSC2 protein (62). In one family a 1-bp deletion in exon 10 in two 
female first degree relatives resulted in a frame shift and premature truncation of the 
protein at codon 480. In three unrelated families a 2-bp insertion (2687insGA) in exon 17 
of the DSC2b gene caused a frame shift and premature truncation of the protein at codon 
900. No disease-associated haplotype was found to link the three families. Two isoforms 
of DSC2 exist due to alternate splicing in exon 16. DSC2a contains 16 exons 
(NM_024422a) and codes for 901 amino acids, DSC2b has 17 exons (NM_004949b) and 
codes for 84 7 amino acids. 
The German team at the Max Delbruck centre investigated 88 unrelated patients with 
ARVC for mutations in DSC2 (63) and identified a heterozygous splice acceptor site 
mutation (c.631-2A-->G) in a 58-year-old male patient with ARVC in intron 5 which 
caused the use of a cryptic splice acceptor site and the creation of a downstream 
premature stop codon. This mutation was not present in 500 control chromosomes. The 
family history was limited, and other than the affected proband, was clinically negative. 
The team looked at cardiac DSC2 expression in lymphocytes and cardiac tissue obtained 
from biopsy and observed a marked reduction in the abundance of the mutant transcript. 
The Italian team screened 54 ARVC probands for DSC-2 mutations and found two 
heterozygous mutations (c.304G>A (p.E102K)) and (c.l034T>C (p.I345T)) in two 
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probands. Both mutations mapped to the N-terminal regwn, affecting the normal 
localisation ofDSC2 (64). 
ARVD12 (MIM # 611528) 
The London group found a PKGB mutation (839 _K40insS; predicted to insert an extra 
serine residue in theN terminus of the protein) in a German family, where a father and 
three sons were affected with ARVC (65). Unlike Naxos disease (where a homozygous 
PKGB mutation causes syndromic ARVC with extracardiac hair and skin 
manifestations), these patients had a heterozygous mutation and presented with only 
cardiac findings. 
1.3.2 ARVC: a disease of the desmosome or too early to tell? 
Of the 12 known ARVC loci, there are now eight known genes for ARVC, including our 
discovery ( 46) (Chapter 2). Five of these eight involve genes coding for proteins present 
in the desmosomal complex (the last six listed in Table 2 page 27). This has been a 
classic example of the 'light under the lamppost' effect. Following the ftrst desmosomal 
gene assignment, other desmosomal genes were assessed. They were ' lit' by that initial 
discovery. However, as the previous pages have hopefully highlighted, the evidence for 
causation for some of the desmosomal mutations described is not always robust. Some of 
these mutations may be modifiers in a complicated pathway, and other genes, currently 
lying in shadow remain to be found. 
Cell adhesion 
Connections between cells are controlled by cell-to-cell junctions, separated into ' tight', 
' gap', 'adherans', and 'desmosomes' (the latter may be considered an adherans junction). 
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Briefly, tight junctions seal adjacent epithelial cells. Gap junctions permit the passage of 
small molecules between cells and are made from transmembrane connexin proteins. 
Adherens junctions provide strong attaclunents between adjacent cells, particularly 
important in areas of high mechanical stress. Adherens junctions comprise cadherin 
transmembrane proteins whose extracellular segments bind to each other and whose 
intracellular segments bind to catenins, which connect to actin filaments. 
Desmosomes 
"The Victorians would have approved of the desmosome- intermediate filament complex 
- a structure that buttons cells together and forms a web of filamentous constraints - a 
system as staid and solid as the queen's corsets. The recent bodice-ripping reports of 
mutant desmosomal proteins that curl the hair, break hearts, and leave us blistered and 
thick-skinned would have reinforced their moral perspective that lapses that undo buttons 
and let down suspenders lead to loss of integrity. "(66) 
Desmosomes are cell-cell adhesion multiprotein complexes (67), critical for providing 
rigidity in epidermal and cardiac tissue (Figure 1 page 40). They function as cell 
junctions, as signall ing centres in embryogenesis, and they anchor cytoskeletal elements 
by linking to cytokeratins (intermediate filaments) at the plasma membrane. The 
desmosomal structure comprises several transmembrane adhesive glycoproteins, 
members of the cadherin superfamily of proteins (desmocollins and desmogleins) and 
cytoplasmic plaque proteins (DSP2, PKGB and PKP2). The physical relationship 
between desmosomes and intermediate filaments provides cellular structural integrity and 
adhesion. This allows for the assembly of cells into three dimensional tissues and organs. 
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Desmosomal protein defects in areas of high mechanical stress, such as the heart and the 
skin thus have a significant impact on tissue integrity (68). 
Figure 1 Desmosome's role in cell adhesion2 
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Plakoglobin (Naxos disease and ARVD12) (MIM *173325) 
PKGB is a cytoplasmic protein found in adherens junctions and desmosomes, thought to 
act as a ' linker molecule' between the inner and outer portions of the desmosomal plaque 
by binding tightly to the cytoplasmic domain of cadherins. The central domain of PKGB 
is formed by highly conserved armadillo repeats. The armadillo gene, involved in 
segment polarity, was initially discovered in Drosophila and many related proteins have 
been identified based on sequence homology. These proteins all have a central domain 
comprising several amino acid repeats forming a highly conserved 3D structure. They 
provide both structural (as cell-cell contact and with cytoskeleton-associated proteins) 
and signalling (by generating and sending signals affecting gene expression) functions 
(69). These functions are seen in PKGB where the central domain adheres to other 
2 http://www.nature.com/nrm/ joumal/vl /n3/images/nrm 1200 208a f4 .gif 
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desmosomal and cytosolic proteins (69) (70), and where changes in adherens junctions 
are signalled directly to the nucleus (71 , 72). 
Desmoplakin (ARVD 8) (MIM + 125647) 
DSP2 is part of the plakin family of cytoskeletal proteins and is exclusive to 
desmosomes. It is the most abundant multi-functional desmosomal protein. It binds 
intermediate filaments at its carboxy-terminal site, it dimerizes through a central coiled 
rod; and with its pair of amino-terminal binding domains, it plugs into desmosomes and 
adherens junctions. DSP2 binds to PKP2, which in turn connects to desmosomal 
cadherins. Additionally, it binds to the juxtamembrane domain of DSC2-la and 
associates indirectly through PKGB, with cadherins in adherens junctions (Figure 1 page 
40) (66). Mouse models over-expressing a DSP C terminal mutation (R2834H) showed 
cardiac hi-ventricular apoptosis (cell death), fibrosis, enlargement and dysfunction. Over 
expression of wild type DSP had no adverse effects on the myocardium (73). 
Plakophilin-2 (ARVD 9) (MIM*602861) 
PKP2 is also an armadillo repeat protein of the desmosome. Plakophilins are located in 
the outer dense plaque of desmosomes, linking desmosomal cadherins with DSP2 and the 
intermediate filament system. Like other armadillo-repeat proteins, plakophilins probably 
have a role in transcriptional regulation in the nucleus. PKP2 (in its two alternatively 
spliced isoforms, a, and b) is the primary cardiac plakophilin. It interacts with several cell 
adhesion proteins, has an important role in the assembly of junctional proteins in 
embryogenesis and is an essential morphological component of the heart. Mouse hearts in 
the absence of PKP2 fall apart (7 4 ). 
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Desmoglein (ARVD 10) (MIM *125671) 
Desmogleins are desmosomal cadherins and with the desmocollins, form the essential 
transmembrane components of the desmosome (75) (Figure 1 page 40). All desmogleins 
(DSG 1-4) have four extracellular cadherin domains and a transmembrane domain. 
Calcium binding to the extracellular domains stabilizes their structure and function. Seven 
of the nine mutations causing ARVDlO (60), were located in the extracellular amino 
terminal domain which directly participates in adhesive interactions. The authors 
postulated that a single amino acid change could result in changes in molecular affinity, 
altering the adhesive capacity of the cadherins (DSG2 andDSC2). In-vitro antisense 
experiments against DSC2 resulted in cell detachment and knockout mice for DSG2 died 
as early embryos (76), supporting the role of impaired cell-to-cell adhesion in some forms 
of cardiomyopathy (77). 
Desmocollin 2 (ARVD 11) (MIM *125645) 
DSC2 is like desmoglein, a desmosomal cadherin: a glycoprotein of between 115 and 13 0 
kD. The potential pathology of DSC2 mutations in ARVC subjects was investigated by 
cloning full-length wild-type and mutated cDNAs in eukaryotic vectors to obtain a fusion 
protein. Constructs were transfected into neonatal rat cardiomyocytes and in 1-IL-1 cells. 
N terminus mutations altered the location of DSC2 to a primarily cytoplasmic position 
compared with wild type (64). Knockout zebrafish embryos had a reduced desmosomal 
plaque area in cardiomyocytes, and had associated contractility defects. A physiologic 
level of DSC2, like other desmosomes, appears to be crucial for normal cardiac 
desmosome formation, cardiac morphogenesis, and cardiac function (63). 
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Non-desmosomal genes in ARVC 
Of the three non-desmosomal genes now known to be involved in causing ARVC, two 
were described before this thesis; the third is described in Chapter 2 (page 74). 
Transforming growth factor ~3 (TGF~3) (ARVDl) 
TGFP3 is a member of the transforming growth factor family, comprising proteins that 
regulate several physiological processes, including embryonic development, homeostasis, 
chemotaxis and control of the cell cycle. TGFP I, p2 and P3 inhibit proliferation in many 
cells and induce apoptosis of epithelial cells. They also stimulate mesenchymal cells to 
proliferate, and can induce a fibrotic response in several tissues in vivo (78). The 
presence of TGF[J3 mutations in ARVC families may thus relate to the production of 
myocardial fibrosis, disrupting the electrical behaviour of the myocardium, predisposing 
to re-entrant ventricular arrhythmias (79). 
Ryanadine Receptor 2 (ARVD2) 
Functional studies have provided good evidence for the role of RYR2 in SCD (37). 
R YR2 channels couple the excitation of myocardial cells to their actin/myosin contractile 
apparatus by a calcium induced-calcium release mechanism. This works by the 
stimulation of voltage sensitive calcium channels in the outer myocardial membrane 
which allows the entry of some calcium ions. This then activates the release of calcium 
into the cytoplasm from the sarcoplasmic reticulum Lumen via RYR2 which thus initiates 
myocardial contraction (80, 81 ). 
RYR2 mutations account for different clinical phenotypes: ARVD2 (36, 82) and 
catecholiminergic polymorphic VT (stress induced polymorphic VT in the absence of 
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structural heart disease and a prolonged QT interval) (83-85). Characteristics shared by 
these diseases are effort-induced ventricular arrhythmias and the risk of SCD. Shared 
pathogenesis would comprise the effect of the mutations on the ability of the calcium 
channel to remain closed. Thus intense adrenergic stimulation due to stress (emotional or 
physical) could lead to calcium overload. These seemingly different clinical phenotypes 
may thus represent variable expressivity or allelic heterogeneity (multiple alleles within 
the same gene causing the same phenotype). 
Genetic subtypes with a common pathophysiological mechanism for ARVC. 
The involvement of multiple desmosomal proteins, and TGF~3 and RYR2 leads to 
several hypotheses regarding a unifying pathophysiology of ARVC (52) (86). Thus 
defective desmosomal proteins would impair cell to cell contact and affect the ability of 
the myocardium to stretch. This would occur preferentially in areas of high strain in the 
RV (which can stretch more than the left (52): the so called ' triangle of dysplasia' (Figure 
6 page 52). Mechanical forces applied to adherens junctions activate 'stretch sensitive' 
calcium channels via cadherin mechanical intracellular signalling (87). These stretch 
activated channels transform mechanical forces into an electrochemical signal due to an 
increase in intracellular calcium concentration (88-90). Those with defective 
desomosomal proteins would produce 'over stretch'. Additionally, stretching of 
cardiomyocytes modulates calcium release from RYR2 release chrumels (91). A 
genetically impaired stretch response thus might affect intracellular calcium 
concentration (resulting in excessive calcium load) and the excitation/contraction 
coupling. The result may be the production of arrhythmias (92). The existence of the 
RYR2 mutations supports the concept of impaired intracellular calcium playing a key 
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pathogenic role in the pathogenesis in at least some forms of ARVC. TGF~'s are known 
to modulate the expression of genes encoding desmosomal proteins (93), suggesting that 
the effect of un-translated region mutations causing over expression of TGF~3 might 
affect cell to cell stability. Links may be made between all the putative genes and at least 
part of the ARVC phenotype. 
Cardiac remodelling and the interdependence of the protein 'players' in the 
myocyte 'orchestra'. 
Although the term ' remodelling' may at first glance imply improvement, it is in fact the 
opposite. Remodelling defines the concept that the size, shape and function of the heart 
change in response to various adverse stressors. The term 'reverse remodelling' is used to 
define an improvement in ventricular mechanics and function after stress. Remodelling 
occurs as a response when strain is applied to the heart, and describes a series of 
histopathological and structural changes in the ventricular myocardium that leads to a 
progressive decline in cardiac performance, and possibly reduced contractile function. 
Heart failure is characterized by impaired systolic and diastolic dysfunction and occurs in 
the final stages of disease caused by the TMEM43 mutation. Both dilatation and 
hypertrophy occur as a remodelling response of the heart to an underlying insult. 
Dilatation is classically thought to be related to volume overload with hypertrophy a 
response to increased pressure (e.g. hypertension). (94). In the case of the primary 
cardiomyopathies however, these occur in the absence of an obvious cause for either 
volume overload or increased pressure. Thus, prior to the definition of some of the 
causative genes, primary cardiomyopathies were known as 'idiopathic' . DCM is 
presumed to be caused by mutations in contractile or calcium cycling proteins, nuclear 
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membrane proteins, or cytoskeletal proteins (95), and HCM by sarcomere protein 
mutations (96), although overlap (where sarcomere protein mutations can cause DCM for 
example) exists. 
1.3.3 How force is generated within the heart 
The sarcomere comprises a group of proteins organised into thick and thin filaments. 
When calcium and A TP are present, they slide past one another creating force. Calcium is 
the most important molecule in this scenario. It enters myocytes by L type calcium 
channels via a sodium (Na+) and calcium ion (Ca2+) exchanger, which causes calcium to 
be released from the sarcoplasmic reticulum via ryanadine receptors. During relaxation, 
calcium is removed from the cytosol via the exchanger. Intracellular calcium rises in 
response to electrical depolarisation which causes calcium to bind to troponin C, I and T, 
and also alpha tropomyosin (Figure 2 page 4 7 and Figure 3 page 48). 
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Figure 2: Schematic illustrating the relationship between the desmosomal, cytoskeletal, 
sarcomeric and nuclear membrane proteins in the cardiac myocyte. (97)3 
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This releases troponin I inhibition of the actin myosin connections (Figure 3 page 48) 
which allows myosin to bind to actin then A TP to myosin, thus allowing for the myosin 
3 http: //www.nature.com/nrg/journal/v5/n I I / thumbs/nrg 1470-t2.jpg 
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head to move along the thin filament generating force following A TP hydrolysis (Figure 
3 page 48). This force is transmitted to the cytoskeleton (intermediate filaments, desmin, 
microfilaments, microtubules and lamin proteins which comprise the intermediate 
filaments of the inner nuclear membrane (Figure 2 page 47)) via the proteins linking the 
sarcomere to the sarcolemma and the outside of the cell. There are multiple costomeres 
that interconnect the cytoskeleton to the sarcolemma, including the complex comprising 
dystrophin, alpha and beta dystroglycans, alpha beta gamma and delta sarcoglycans, 
dystrobrevin and a and ~ syntrophin (Figure 2 page 4 7). 
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Phenotype/Diagnosis/Natural History 
Clinical presentation 
ARVC is an arrhythmic disorder, thus it alters the normal heartbeat (Appendix C page 
284). 'Classic ' ARVC presents with palpitations, presyncope (light-headedness), syncope 
(temporary loss of consciousness), and dizziness: symptoms related to VT (Appendix C). 
A common mechanism for VT in ARVC is re-entry (99, 100). Re-entry occurs when a 
conducting pathway is blocked in one direction, and re-stimulation of the pathway 
occurs. Thus in ARVC, the fat and fibre lead to unidirectional block and slow 
conduction, creating re-entry circuits and injtiating VT (100), a similar mechanism tore-
entry (and VT) after a myocardial infarct (MI), as a result of scarring following the death 
of a portion of the myocardium (101). After presenting with symptoms, classic ARVC 
features on 12 lead ECG include epsilon waves (small notched deflections just after the 
QRS in lead V1) and inverted T waves in leads v1 to v5 in the absence of right bundle 
branch block (RBBB). 
Figure 4 Epsilon wave in 12lead ECG5 and normal V1 lead 
5 http://en.ecgpedia.org/wiki/Arrythmogenic Right Ventricular Cardiomyopathy 
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Figure 5 T wave inversion in ARVC6 
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The etiology ofT wave inversion in ARVC in general is not understood (102). Epsilon 
waves however are thought to relate to the fractionation of the electrical activity due to 
myocardial scarring and the position of the epsilon wave in Vl and V2 indicates RV 
involvement (1 02). 
The early, prodromal stages of ARVC have been called the 'concealed phase' of the 
disease (34), where patients present with mild symptoms (or have inadvertent findings on 
clinical tests). Subsequent testing of such patients over time reveals fat and fibre on 
cardiac biopsy, ventricular arrhythmias and 12 lead ECG findings (103). 
Heart failure is an ARVC presenting feature in some circumstances, with an enlarged RV 
and oedema (12) ( 104 ). Occasionally the first presentation is SCD, which occurs when 
6 http://www.health.gov.mt/impaedcard/issue/issue6/183 7/ 183 7 .htm 
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VT progresses to VF (Appendix C). SCD due to ARVC may be more common in athletes 
(related to exertion) (1 05). In general, SCD accounts for about 50% of all deaths from 
cardiovascular causes (1 06), with about 20% of these deaths due to a genetic 
cardiomyopathy, or congenital heart defect (1 07). SCD occurs with many myocardial 
diseases, including, heart failure, coronary artery disease, other arrhythmias and various 
cardiomyopathies. In all situations, the VT may terminate spontaneously. 
Diagnosis of ARVC 
The quotation by Sosman which opens this introduction was used by Frank Marcus in the 
only book so far written on ARVC (7). Both Sosman and Childs (page 19) eloquently 
underline the difficulties associated with disease definition in general. ARVC is like the 
tip of the iceberg (a fitting analogy for Newfoundland and Labrador) where the disease 
that presents to clinical services probably represents about 1/10 of the true prevalence in 
the population. 
A definition of phenotype is problematic for any disease. In most diseases it is that which 
presents clinically because the disease has caused problems significant enough to require 
assistance. For a true understanding of the disease process however, longitudinal data is 
required: to recognise the prodromal stages, the presenting stages, and the terminal 
stages. For a disease which causes SCD, the terminal event may be the only stage 
recognized. For ARVC, the definition of phenotype has proved difficult from the earliest 
recorded cases. Initially, the disease was described as manifesting VT, with massive RV 
involvement, and a myocardium infiltrated by fat and fibre. The pathological signs and 
symptoms thus became a gold standard, defined following a RV biopsy or at autopsy. 
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Pathology and proposed pathophysiological mechanisms for ARVC 
In the 24 patients originally described by Marcus (12) the pathophysiological findings 
were outlined. Marcus described the process as affecting the posterior and inferior areas 
of the RV inflow tract adjacent to the tricuspid valve, the anterior infundibulum and the 
apex, forming the 'triangle of dysplasia' (Figure 6 page 52). 
Figure 6 Triangle of dysplasia7 
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The restriction of ARVC to the RV may be pathognomonic to many. Sole involvement 
has historically been assigned to the right free wall, sparing the septum (and the LV) 
( 108, 1 09), with a loss of myocardium due to fibrofatty replacement leading to aneurysms 
(bulges) (24). In Marcus's original description, aneurysms were described in the triangle 
of dysplasia. Other pathology findings included a decrease in the number of myocardial 
fibres and their replacement by fat and fibre; white thick sclerotic endocardium in the 
areas of dysplasia, and hypertrophy of the few remaining myocytes. 
7 
www.aafp.org/afp/200604 15/139 l.html 
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Much of our knowledge of the pathology of ARVC has come from Padua in Italy, due to 
the prevalence of ARVC in the Veneto region. The Italian group describe two types of 
ARVC based on pathology: the first a lipomatous pattern (infiltrative group) comprising 
mainly fatty tissue, restricted to the RV sparing the septum and the LV, and the second, a 
fibrolipomatous pattern (cardiomyopathic group), comprising fat and fibre, with 
parchment thin walls and translucent and sac like aneurysms at the apex, including the 
LV (1 08, 110, 111 ). It is likely that these descriptions will be modified following the 
determination ofthe genetic etiologies for ARVC. 
Several mechanisms have been postulated for the pathological findings in ARVC. These 
include incremental apoptosis, leading to loss of normal cardiac myocardium; 
transdifferentiation (myocardial cells changing from muscle to fat and fibre) , following 
an infectious or inflammatory pathological injury repair process. The obvious genetic 
heterogeneity in ARVC may mean that the pathology reflects different genetic subtypes 
of ARVC. Alternately the pathology may reflect different stages of a progressive disease 
process. 
ARVC may be an injury repair process, where fat and fibre replace myocardium 
following myocyte degeneration and death (112). Two thirds of Italian cases, following 
autopsy or biopsy, exhibited inflammatory cell infiltrates (CD43 positive T lymphocytes) 
associated with a focal myoctye necrosis (112). The authors suggested that a recurrent 
myocarditis occurs, triggering electrical instability leading to SCD, or a progression to 
heart failure to mimic DCM (112). Similar features of repair and injury and an infectious 
inflammatory process have been described in a cat model of ARVC (113). 
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Whether viruses play a role in some forms of ARVC has been explored with both 
negative (114) and positive (115) results. In the latter, Bowles et al 2002 publication 
(115), where the role of viruses was implicated, all cases were considered to be sporadic 
based on the lack of a fan1ily history of cardiac disease or SCD, and following negative 
clinical screening of family members. The authors recognized that viruses may cause a 
diseased myocardium, or be a secondary effect in a diseased heart rendered susceptible to 
infection. That the latter is a possibility is supported by the observation of viruses in the 
myocardium of cardiac pathology specimens exhibiting signs of rejection from routine 
heart transplant biopsies (116). Dystrophin deficient mice have also developed 
enteroviral cardiomyopathy. This may be due to the disruption to the sarcolemma 
resulting in an increased susceptibility to the virus (117): a case where an underlying 
mutation predisposes to an infectious process. 
Apoptosis has been documented many times in both ARVC post mortem specimens (118) 
(119) and biopsies (120) (121) (122) as well as DSP2 mutation positive mice (73). 
However whether apoptosis is a primary cause, or a secondary response, to the disease 
process is unknown. 
Fat in the heart: what is the relevance? 
The question of whether fat in the myocardium is pathological or a natural secondary 
phenomenon has been raised (123) (124). Burke suggested that the site of the fat, rather 
than the gross amount, was the relevant issue, (125). Thus fat in the RV outflow tract was 
abnormal but the same amount in the anterior wall near the apex was not. Fat had also to 
be associated with 'significant' fibrosis for a diagnosis of ARVC to be made (125). The 
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Padua group have tried to quantify 'significant amount' and their pathological diagnosis 
was based on the relative quantities of fat and fibre (8), where fat and fibre at > 3% and > 
45% respectively were considered pathognomonic for ARVC (8). Pathology is extremely 
important in the absence of a presymptomatic genetic test, so in many families a biopsy 
documenting pathological change may be the principal method of diagnosis of ARVC. 
Diagnostic Criteria 
In an attempt to create order from the diagnostic maelstrom of ARVC, in 1994 a 
consensus committee of leading cardiologists produced diagnostic criteria (25). Six major 
classes of anomalies were defined: dysfunction and structural abnormalities, histological 
changes, repolarisation and depolarisation abnormalities, arrhythmias and family history. 
Muliple features were defined for each class, separated into major and minor criteria, 
where 2 major or 1 major plus 2 minor, or 4 minor criteria were required for diagnosis 
(Table 3 page 57). 
These criteria were based upon the experience of those on the committee and are thus the 
direct result of a selection bias, determined from patients with a disease severe enough 
(yet who were still alive) to bring them to medical attention. Those with mild disease may 
never present, and more severe cases may die before presenting, and the cause of death 
misclassified or misunderstood. How we diagnose and understand a disease thus takes on 
aspects which become almost philosophical in nature. This is exemplified by the example 
of cystic fibrosis (CF), which for years was diagnosed exclusively by clinical signs and 
symptoms (126). However, the determination of the causative gene (127) and the 
recognition that there are thousands of pathological mutations within the CF gene (allelic 
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heterogeneity) has resulted in an expansion of the clinical picture. In some cases the 
'disease' expression is so mild as to be considered a normal variant rather than pathology 
( 128) (1 29) ( 130). It is likely that this scenario will recur for many single gene disorders. 
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Table 3; Task Force of the Working Group Myocardial and Pericardia! disease of the 
European Society of Cardiology and the Scientific Council on Cardiomyopathies of the 
International Society and Federation of Cardiology diagnostic criteria (25) 
Ma.ior criteria Minor criteria 
Global and/or Severe dilatation and reduction of Mild global right ventricular 
regional right ventricular ejection fraction dilatation and/or ejection 
dysfunction and with no (or only mild) LV fraction reduction with 
structural impairment normal left ventricle 
alterations Localised right ventricular Mild segmental dilatation of 
aneurysms (akinetic or dyskinetic the right ventricle 
areas with diastolic bulging) Regional right ventricular 
Severe segmental dilatation of the hypokinesia 
right ventricle 
Tissue Fibrofatty replacement of 
characterization myocardium on endomyocardial 
of walls biopsy 
Repolarisation Inverted T waves in right 
abnormalities precordial leads (V2 and V3) 
(people aged older than 12 
years in the absence of right 
bundle branch block) 
Depolarisation Epsilon waves or localized Late potentials (signal 
/conduction prolongation (> 11 Oms) of the averaged ECG) 
abnormalities QRS complex in right precordial 
leads (V1-V3) 
Arrhythmias Left bundle branch block type 
ventricular tachycardia 
(sustained and non-sustained) 
(ECG, Holter, exercise 
testing) 
Frequent ventricular 
extrasystoles (more than 
1000/24 hours on Holter) 
Family History Familial disease confirmed at Family history of premature 
necropsy or surgery sudden death(< 35 years) due 
to suspected ARVC 
Family history (clinical 
diagnosis based on present 
criteria) 
2 major or 1 major plus 2 minor, or 4 minor cnteria requued for diagnosis 
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The early report on 24 patients with ARVC suffered an ascertainment bias (a 
complication present in virtually all reports), focusing on cases with a severe phenotype 
(12). All patients had a dilated RV, sustained VT and LBBB. The conclusion was that 
this was a rare, severe, disorder. Over time, the spectrum of ARVC expanded, where less 
severe cases were recognised ( 19) and where the prevalence of SCD, and the relevant 
histopathology was noted (44). With time, it became clearer that many cases exhibited 
biventricular disease, with some exhibiting mainly LV disease(l31-141), and the 
spectrum became wider. 
The clinical diagnostic criteria therefore suffer the same 'severe case' bias. This becomes 
a concern when relatives are assessed, who despite manifesting minor clinical features, 
do not fulfill the defined criteria. This issue was addressed in 2002 by Hamid and Dr. 
McKenna's London group of researchers, who found that the accepted criteria were 
insufficient to make a diagnosis of ARVC in a subject with a definitely affected relative 
(142). This team modified the criteria to require fewer clinical features for diagnosis 
within a known family. These families were not defined by an underlying ARVC 
mutation; rather they were defined by their clinical presentation. The relatives thus had 
cardiac testing in order to look for cardiac clinical signs which might be considered part 
of the diagnostic spectrum. Despite the fact that 21% of affected relatives had LV 
involvement, and 3% fulfilled a DCM diagnosis, the modified criteria did not add LV 
findings to the modified listing (Table 4 page 59). 
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Table 4 Modification of original task force diagnostic criteria (142). 
ARVC in first degree relative plus one of the following 
ECG T wave inversion in right precordial leads 
(V2 and V3) 
Signal averaged ECG (SAECG) Late potentials seen on SAECG 
Arrhythmia LBBB type VT on ECG, Holter monitor or during exercise testing 
> 200 PVCs over a 24 hour period 
Structural or functional abnormality of Mild global RV dilatation and/or reduced 
ejection fraction with normal LV. 
theRV Mild segmental dilatation of the RV 
Regional RV hypokinesis 
The London group has recently assessed the utility of the original and the modified 
criteria (61). They looked at family members with DSG2 mutations and showed that the 
penetrance of the disease was 58% if the original Task Force criteria were used (25), and 
75% using the modified criteria (142). Of interest in this paper was the absence of RV 
anomalies in 34% of gene carriers: 25% of whom had LV involvement, and in whom 
74% did not show the classic T wave inversion. The phenotype of ARVD5 presented in 
this thesis supports the need to widen the diagnostic criteria even further. 
Diagnostic Criteria developed for ARVDS 
The diagnostic criteria as defined and discussed above cannot be used for a large 
epidemiological study as presented in this thesis. The pedigree structures of the families 
have SCD as a presenting feature, with an autosomal dominant mode of inheritance. 
Whilst autopsy may have defined ARVC in several deceased individuals, an autopsy 
diagnosis alone could not diagnose ARVC based on the original criteria (25). 
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Additionally, the tertiary nature of the clinical testing would minimise the ability to 
define affected individuals. We therefore created our own straightforward diagnostic 
criteria, which utilised even minimal information. 
Table 5 The ARVD5 epidemiological diagnostic criteria 
All subjects at a priori Definition 
50% birth risk 
ascertained 
Disease Status 
Affected 1. Obligate carrier. 
2. SCD under 50 years. 
3. Cardioversion for VT or 
VF under 50 years. 
4. Genetic diagnosis: high-
risk DNA haplotype or 
gene mutation positive. 
Unaffected 1. Low risk DNA haplotype 
or gene mutation 
negative. 
Unknown 1. Did not fulfil criteria as 
set out above. 
1.4 VARIABLE EXPRESSION AND REDUCED PENETRANCE 
All autosomal dominant disorders are variably expressive; some have reduced 
penetrance. Variable expressivity describes the tendency for a disease to affect related 
individuals in different ways: thus the disease does not necessarily run ' true' within a 
family, or between families with the same mutation. Reduced penetrance is the extreme 
form of variable expression: where the presence of the gene does not always result in 
manifestation of the full disease. A non penetrant disease is one where no sign of the 
disease is present (143). Diagnosis relies upon finding clinical features that are associated 
with disease. The move towards modified criteria for ARVC (142), and the recognition 
that gene carriers manifest a varied phenotype (61) speak to a growing recognition within 
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cardiology of the variability in disease presentation. In genetic disorders, variable 
expression is ubiquitous: ARVD5 is no exception. 
1.5 DIFFERENTIAL DIAGNOSES FOR ARVC 
Adipositas cordis This rare disorder is characterized by fatty infiltration of myofibers, 
and often causes restrictive cardiomyopathy (144). The fatty infiltration may be confused 
with ARVC. 
Right ventricular outflow tract (RVOT) disorder. This is a primary disorder of the 
outflow tract of the RV, presenting usually with VT. It is considered to be benign and 
non-familial. It usually responds to beta blockers and calcium channel blockers and is 
considered distinct from ARVC (145). 
Ubi's anomaly (146) Tllis presents with a paper tllin RV free wall that is almost 
transparent. It is a rare lethal condition that presents during infancy and childhood leading 
to congestive heart fai lure and death. Although named after Uhl, it was originally 
recognised by Osler who described a 'parchment' heart in 1905 (147). ARVC was (and 
sometimes still is) considered part of Uhl's anomaly although it is usually now 
considered a separate entity (148-1 50). Supporting this conclusion is the lack of evidence 
that Uhl' s anomaly is fami lial (145, 151). 
Chagas disease ( 152) Chagas' disease is a human tropical parasitic disease caused by the 
flagellate protozoan trypanosoma cruzi transmitted primarily by insect bite. The chronic 
stage may occur decades after initial infection, and can cause cardiomyopathy which can 
be mistaken for ARVC. Apoptosis has been recognised in this disease (153). 
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Viral cardiomyopathies: Multiple viral infections that have been considered part of the 
differential diagnosis of ARVC including Enterovirus infection (154) and Bartonella 
infection (155). 
1.5.1 Prevalence and incidence 
Prevalence and incidence are measures of the frequency of disease events in a population. 
Prevalence is derived by counting 'cases' at a single point in time. Incidence is derived 
by counting cases over a specified period of time: both require a definitive diagnosis. As 
ARVC is difficult to clinically diagnose, incidence and prevalence figures are unreliable 
(156). The prevalence in Italy is quoted as 115000 accounting for 20% of deaths in young 
adults (11 0). A higher frequency is noted in Padua, Northern Italy where an incidence of 
6110,000 is quoted (31 ). Rampazzo recognised that this figure had limitations as they had 
actively searched for cases with ARVC as part of a research project, yet they may still 
have missed prodromal forms of the disease, yet in one small geographic area the 
incidence was believed as high as 4.4/1000 (31 ). The incidence remains essentially 
unknown in the USA. One study reported a frequency at autopsy of 0.55% among young 
adults following SCD in Maryland (157), and 17% of sudden death victims between 20 
and 40 years of age were diagnosed with ARVC in a subsequent study (158). In 'France, 
18/50 cases of sudden perioperative deaths were considered to have ARVC (159). There 
are those who consider that this disease is both under diagnosed (because of reduced 
penetrance, biased ascertainment, and because family history is not present) (160) and 
those who think that it is often over diagnosed, particularly with newer imaging 
techniques (161 , 162). Issues of diagnosis make incidence and prevalence difficult to 
quantify: a situation which will hopefully be rectified with the more widespread use of 
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genetic testing. Whatever the true incidence and prevalence, ARVC has been reported 
worldwide (163) (164) (165) (166). 
1.6 NATURAL HISTORY 
The natural history of disease is the clinical presentation from birth to death. In ARVC 
this has historically been subdivided into four discrete stages ( 156). The first is a 
'concealed' phase, with subtle RV changes, where SCD may present catastrophically and 
unexpectedly. The second is an 'overt electrical disorder' phase, with RV arrhythmias 
and clear RV manifestations. The third is a RV failure stage, with preserved LV function. 
The final stage is biventricular pump failure, with significant LV involvement that 
mimics other causes of DCM. These stages are necessarily descriptive, and suffer major 
biases. Studies are scarce. Most have involved small genetically heterogeneous groups 
(multiple genetic causes) and/or groups of subjects with variations in presentation, family 
history, causes of death and rates of death (167-169). Most natural history data comes 
from Italy (1 03, 1 08) (170), is descriptive, and uses etiologically heterogenous ARVC 
subjects. Comparing heterogeneous groups with ARVC will miss differences due to the 
differing genetic (and possibly environmental) causes. Using the homogeneous group 
with ARVD5 in Newfoundland has allowed us to define in a robust manner the natural 
history of this genetic subtype. 
Cardiac Tests 
Many cardiac clinical tests are used to diagnose ARVC (Appendix C page 284). Their 
utility in the ARVD5 population is presented in chapter 3 page 105. 
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Electrocardiography 
ECG abnormalities considered part of the ARVC spectrum (25) include T wave (Figure 5 
page 50), and epsilon waves (Figure 4 page 49) indicating right ventricular late 
potentials (171) detected by running the ECG at double speed and amplitude using a 40 
hz filter (172). Extended QRS duration on 12 lead ECG in Vl , V2 or V3 is also part of 
the ARVC diagnostic criteria (25, 173) (Table 3 page 57). 
The benefit of the ECG is that it is easy to apply, inexpensive and ubiquitous compared 
with many other cardiac tests that are only available at tertiary health care centres. It has 
been recognised as a valuable first test for the clinical detection of ARVC, with 
lengthened QRS duration in the right precordial leads (V1-V3) present in 98% of 
clinically diagnosed ARVC patients (174). 
The signal-averaged ECG (SAECG) 
The first use of SAECG in ARVC was in the late 1980' s (175), when diagnostic criteria 
were assessed and the test considered diagnostically useful (176). However, the problem 
of assessing utility in individuals already diagnosed by another method (in this paper by 
angiography (176)) remains methodologically problematic. 
The Holter monitor 
The Holter monitor has been used to document ectopy in those with ARVC from the 
1980s. It has also been used to assess heart rate variability and diurnal variations in 
arrhythmia activity (177). It is considered the most sensitive test for determining ARVC 
in Boxer dogs (178). 
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Echocardiography 
Echocardiography provides important diagnostic information with which to diagnose 
ARVC (179) (180) (181) (182). Its value is constantly being reassessed. For example, a 
recent study compared ARVC probands with matched controls (by age, sex, body size 
and year of echo) (183). The enlarged right sided heart structures were 'obvious' on 
echocardiography, but as the subjects were already diagnosed by standard criteria (25), a 
major ascertainment bias existed. Echocardiography has been used by some as a gold 
standard for diagnosing ARVC (184) correlating well with MRI findings in patients for 
RV measurements, volumes and ejection fractions (185). As newer techniques evolve 
(e.g. real-time 3 dimensional echocardiography (186) and Doppler tissue imaging) and 
evaluated in ARVC (140) (187, 188) echocardiography may become even more useful. 
Like the ECG, echocardiography is available in many non-tertiary centres. Unlike the 
ECG, it is operator and analyser dependent. As the phenotype of ARVC expands and as 
patients are followed prospectively, heart failure is one outcome that is readily diagnosed 
by echocardiography (I 04). 
Cardiac Biopsy 
Cardiac biopsies remove cardiac tissue in vivo, and the tissue is assessed for the presence 
of fat and fibre. The procedure carries a risk of serious sequalea8. It is dependent upon the 
location bf the tissue sample, as a negative biopsy (an absence of fat and fibre) may rule 
out ARVC, or, more problematically, may indicate that the sample was taken from an 
unaffected area of the myocardium. Of serious concern is ventricular perforation, which 
8 http://www .health.q ld.gov .au/ in formedconsent/ConsentF orms/card iac/cardiac _ 08. pdf. 
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may occur m thin and friable ventricular free walls (111). Genetic testing would 
overcome these limitations. 
Magnetic Resonance Imaging (MRI) 
The first use of nuclear MRI in humans was as recent as 1977 ( 189), and it has overtaken 
cardiac biopsy as the diagnostic tool of choice for diagnosing ARVC by assessing the 
presence of fat and fibre in the myocardium. This is despite that when MRI diagnosis was 
compared with histopathological biopsy diagnosis, the latter was considered more 
sensitive (190). However, MRI is a much less invasive clinical test. MRI differentiates fat 
from fibre through signal density compared with normal myocardium, as the former 
increases signal density (the image is brighter) and the latter decreases signal density. A 
more recent MRI technique uses contrast to better visualise fibre (191) (192). The 
eventual reliability of MRI in terms of diagnostic accuracy remains to be determined 
(193) (161). MRI as a technique is restricted to tertiary centres. The use of MRI in 
Newfoundland for ARVC diagnosis was terminated for ARVD5 following the use of the 
3p25 DNA haplotype. 
1.6.1 Left ventricular enlargement in ARVC and overlap with DCM 
Early descriptions of ARVC recognised that the LV could be affected in the same way as 
the RV (131 , 133, 134, 194, 195), and decades of evidence suggests that ARVC is a 
biventricular disease (131-141, 196-198) that may mimic DCM (44) (199) with the 
involvement of the LV reflecting disease progression. Forty-two hearts from autopsy and 
transplant ARVC patients showed histological involvement of the LV 76% of the time 
(199), and five of the seven individuals affected in the four families with ARVDIO 
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( desmoglein mutations) ( 61) had evidence of significant LV involvement that was more 
obvious than the RV disease in two individuals. 
DCM is a cardiomyopathy where the cardiac wall is the correct size, but the internal 
dimensions are enlarged. Mitral regurgitation occurs and the heart muscle becomes thin 
and floppy, with systolic dysfunction and eventual heart failure. There are many possible 
causes of DCM including hypertension, coronary artery disease, valvular disease, viral 
infections (e.g. cocsackie B virus), alcohol abuse, drugs (particularly some 
chemotherapies), hemochromatosis, sarcoidosis, amyloidosis, mitochondrial disorders, 
some inborn errors of metabolism and pregnancy (which may unmask a genetic type or 
be pregnancy related). Familial DCM requires the presence ofother family members with 
DCM or SCD less than 35 years (200). 
Like ARVC, there are descriptive criteria to diagnose DCM (15, 201) (200). The 
presence of an ejection fraction (the fracti'on of blood pumped out of a ventricle with each 
heart beat) less than 45%, or fractional shortening (FS) less than 25% where FS is defined 
as left ventricular end diastolic dian1eter (LVEDD) minus left ventricular end systolic 
diameter (L VESD) divided by L VEDD, and L VEDD > 117% indexed to height and 
weight (202, 203) makes the diagnosis. Like the alternate criteria determined for ARVC 
(142), it is recognised that relatives ofprobands with DCM may variably express disease, 
so major and minor criteria for assessment of familial DCM have been proposed (204, 
205). 
There are an ever increasing number of genetic causes of DCM. They include sarcomere 
genes, known to cause hypertrophic cardiomyopathy (HCM), and genes coding for 
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cytoskeletal proteins (206). To date, the only overlapping gene with mutations shown to 
cause both a DCM and ARVC phenotype is desmoplakin which is implicated in both 
autosomal recessive DCM (Carvajal syndrome) and ARVD9. 
1.6.2 Treatment of ARVC 
Disconnection of the right ventricular free wall (RVFW) 
Early treatment for ARVC involved surgical disconnection of the RV free wall (RVFW) 
from the LV, separating the electrical activity of the two lower heart chambers. 
Theoretically VT arising from the RV would then be restricted to the RV. The RV flow 
of blood was apparently maintained by ·the contraction of the right atrium and the 
movement of the septum towards the RVFW during LV contraction. This operation in 
humans was first done in the early 1980's (41), and a patient in this early publication 
(case 1) was a member of fan1ily ARl (Figure 8 page 79). This early paper reported 
positive postoperative recovery and hemodynamic function after 4 months of follow up. 
Multiple animal studies followed which showed that although the procedure worked, 
hemodynamic compromise often occurred because of a lack of contractility of the RV 
resulting in RV failure. Although a rare form of treatment now, it is occasionally still 
used, alongside adjunct therapy ofRV pacing to maintain RV contractility (207, 208). 
Antiarrhythmic drug therapy 
Antiarrhythmic drugs are placed into one of five classes based on the primary mechanism 
of their antiarrhythmic effect (209). This is a limited classification, as many agents have 
more than one primary mechanism and the metabolites of several drugs themselves have 
an antiarrhythmic effect which would place them in another class. The most common 
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antiarrhythmic drugs for ARVC are amiodorone and sotolol, (210-212) both class III 
agents acting primarily as potassium channel blockers prolonging the cardiac action 
potential. Amiodarone is the drug of choice for reducing the frequency of fatal 
arrhythmias. It has significant side effects, including hypothyroidism, liver problems 
(including jaundice and hepatitis), a bluish tinge to the skin (the 'smurf syndrome') and 
interstitial lung disease. Sotalol has additional beta blocking properties (slowing down the 
heart rhythm by acting upon the ~ adrenergic receptors in the heart). One of the most 
serious side effects to Sotolol is the proarrythmic response to the drug in some 
individuals. Procinamide (class la) which acts on sodium channels is occasionally used. 
Catheter ablation 
ARVC may be suitable for an ablation procedure: a decision most often made during an 
electrophysiological study (where catheters are introduced into the heart to map abnormal 
electrical circuits) (213). Ablation therapy destroys areas of re-entry in the myocardium 
that lead to VT by burning the foci of re-entry away. This is done via a catheter which 
burns away the foci, creating a myocardial scar disrupting the abnormal circuit. Typically 
this is reserved for either VT in a structurally normal heart or for a patient with frequent 
episodes refractory to drug therapy. It was treatment with a catheter ablation, and 
mapping of the myocardium in the 1970' s that first brought ARVC to the attention of 
French cardiologists (214). Ablation continues to be used in ARVC (215), and may be 
considered as a possible ICD alternative (216). 
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Implantable Cardioverter Defibrillator (lCD) 
Pharmacological treatment for serious arrhythmias has, since the 1990's, been supplanted 
by lCD therapy. The lCD is a battery-operated system that recognizes VT and VF and 
terminates them by synchronized counter shocks, thus preventing SCD. The ICD can also 
pace abnormal heart rhythms back to sinus rhythm. 
The first cardiac defibrillator was implanted in Seattle in 1980 (217), and until 1985 
(when the US Food and Drug Administration approved commercial devices), ICDs were 
limited to patients following cardiac arrest due to VF. The early implants were 
cumbersome, abdominally placed and had wires running through the diaphragm leading 
to external patches on the heart (218). In the 1990's ICDs evolved to incorporate pacing 
and Holter functions, and were placed pectorally (219). lCD sizes have decreased until 
now they are smaller than a pager. The recognition of major side effects following anti-
arrhythmic therapy (220) (221 ), and the randomized studies comparing anti-arrhythmic 
medication with the lCD has meant that the lCD is the standard of care for high-risk 
arrhythmia patients (222). The randomised trials included both primary (assessment of 
those at high risk of MI or death from cardiac compromise before the first Ml) (223, 224) 
and secondary (assessment of those given drug or lCD therapy following a previous Ml) 
(225-228) studies. lCD was also found to be effective in those at risk for SCD due to 
HCM (229). 
Rare problems occur with ICDs, including device failure issues, infections (230), surgical 
complications (231) and intractable numbers of shocks (232). Although usually 
discounted, the possibility that the lCD itself is pro-arrhythmic has been raised (233). The 
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mortality rate in the initial patients implanted (a very high-risk group) was 2% per annum 
(234). In the series studying HCM, the m01tality rate post lCD was 1% per annum (229). 
Few studies have assessed the efficacy of lCD therapy in ARVC (235) (236-238). In an 
Italian series (238), a heterogeneous group of 132 patients was described, but the absence 
of a control group restricted the conclusions. The same problem occurred with a more 
recent report on ICDs in ARVC, where frequency of shocks and survival was assessed 
(239). The most recent paper was descriptive and detailed 15 ARVC patients matched to 
patients with coronary artery disease, and again lacked a disease based control group 
(240). The efficacy ofiCD for ARVD5, utilising a control group is presented in chapter 4 
page 139. 
Genetics and ethics 
Genetic information burgeoned following the re-discovery of Mendel ' s laws of 
segregation in the early 20th century. Progress was fast, with the first human gene to be 
assigned to a locus occurring in 1911 (colour blindness on the X chromosome) (241 ). The 
determination of gene loci accelerated following the advent of recombinant DNA 
technology in the 1970's and over the last 40 years, thousands of human genes have been 
mapped and cloned9. Alongside the genetic information have been parallel ethical issues, 
exemplified in the early 20thcentury in the USA by the Cold Spring Harbour Eugenics 
Office mirrored by eugenics issues in Canada and Europe, culminating in the Nazi 
atrocities of WWII. Following WWII, the Nuremberg laws were enacted to protect 
research subjects, in all biomedical research (242). Our cunent ethical disquiet over 
9 
www.ncbi.nlm.nih.gov/sites/entrez?db=omim 
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genetics has its roots in the old eugenics horrors, and in the perceived tension between the 
needs of researchers and the clinical needs of individuals. 
As the scientific part of this thesis was being conducted, several ethical issues arose 
which reflect some of these historic situations. I present those in chapters 5 and 6, but do 
not provide in this introduction an exhaustive literature review of the subject matter. 
These chapters are added as additional information, tangential to the thrust of the thesis, 
but hopefully interesting and thought provoking. 
Thus the thesis is separated into seven chapters. Chapters one and seven are the broad 
introduction and conclusion for the body of work contained in the five middle chapters. It 
should be noted that the manuscript nature of this thesis means that each chapter contains 
its own introduction and discussion. 
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1.7 Co-AUTHORSHIP STATEMENT 
Design and identification of research proposal 
The design of the clinical and genetic epidemiology sections of the research proposal was 
by Kathy Hodgkinson, except for the gene discovery portion of chapter 2. 
Practical aspects of the research 
Kathy Hodgkinson collected all the clinical and genetic epidemiology data, and the 
majority of the blood samples for DNA analysis. The DNA analysis in chapter 2 was 
done by members ofTerry Young's laboratory. 
Data analysis 
The author analysed all the clinical epidemiology data. The molecular data in chapter 2 
was analysed by members of Terry Young' s laboratory. 
Manuscript preparation 
The clinical and genetic epidemiology sections of chapter 2 were authored by Kathy 
Hodgkinson. The molecular genetic sections were authored by Ten·y Young. 
Chapters 5 and 6 were co-authored with Daryl Pullman. 
Chapters 1, 3, 4, and 7 were authored by Kathy Hodgkinson 
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2 ARRHYTHMOGENIC RIGHT VENTRICULAR 
CARDIOMYOPATHY TYPE 5 (ARVDS) IS A FULLY 
PENETRANT, LETHAL ARRHYTHMIC DISORDER 
CAUSED BY AN AMINO ACID SUBSTITUTION IN THE 
NOVEL TMEM43 GENE 
"Each success only buys an admission ticket to a more difficult problem. " 
Henry Kissinger 
Nancy D. Merner,* Kathy A. Hodgkinson,* Annika F. M. Haywood, Sean Connors, 
Vanessa M. French, Jorg-Detlef Drenckhahn, Christine Kupprion, Kalina Ramadanova, 
Ludwig Thierfelder, William McKenna, Barry Gallagher, Lynn Morris-Larkin, Anne S. 
Bassett, Patrick S. Parfrey, Terry-Lynn Yoilllg. 
Equal Contribution: 
* These authors contributed equally to this body of work. Nancy Merner took the senior 
role for the molecular component, responsible to Dr. T-L Yoilllg, and Kathy Hodgkinson 
took the senior role for the clinical epidemiology component, responsible to Dr. P 
Parfrey. 
Published in The American Journal of Human Genetics 2008 Apr; 82(4):809-21. 
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2.1 ABSTRACT 
Autosomal dominant arrhythmogenic right ventricular cardiomyopathy/dysplasia 
(ARVC/D) causes sudden cardiac death and is characterized by clinical and genetic 
heterogeneity. Fifteen unrelated ARVC families with a disease associated haplotype on 
chromosome 3p (ARVD5) were ascertained from a genetically isolated population. 
Identification of key recombination events reduced the disease region to a 2.36 Mb 
interval containing 20 annotated genes. Bi-directional resequencing showed one rare 
variant in transmembrane protein 43 (TMEM43 1073 C>T, S358L), was carried on all 
recombinant ARVD5 ancestral haplotypes from affected subjects and not found in 
population controls. The mutation occurs in a highly conserved transmembrane domain 
ofTMEM43 and is predicted to be deleterious. Clinical outcomes in 257 affected and 151 
unaffected subjects were compared, and penetrance determined. We concluded that 
ARVC at locus ARVD5 is a lethal, fully penetrant, sex-influenced, morbid disorder. 
Median life expectancy was 41 years in affected males compared to 71 years in affected 
females (relative risk 6.8, 95% CI 1.3-1 0.9). Heart failure was a late manifestation in 
survivors. Although little is known about the function of the TMEM43 gene, it contains a 
response element for PPARy (an adipogenic transcription factor), which may explain the 
fibrofatty replacement of the myocardium, a characteristic pathological finding in ARVC. 
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2.2 INTRODUCTION 
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (AR VC/D [MIM 1 07970]) is 
an inherited disorder, often involving both ventricles, and is characterized by ventricular 
tachycardia (VT), heart failure, sudden cardiac death (SCD) and fibrofatty replacement of 
cardiomyocytes (151 ). It is usually inherited as an autosomal dominant disorder, although 
recessive forms exist (28). To date, eleven genetic loci have been mapped, and seven 
genes identified (60, 63, 74, 243, 244). Five genes code for desmosomal proteins 
(desmoplakin [MIM 125647], plakophilin-2 [MIM 602861] , desmoglein-2 [MIM 
125671], desmocollin-2 [MIM 125645] and plakoglobin [MIM 173325]) that are 
predicted to succumb to mechanical stress (74, 243). The remaining two genes are 
cardiac ryanadine receptor 2 (RYR2 [MIM 180902]) (36) and transforming growth 
factor beta-3 (TGF/33 [MIM 190230]) (33). 
Clinical diagnosis of ARVC is difficult as it relies on physiological and pathological 
testing for the presence of right ventricular structural and functional anomalies, fibrofatty 
replacement of the ventricular myocardium, premature ventricular contractions (PVC's) 
on Holter monitor, extended QRS, epsilon waves and T wave inversion on 12 lead ECG 
and late potentials on signal averaged ECG (SAECG) (25). Phenotypic variation of 
ARVC, in both presentation and clinical course, has led to a modification of the 
McKenna diagnostic criteria (25) to faci litate the identification of relatives at risk in 
ARVC families (142). ARVC can have both adverse (sudden death and heart failure) 
(245), and favourable outcomes (246), which may be due to genetic heterogeneity, 
although clearly mutations at different loci do not explain intrafamilial variation (247) or 
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the sex-influence towards greater clinical severity in males (167). There are no known 
studies to date that assess clinical features in mutation-negative subjects born at a-priori 
50% pedigree risk to determine mutation specific cardiac features: most studies assess 
small families to determine cardiac features, and gene specific (not mutation specific) 
penetrance (61 ). Ultimately, the determination of the penetrance of mutation specific 
clinical manifestations of ARVC will provide accurate, mutation specific, clinical 
information for appropriate genetic counselling and treatment options. 
The ARVD5 locus (MIM 604400) on 3p was mapped in an extended 8 generation family 
from the genetically isolated population of the island of Newfoundland, Canada ( 4). This 
fami ly was first identified in the 1980's (3) and at least one family relative participated in 
right ventricular disconnection studies, as a possible treatment for ARVC (41). We have 
identified 14 additional families with Newfoundland ancestry that share the ARVD5 
haplotype and have previously shown that the use of prophylactic treatment with 
implantable cardioverter defibrillator (lCD) therapy in relatives at risk of ARVC greatly 
improved survival (248). We report here that we have identified the ARVD5 disease gene 
and determined the mutation specific penetrance of its major clinical manifestations. 
2.3 MATERIALS AND METHODS 
2.3.1 Study population 
Fifteen of 150 apparently unrelated families referred either to the Newfoundland 
Provincial Medical Genetics Program, or the Newfoundland Labrador genetics 
cardiomyopathy clinic because of a fan1ily history of cardiomyopathy and sudden death 
were included int his study. These families were determined to have ARVC based on 
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clinical testing using established criteria (25), post mortem pathology (Figure 7 page 78) 
and an autosomal dominant pattern of inheritance (Figure 8 page 79). These families are 
characterized by deep genealogies, a Newfoundland ancestry and a disease associated 
haplotype originally identified in family ARl used to map ARVD5 (Figure 8 page 79). 
A total of 496 subjects born at a priori 50% risk (clinically affected and their first-degree 
relatives) were available for study across the 15 families (Figure 8 page 79). Subjects 
were determined to be clinically affected if they fulfilled the ARVC modified criteria 
(142). Blood samples from 295 subjects born at a priori 50% risk were collected and 
informed consent obtained in compliance with the Human Investigation Committee 
requirements of the Eastern Health Corporation of St. John's, Newfoundland, Canada 
(study number 00-176). 
B 
-
Paraffin-embedded post mortem right ventricular myocardium stained with masson trichrome showing 
fibrofatty replacement of myocytes from a male teenager following sudden cardiac death (left: 40x 
magnification) and a second degree relative with sudden cardiac death in his 8111 decade (right: 20x 
magnification). Pink = normal myocardium, blue = fibre, white = fat. 
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Figure 8: ARVC families linked to chromosome 3p 
Pedigrees of 15 autosomal dominant ARVC families linked to ARVD5. Affected subjects are shown as 
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Fine mapping of the ARVD5locus 
Mapping the ARVD5 locus in family ARl (Figure 7 page 78) previously defined a 9.3 eM 
disease region between markers D3S3610-D3S3659 (4). Eighteen polymorphic 
microsatellite markers were genotyped on clinically affected subjects across all families 
to identify a disease associated haplotype at 3p25 that was shared amongst families from 
this genetic isolate and presumed to be ancestral. We identified key recombination events 
on the ARVD5 ancestral haplotype and recombinations seen in two or more families were 
used to narrow the region. 
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Screening candidate ARVDS genes 
A mutation-screening panel was established that comprised seven genomic DNA samples 
from four clinically affected subjects from three families (AR1 , AR8, AR15; Figure 8 
page 79) and three spouses (controls). All coding and non-coding exons and intron-exon 
boundaries of positional candidate genes for ARVD5 were sequenced. All sequences were 
amplified by polymerase-chain reaction (PCR) assay from genomic DNA in 25 f .. d 
reaction volume. Primer sequences are available from the authors on request. The PCR 
products were purified using 50% sephacryl (Amersham Biosciences) and MultiScreen 
HTS filter plates (Millipore Corporation). Purified PCR products were cycle sequenced in 
both forward and reverse directions with the use of BigDye Terminator V3.1 cycle 
sequencing kit on an automated ABI 3700 DNA analyzer (Applied Biosystems). 
Sequencing electropherograms were inspected manually and analyzed with Mutation 
Surveyor software (Transition Technologies). Sequencing variants found exclusively in 
clinically affected subjects on the mutation-screening panel were experimentally 
determined to reside on the ARVD5 haplotype by segregation analysis in family AR14 
(Figure 8 page 79). The allele frequencies of the ARVD5 sequencing variants were 
determined using Newfoundland population-based controls obtained through random 
phone dialling, as part of a large colorectal cancer study (249). Newfoundland is a known 
genetic isolate where 98% of its residents are of English and Irish descent (250, 251 ). 
Key recombinant families (AR2 and ARl 0) were analyzed to determine which rare 
variants ( <1% of the alleles screened) were retained on recombinant ancestral haplotypes 
in clinically affected subjects. 
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Expression of TMEM43 in myocardium and lymphocytes of clinically affected 
subjects 
Total RNA was extracted from Epstein Barr virus (EBV) transformed B lymphocytes 
from two affected subjects and one unaffected control and cardiac tissue from one 
affected subject and an unrelated control using Trizol (Invitrogen) followed by DNase l 
treatment (Ambion). Complementary synthesis was performed and analyzed by both size 
fractionation and direct sequencing with over-lapping primers designed to cover the 
complete coding sequence of TMEM43. 
Bioinformatic Analysis 
Conservation of the TMEM43 protein across species was determined using ClustalW and 
Weblogo (252-254). Potential protein localization, function, structure and post-
translational modification sites were predicted using the online tools via the ExP ASy web 
site (254). The effects of amino acid substitutions on protein function were predicted 
(255-259). 
Clinical assessment of affected vs. unaffected subjects 
Clinical data were prospectively collected over eleven years. This involved annual visits 
by subjects to the genetics cardiomyopathy clinic where 12 lead ECGs, Holter monitors, 
MRI's, signal averaged ECG's and echocardiograms were done. All cardiac anomalies 
were noted following clinical testing. Clinical data were also obtained retrospectively 
from medical records including 'at risk' relatives not seen in clinic and autopsy results. 
Subjects were categorized as affected, unaffected or unknown (Figure 9 page 83). Only 
subjects from well ascertained sibships (where disease status was known in 2:50% of 
siblings) were included in this study. 
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Anomalies on 12 lead ECGs were determined by two physicians blind to disease status. 
Left ventricular enlargement (LYE) was defined as ~2 standard deviations (SD) above a 
predicted mean: left ventricular end diastolic diameter (LVEDD)> 112% (>2SD) (202). 
Late potentials on SAECG were classified based on recognized criteria: QRS (filtered 
QRS duration)> 114 ms, LAS (low amplitude signals)>38 ms, and RMS (root mean 
square voltage of the terminal 40ms of filtered QRS)<20 ms (260). The presence of 
arrhythmias in the form of PVCs was determined from Holter monitor analysis. Heart 
failure was classified according to the New York Heart Association (NYHA) Functional 
Classification (261). Subjects were identified with heart failure (NYHA categories 1-4) if 
they presented prospectively in the study with heart failure, or it was documented in a 
medical record. Date of death was confirmed via autopsy records and archival records. 
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Figure 9: Workflow and mutation status of subjects born at a priori 50% risk of ARVC. 
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Penetrance is defined as the proportion of subjects with a specified genotype known to 
cause a disease who have any signs or symptoms of the disease (262). To determine the 
disease penetrance of ARVC at ARVD5, a subset of disease features based on the ARVC 
modified diagnostic criteria (142) were assessed from the first available clinical test result 
to show an anomaly to determine which clinical features truly segregated with affection 
status in this population. A Kaplan Meier analysis was then done using a subset of 
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subjects alive at the start of the prospective study (1996), who had an available medical 
record, and who were either mutation positive or an obligate carrier (60 males and 77 
females). Based on the analysis of prevalent disease features, a male subject was 
considered 'penetrant' at the age when any one of the following clinical events occurred: 
(i) SCD (ii) VT on clinical testing (iii) heart failure (iv) >200 PVC' s in a 24 hour period 
(v) LVE>2SD (vi) QRS>110 ms on 12 lead ECG or (vii) any late potential on SAECG 
(142). Female subjects were considered penetrant for all these features apart from 
QRS> llO ms on 12lead ECG, and any late potential on SAECG. We also determined the 
penetrance of two major morbid outcomes of the disease, death and heart failure, using 
both the prospective and retrospective data set (n=257, 148 males, 109 females). 
Cardiac tests were not available in all subjects at a priori 50% risk, mainly due to SCD as 
a presenting feature for many family members. For example, of 114 affected subjects 
who did not have an available echocardiogram, 86 were deceased (75%) whereas only 2 
were dead in 50 unaffected subjects with no echocardiogram. Testing is in progress in 
this latter group. 
Statistical Analysis 
Comparisons between affected versus unaffected subjects were calculated by the Kaplan 
Meier product limit method with censoring occurring at the time ofiCD therapy, heart 
transplantation or last follow-up (defined as the age at the last clinic visit). Relative risk 
was calculated using Cox's Regression model. A p-value of <0.05 was considered 
significant (SPSS software, version 14, Chicago USA). Documentation of the statistical 
methods utilised throughout this thesis are described in detail in Appendix C page 284. 
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2.4 RESULTS 
Fine mapping and mutation screening/gene sequencing 
Comparison of the ARVD5 ancestral haplotypes at 3p25 across clinically affected 
subjects identified key recombinations and reduced the disease region to a 2.36 Mb 
interval containing 20 annotated genes (Figure 10 page 86, Table 6 page 89). Bi-
directional resequencing of the 20 physical candidate ARVD5 genes revealed 240 variants 
(Table 6 page 89). Nineteen variants were found exclusively in clinically affected 
subjects on the mutation screening panel and 11 were determined to reside on the ARVD5 
ancestral haplotype through segregation analysis in AR14 (Table 7 page 90, Figure 11 
page 87). Screening of population controls showed that five of these variants were rare 
(<1% ofthe alleles screened; Table 7 page 90). Only one ofthe five, TMEM43 1073 C>T 
(S358L) (Figure 13 page 91 D), was shared by all clinically affected subjects across the 
15 families, and was retained on key recombinant ARVD5 haplotypes identified in 
clinically affected subjects from families AR1 0 (Figure 12 page 88) and AR2 (data not 
shown). This suggested that TMEM43 is ARVD5. Additional supportive evidence 
included clinically unaffected adult subjects who shared distal sections of the ARVD5 
haplotype and lacked the TMEM43 mutation (e.g. Figure 11 page 87). All available 
spouses (n= 47) and population controls (n= 161) were negative for the TMEM43 
mutation (416 mutation negative chromosomes). 
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Panel A: Summary recombinant ARVD5 haplotypes identified across the 15 ARVC 
families using microsatellite markers (alleles are either numbered (1-9) or given in base 
pairs). 
Panel B: The physical map of the ARVD5 critical region. Physical distances were 
captured from the March 2006 freeze of the UCSC Genome Browser. Arrows show the 
direction of transcription of each annotated gene. 
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Figure 11: Segregation analysis in sub pedigree AR 14 
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Of the 19 variants found exclusively in clinically affected subjects on the mutation screening 
panel, only 11 were found to reside on the ARVD5 ancestral haplotype (yellow) through 
segregation analysis of clinically affected subjects (Global ill's 709, 710, and 71 2). Note that a 
clinically unaffected subject (Global ill 708) inherited a recombinant AR VD5 haplotype from her 
clinically affected mother that lacks TMEM43. Alleles in brackets have been inferred. 
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Figure 12: Segregation analysis in sub pedigree ARlO 
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Clinically affected subjects (Global ID 794 and 796) only have one of the five rare 
variants due to a historical recombination event on the ARVD5 haplotype (yellow). 
Alleles in brackets have been inferred. 
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Table 6: The 20 physical candidate genes for ARVD5 
Genes Accession Number MIM Strand Genomic Position Exons 
number Start End 
IQSECJ NM 014869 610166 - 13003536 12917079 13 
NUP2 10 NM 024923 607703 - 13436809 13332737 40 
HDAC JJ NM 024827 607226 + 13496824 13521834 10 
FBLN2 NM 001004019 13582 1 + 13565625 13654922 18 
WNT7A NM 004625 60 1570 - 13896619 13835083 4 
TPRXL AK092426 6111 67 + 13953902 14082480 3 
CHCHD4 NM 144636 611077 - 1414 1323 141 28584 4 
TMEM43 NM 024334 na + 14141546 14160180 12 
XPC NM 004628 278720 - 14195143 14161651 16 
-
LSM3 NM 014463 607283 + 14195341 14214840 4 
SLC6A6 NM 003043 186854 + 14419110 14503973 15 
GRIP2 NM 00 I 080423 na - 14558592 14510177 25 
-
C3orf/9 NM 016474 na + 14668278 14689167 I I 
C3orj20 NM 032137 na + 14691658 14789544 17 
FGD5 NM 152536 na + 14835810 14950899 20 
NR2C2 NM 003298 601426 + 14964240 15065782 15 
MRPS25 NM 022497 na - 1508 1820 15065024 4 
ZFYV£20 NM 022340 6095 11 - 151 15659 15086584 14 
CAPN7 NM 014296 606400 + 15222737 15269426 21 
SH3BP5 NM 004844 6056 12 - 15349108 15271250 9 
Total 275 
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Table 7 Sequencing variants identified exclusively in clinically affected subjects 
Gene Accession Variant Nomenclature Classification Allele Frequency Name number (#of chromosomes) 
!-/DAC/1 NM 024827 c.369+ 18 369+ 19insG Non-coding nd nd 
TMEM43 NM 024334 c.I073C>T Missense (S>L) 0 I 322 0.00%* 
TMEM43 NM 024334 c. l203+ I 15T>C Non-coding nd nd 
XPC NM 004628 c.2823+684G>C Non-coding nd nd 
SLC6A6 NM 003043 c.I -27420G>A Non-coding nd nd 
SLC6A6 NM 003043 c.S99+370A>G Non-coding dbSNP 46.00% 
SLC6A6 NM_003043 c. 733-1226A>G Non-coding so 190 SS.60% 
FGD5 NM IS2S36 c.934G>A Missense (V>M) 2 I 318 0.60%* 
FGD5 NM 152536 c.2186+22G>A Non-coding nd nd 
FGD5 NM 152536 c.2187-82G>A Non-coding nd nd 
FGD5 NM 152536 c.2220G>T Synonymous (L>L) nd nd 
FGD5 NM 152536 c.2613+50C>T Non-coding nd nd 
FGD5 NM_ IS2S36 c.308S-7 4G> A Non-coding IS I 166 9.00% 
NR2C2 NM 003298 c.8SS+70G>A Non-coding 8 I 88 9.10% 
NR2C2 NM_003298 c.l848+ 36ST> A Non-coding 16 I 90 17.80% 
NR2C2 NM_003298 c.1848+ 296S _1848+ Non-coding 23 I 126 18.30% 2966insGA T A 
MRPS25 NM_022497 c.S22+ I OS9G> A Non-coding 0 I 138 0.00%* 
CAPN7 NM 014296 c.l289+68C> T Non-coding I I 162 0.01%* 
CAPN7 NM 014296 c.I430-28T>C Non-coding 0 I 160 0.00%* 
Eleven of the 19 variants were determined to be in phase on the ARVD5 ancestral 
haplotype and were subsequently sequenced on population controls (bold). The allele 
frequency of variants previously reported in the NCBI dbSNP was used. Rare variants 
( <1% of the alleles screened) are marked with an *. 
ARVC at locus ARVDS is caused by a missense mutation in TMEM43 
The longest isoform of transmembrane protein 43 (TMEM43, Genbank Accession 
number NM_024334) has 12 exons (Figure 13 A page 91) predicting a 400 amino acid 
protein that is 98% similar to the mouse protein (Figure 14 page 92). This conserved gene 
is found across all eukaryotic and prokaryotic species (Figure 14 page 92). We were able 
to extract full-length TMEM43 eDNA from white blood cells and cardiac tissue from 
both patients and controls, demonstrating that TMEM43 is expressed in both blood and 
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cardiac tissue and that the TMEM43 1073 C>T (S358L) mutation does not appear to 
affect splicing (Figure 13 B, C and E page 91 ). 




c Genomic sequence E eDNA sequence 




1 1---~-.~--~~~~--~---~ v ________ , ___ s~•--------~.--
FOtWard ~nomic Mforenca sequtnct F orword eDNA roferenet uqu nee 
::>l :lS :30 li &IS ..,;.. .:.-.---;;;-::-----; 
I 11.: c c • ( ( c 0 c I 0 ~ c ( ( ~ 1\3. t A • 'vC... .' j 
' J ~rJ\ · /\[\ '\t ~\f f\J\./\1 L.x:.r!'-. .U ~--~~..L...--~ 
. Focwarl! genomic sample (Afl13} seguenct Forward eDNA umplt (AR13) sequence 
~--;:;;<""""".........,,....., 
Panel A: Gene structure ofTMEM43. Exons are represented by boxes. Translated exons 
are solid green and un-translated exons are clear. Introns are represented by green lines. 
Panel B: Coverage of primers designed to amplify eDNA showing position ofPCR 
primer pairs: Exons 1-4 (purple), Exons 4-9 (red), Exons 9-12 (green); Exons 1-10 (blue) 
5-12 (yellow). 
Panel C: PCR products amplified from eDNA ofEBV transfected B cells of affected 
subjects from the mutation screening panel (affected ARl and affected AR15) and 
unaffected (control) subjects. eDNA of heart tissue from both the left and right ventricle 
of an affected subject (AR13) and a heart biopsy from a control subject were size 
fractionated by electrophoresis. 
Panel D and E: Forward and reverse sequencing traces showing the TMEM43 1073 C>T 
mutation of an affected subject's (AR13) genomic and eDNA. The amino acid 
translations (top) shows the S358L amino acid substitution. 
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Panel A: Clustal W align was used to align orthologues from Homo sapiens 
(NP _077310), Pan troglodytes (XP _516299), Canisfamiliaris (XP _541751), Mus 
musculus (NP _083042), Gallus gallus (XP _ 414378), Zenopus tropicalis 
(UP10004D5297), Tetraodon nigroviridis (Q4RXL8), Drosophila melanogaster 
(NP _64162) and Rhizobium loti (Q98HF3) (253). The blue box outlines the DUF1625 
domain and the black boxes outline predicted transmembrane domains. Completely 
conserved residues are red, strongly similar residues are green and weakly similar 
residues are blue. The S358L mutation is marked by a yellow arrow. 
Panel B: The web logo format was used to align eukaryotic species. The third 
transmembrane domain is outlined (black box). The S358L mutation is marked by a 
yellow arrow. 
Page 92 of 292 
Bioinformatic analysis of TMEM43 predicts it to be a cytoplasmic membrane protein 
with several potential post-translation modification sites (Figure 15 page 94). Unlike the 
transmembrane proteins of the desmosome (desmocollin and desmoglein), TMEM43 
does not have a cadherin domain. Furthermore protein sequence alignments with 
desmocollin and desmoglein show less than 10% identity and less than 12% similarity 
(254). The mutation, S358L, occurs within the third predicted transmembrane domain 
and is highly conserved in mammalian, avian, amphibian, and insect orthologs (Figure 14 
page 92, Figure 15 page 94). Interestingly, a leucine at this position is found in the 
bacterium Rhizobium loti but it is not found in any multicellular organisms (Figure 14 
page 92). The S358L mutation is predicted to be deleterious (Table 8 page 93) but little is 
known about the function of TMEM43 protein. 
Table 8: Prediction of the TMEM43 1073 C>T (S358L) mutation effect. 
SIFT Panther SNPs3D PMut 
deleterious de leterious deleterious de leterious 
Five different bioinformatic programs were used to predict the effect of the S358L 
mutation. Note that sequence homology used by the PolyPhen analyses was calculated 
with alignments of orthologs from Eukaryota and bacteria. 
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Figure 15: Predicted topography ofthe TMEM43 protein 
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Indicated are transmembrane domains (beige), phosphorylation sites (green), a 
transactivation domain (red), YingOYang sites (orange), a SUMO attachment site 
(purple), and an 0-glycosylation site (blue open). The extracellular and cytoplasmic 
regions may be reversed: there is evidence supporting either orientation. 
TMEM43 mutation screening in ARVD5linked families 
We sequenced genomic DNA from all available subjects born at a priori 50% risk 
(n=295) across the 15 ARVC families for the presence of the 1073 C>T TMEM43 
mutation. All clinically affected subjects (n=83/83, 40 males, 43 females) and 28.8% of 
clinically unaffected subjects (n=61/212, 18 males, 43 females) were mutation carriers 
(Figure 9 page 83). Interestingly, 57% (35/61) of unaffected mutation carriers were found 
on subsequent testing to have clinical signs of ARVC. These included ectopy on Holter 
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monitor (2: 200 PVC's over 24 hours (142)), extended QRS on 12 lead ECG or SAECG 
(25), or an enlarged left ventricle (>2SD above the mean). The remaining 26 clinically 
unaffected mutation carriers (3 males, 23 females) were at a median age of 22 years, and 
33 years respectively. The 151 subjects with no clinical signs who did not have the 
TMEM43 variant were considered unaffected (Figure 9 page 83). 
2.4.1 Clinical assessment of penetrance in ARVDS 
12lead ECG 
Data on a total of297 subjects (167 affected, 130 unaffected) that had at least one 12 lead 
surface ECG was available. Extended QRS> 110 ms was significantly different between 
affected vs. unaffected males (Table 9 page 97). Epsilon waves and T wave inversion 
commonly seen in ARVC (25) were seen in less than 3% of affected subjects in this 
cohort. 
Holter Monitor 
Of the 239 subjects (146 affected, 93 unaffected) with at least one Holter Monitor report, 
the most prevalent feature was PVC's 2: 200 and the presence of at least one run of non 
sustained VT (Table 9 page 97), both significantly more common in affected than 
unaffected subjects. 
Echocardiography 
Of the 244 subjects (143 affected, 101 unaffected) that had at least one 2D 
echocardiogram available for analysis, the most prevalent feature was L VE based on 
LVEDD (Table 9 page 97) (202, 203), and was significantly different between affected 
and unaffected subjects. 
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SAECG 
Of the 198 subjects (97 affected, 101 unaffected) who had at least one SAECG available 
for analysis, all late potentials were significantly more common in affected versus 
unaffected males, although not in females (Table 9 page 97). 
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Table 9: Prevalent cardiac features on first clinical test 
12 lead ECG, Holter, Echocardiographic and SAECG manifestations used in penetrance 
I b' fi 15 f: T . h ARVC d . TMEM43 analysts m su >Jects rom am1 tes wit ue to a mutatiOn m 
121ead ECG 
Affected Unaffected 
Male Female Tot. Male Female Tot. ·l ·l 
N 78 89 167 64 66 130 
Mean Age 30 37.7 33.1 38.2 Affected Affected Males vs Females vs 
SD 12.1 15.8 16 13.2 Unaffected Unaffected 
% % N % % N Males Females n n (%) n n (%) 
QRS> 25 3 8 9 33 4 6 2 3 6 p~O.OOI p~0.2ns 110 ms 2 (I 9.8) (4.6) 
Holter Monitor 
Affected Unaffected 
Sex Male Female Total Male Female Tot. l l 
N 67 79 146 49 44 93 
Mean Age 31.1 37.7 33.1 38.2 Affected Affected Males vs Females vs 
SD 13.3 15.5 15.9 12.8 Unaffected Unaffected 
OJo % N % % N Males Females n n (%) n n (%) 
PVCs 47 7 47 5 94 0 0 I 2.3 1.0 p<O.OOI p<O.OOI 
>200/24 h 0 9 (64.4) 
~ I run ns 13 I 18 2 31 0 0 0 0.0 0.0 p<O.Ot p<O.OOI VT 9 3 (2 1.2) 
Echocardiograph 
Affected Unaffected 
Sex Male Female Tot. Male Female Tot. l -/ 
N 67 76 143 50 51 101 
Mean Age 31.58 39.61 32.46 38.27 Affected Affected Males vs Females vs 
SD 13.15 15.14 14.91 .13.28 Unaffected Unaffected 
% 0/o N % 0/o N Males Females n n (%) n n (%) 
LVE>2SD 35 5 27 2 62 10 2 4 8 14 p<O.OOI p<O.OOI 2 0 (43.3) 0 (13.9) 
SAECG manifestations 
Affected Unaffected 
Sex Male Female Tot. Male Female Tot. ·l X2 
N 32 65 97 50 51 101 
Mean Age 30.91 39.83 36.74 38.86 Affected Affected Males vs Females vs 
SD 14.54 14.49 16.25 10.99 Unaffected Unaffected 
% % N % % N Males Females n n (%) n n (%) 
QRS>II4 19 5 19 2 38 10 2 2 4 12 p~ 0.001 p<0.1 ns 
ms 9 9 (39.2) 0 (I 1.9) 
RMS<20 15 4 18 2 33 12 2 9 18 21 p~0.05 p< I.O ns 
ms 7 8 (34) 4 (20.8) 
LAS>38 17 5 2 1 3 38 14 2 13 25 27 p~0.025 p< l.O ns 
ms 3 2 (39.2) 8 (26.7) 
PVC: premature ventncular complex, VT: Ventncular tachycardia, LVE: Left ventncular enlargement mdexed to he1ght and we1ght, 
RMS: root mean square voltage of the terminal 40millisecond of filtered QRS, LAS: low amplitude s ignals. 
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ARVC penetrance 
One hundred and thirty seven subjects (60 affected males, 77 affected females) were used 
to determine penetrance. Median age to develop an ARVD5 associated phenotype was 32 
years (95% CI 28-35) for males and 44 years (95% CI 39-48) for females, with 100% of 
males and females penetrant by 63 and 76 years respectively (Figure 16 page 99). Males 
were twice as likely to reveal the disease phenotype than females (RR 2, 99% CI 1.2-3.3) 
(p:S0.0001). The commonest clinical features for which subjects were initially penetrant 
were ectopy (44%), and LYE (27%), then VT (9%), QRS>110 ms (9%), late potentials 
on SAECG (7%), SCD (2%) and heart failure (2%). 
Heart Failure 
Fourteen of 89 affected males developed heart failure at a median age of 63 years (95% 
CI 4I-84 years) compared with no unaffected males (p:SO.OOO 1, log rank) (Figure 17 A I 
page I 00). One unaffected female at age 79 developed heart failure compared to seven 
affected females (median age 73 years, 95% CI 69-77 years) (p:S0.001 , log rank) (Figure 
17 A2 page 1 00). Affected males were three times more likely to develop heart failure 
than females (RR 3.4, 95% CI 1.36-8.57, p:S0.009) (Figure 17 A3 page 1 00). 
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Panel A: Cumulative proportion by age at which male (n=60) and female (n=77) 
mutation positive affected subjects manifested a first clinical sign of ARVC. Subjects 
were censored at last follow-up. 
Panel B: Cumulative percentage of subjects penetrant by decade. 
1:1-20 21-30 31-40 41-50 51-60 61-70 71-80 
13 39 68 89 96 100 100 
Females 3 18 38 67 80 97 100 
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Figure 17: Time to event analysis of heart failure and death in affected subjects 
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Panels Al-3: Cumulative incidence of heart fai lure: Al) Affected males (n=89, dark 
blue) compared to unaffected males (n=71 , light blue) (p:SO.OOO 1: log rank), A2) Affected 
females (n=87, dark pink) compared to unaffected females (n=68, light pink) (p:SO.OOl , 
log rank), A3) Affected males (dark blue) vs. affected females (dark pink). 
Panels Bl-3: Life expectancy: Bl) Time to death in affected males (n= l48, dark blue) 
and unaffected males (n=77, light blue), B2) Time to death in affected females (n= l 09, 
dark pink) and unaffected (n=74, light pink), B3) Affected males (dark blue) vs. affected 
females (dark pink). 
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Life expectancy 
In affected subjects (n=257) there were 123 (48%) deaths (99 males and 24 females). 
Sudden cardiac death occurred in 86% (86/99) of the males and 42% (1 0/24) of the 
females. Survival was significantly reduced in affected versus unaffected subjects. 
Median survival was 41 compared to 83 years (p:SO.OOO 1, log rank) in affected vs. 
unaffected males (Figure 17 B 1 page 1 00) and 71 compared to 83 years in affected vs. 
unaffected females (p :::;0.002, log rank) (Figure 17 B2 page I 00). The relative risk of 
dying was 6.8 times higher in affected males versus affected females (95% C.I: 4.3- 10.9, 
p:SO.OOOI) (Figure 17 B3 page 100). 
2.5 DISCUSSION 
Mutations in desmosomal genes underlie several genetic subtypes of ARVC, suggesting 
that ARVC is primarily a disease of the desmosome (74, 243). We used a positional 
mapping approach and 15 ARVC families that shared a disease associated haplotype on 
3p from a genetic isolate to identify ARVD5. All clinically affected subjects that were 
screened for the TMEM43 1073 C>T mutation (n=83) were mutation carriers. This 
mutation was not detected in spouses or population controls. The TMEM43 gene is 
expressed in cardiac tissue, is evolutionarily conserved and the amino acid substitution is 
predicted to be deleterious. 
Recently, signalling pathways have been implicated in ARVC pathogenesis (74, 263). 
For example, plakoglobin, when freed from desmosomal complexes, translocates to the 
nucleus where it competes and opposes the action of P-catenin and down regulates the 
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canonical Wnt/P-catenin signaling pathway (263). Suppression of the canonical Wnt/P-
catenin signaling up regulates two adipogenic transcription factors, C/EBP-a. (MIM 
116897) and PPARy (MIM 601487) (263). A genome wide scan for peroxisome 
proliferator response elements (PPREs) identified 1085 potential target genes of PPARy, 
including TMEM43 (264). If TMEM43 is a part of an adipogenic pathway regulated by 
PPARy, then perhaps dysregulation of this pathway may explain the fibrofatty 
replacement of the myocardium in ARVC patients. 
Studies that assess the ARVC phenotype in patients with mutations in plakophilin-2 
(265), desmoglein-2 (61) and plakoglobin (28) typically evaluate clinical features in 
mutation caniers only. The assumption is that all cardiac signs present in affected 
subjects are due to the underlying genetic defect. However, it may be that some signs are 
due to the genetic background of either the family or the source population. The size of 
the ARVC cohort in this study provides an opportunity to compare and define ARVC-
specific clinical features in affected and unaffected subjects. 
Using the benefit of a control group, we evaluated modified clinical criteria (142) in 
affected versus unaffected subjects. We included LYE, a clinical feature noted in other 
ARVC studies, (132, 135, 140, 266, 267) and prevalent in this cohort. For all clinical 
features examined, a significant difference was found between affected versus unaffected 
males. Females were significantly different for all features with the exception of late 
potentials on SAECG and a QRS> l10 ms on 12lead ECG. 
For the penetrance study, we followed subjects who were alive at the start of the study 
(1996), who had a medical record and had a genetic diagnosis (mutation caniers or 
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obligate carriers). The results showed that ARVC was fully penetrant in males by the age 
of 63 and in females by the age. of 76; ectopy and LVE were often the first presenting 
features, and few presented with death or heart failure. Therefore, in order to assess the 
penetrance of heart failure and death, we used all affected subjects. Heart failure and 
death were morbid outcomes at early ages in both males and females, with far more 
serious early events in males. In both sexes heart failure occurs as a later manifestation in 
subjects who did not succumb to SCD. These major manifestations define ARVC, due to 
the TMEM43 mutation, as a lethal, fully penetrant, sex-influenced, autosomal dominant 
disorder. 
Biases exist in studies that use both retrospective and prospective data; the use of well 
ascertained sibships may mitigate some of these. Although formal assessment of right 
ventricular structure is not available for the majority of subjects in this cohort, the 
cardiomyopathy fulfills diagnostic criteria for ARVC (142), it has been historically 
diagnosed as ARVC (4, 41) and fibrofatty replacement of the myocardium is present. The 
involvement of the left ventricle in this cohort supports the recent call to place ARVC 
within a group called 'arrhythmic cardiomyopathies,' which would take into account 
various presentations of disease (268). These findings may not be applicable to other 
fom1s of inherited ARVC. However, it is likely that mutations in TMEM43 are present in 
other populations. Issues of classification in the cardiomyopathies in general will be 
solved by their underlying genetic etiology, thus disease specific genotype/phenotype 
information will become the most useful and relevant. 
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This study has the advantage of having access to past medical records and extensive 
genealogical data, and a single cardiac care team followed all subjects. Clinical signs due 
to the genetic background of either the family or the source population were controlled 
for by the use of unaffected subjects from well ascertained sibships. This genetic subtype 
does not show the typical ARVC ECG findings ofT wave inversion or epsilon waves 
(25). A direct benefit of this process therefore has been the provision of accurate 
mutation specific clinical data for precise genetic counselling and follow-up of those at-
risk (248). 
We have identified the gene that causes ARVC at locus ARVD5. A missense mutation in 
TMEM43 causes a fully penetrant, sex-influenced lethal form of ARVC. Although little is 
known about the function of this gene, it encodes a transmembrane protein that could be a 
target of PPARy, which may explain the fibrofatty replacement of the myocardium in 
ARVC patients. Future directions include ·functional studies ofthe TMEM43 protein. 
Web Resources 
UCSC Genome Browser (http://genome.ucsc.eduD 
Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/Omim) 
NCBI dbSNP (http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp&cmd=search&term=) 
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3.1 ABSTRACT 
Objective 
To determine the phenotype and natural history of arrhytlunogenic right ventricular 
cardiomyopathy (ARVC) caused by a 1073 C>T mutation in TMEM43 (ARVDS). 
Background 
The phenotype and natural history of ARVC caused by a mutation in TMEM43 have not 
been described. 
Methods 
We studied the age of onset of cardiac symptoms, clinical events and test abnormalities in 
412 subjects from 15 families. Subjects were considered positive (n=258) if they had the 
TMEM3 mutation, were an obligate carrier, or major clinical sequalea occurred before 
age 50 years. We compared their outcomes to mutation negative relatives (n= l54). 
Results 
All cardiac symptoms and outcomes occurred in positive males significantly earlier, and 
more often than negative males. Positive males were hospitalised four times more often 
than positive fema les and died at a younger age (p:S0.001). The temporal sequence from 
symptoms to death was prolonged in females by 1-2 decades. The most prevalent ECG 
manifestation was poor R wave progression (PR WP) with positive males twice as likely 
to develop PRWP as positive females (p:S 0.05). Forty three percent of positive subjects 
had left ventricular enlargement, with 11% fulfilling criteria for dilated cardiomyopathy. 
The most sensitive test for diagnosis of ARVC was Holter monitoring. 
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Conclusions 
Cardiac symptoms occurred at a young age in ARVC males with a TMEM43 mutation, in 
whom onset of symptoms was often closely followed by death. Heart failure was a later 
manifestation of ARVC in survivors. The ARVD5 genetic subtype of ARVC is both an 
arrhythmogenic and a cardiomyopathic disease. 
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3.2 INTRODUCTION 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a recognised cause of 
sudden cardiac death (SCD) in young people (105), making early diagnosis for 
prophylactic treatment critical. Clinical diagnosis of ARVC is based on a combination of 
electrophysiological, structural and functional abnormalities (25). Multiple genetic causes 
of ARVC have been described (269). Variable expressivity (gene carriers manifest 
different phenotypes), reduced penetrance (some gene carriers show no signs of disease) 
and difficulty imaging the right ventricle make diagnosis problematic. It is likely a 
disease of both ventricles, as left ventricular involvement is common in ARVC (61 , 132, 
134, 135, 138-140, 194, 266, 267, 270, 271)and clinical overlap is increasingly 
recognised (141, 142, 272-275). 
The latest gene to be found as a cause of autosomal dominant ARVC is TMEM43, a 
transmembrane protein of unknown function (46). A missense TMEM43 1073 C>T 
mutation (S358L) is causative in Newfoundland families with ARVD5. In subjects born 
at a priori 50% risk of inheriting ARVC, the identification of the mutation, 
comprehensive analysis of the pedigree and the documentation of the early onset of 
severe cardiac events has allowed us to determine clinically affected and/or mutation 
positive subjects with ARVC and mutation negative subjects who do not have the 
TMEM43 mutation. To ease this accurate (cumbersome) terminology, we will refer to 
these groups in this manuscript as 'positive' and ' negative' respectively. The ability to 
define mutation carriers has allowed for presymptomatic diagnosis of ARVC, and the 
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recognition of the negative subjects has allowed us to determine the natural history and 
the true phenotype by utilising an in-built control group. 
Most studies of the natural history of ARVC have involved small heterogeneous samples 
where variable clinical presentation, family history, causes of death and rates of death are 
described (167-169). Corrado et al defined the natural history as having four discrete 
stages (156). An Italian study of 37 families, ten of whom had an assigned genetic locus, 
found similar variable expression but they did not report clinical symptoms, nor 
differentiate subjects according to locus (170). 
We have previously reported that ARVD5 is a lethal disease, particularly in males who 
often die suddenly at a young age, that survival is improved with implantable cardioverter 
defibrillator (lCD) therapy (248), and that the disease appears to be 100% penetrant for 
known disease clinical manifestations by age 70 years in males and 80 years in females 
(46). In the current study, we obtained comprehensive clinical data from medical charts 
and interviews, assessed the prevalence and incidence of symptoms and clinical events 
and analysed serial electrocardiogran1s (ECG), echocardiograms, Holter monitors and 
signal averaged ECGS (SAECGs). We compared the prevalence and incidence of clinical 
manifestations in positive and negative subjects from 15 families segregating ARVD5, 
and assessed the diagnostic utility of symptoms and clinical tests. 
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3.3 METHODS 
3.3.1 Study population 
Of 150 families with a history of SCD and/or cardiomyopathy referred to the provincial 
medical genetics program in Newfoundland and Labrador, 15 were found to have a 
disease associated haplotype at the ARVD5 locus at 3p25 (248) (OMIM: 
http://www.ncbi.nlm.nih.gov/omirnl) and subsequently shown to have a missense 1073 
C>T mutation (S358L) in TMEM43 (46). Cardiac disease in these large families was 
characterized by autosomal dominant (AD) inheritance, a single causative mutation and 
cardiac pathology consistent with ARVC. We first identified all individuals born at a 
50% a priori risk of ARVC as potential subjects for the study. Subjects in these families 
were identified as positive if they met one or more of the following criteria: 1) they had 
the TMEM43 1073 C>T mutation 2) they were an obligate carrier (that is, they had an 
affected first degree ancestor and descendant in the pedigree), 3) SCD occurred under age 
50 years or 4) they were resuscitated for ventricular tachycardia (VT) or fibrillation (VF) 
under age 50 years. Subjects were defined as negative if they were proven not to have the 
TMEM43 1073 C>T mutation. All remaining subjects were considered to have unknown 
disease status. 
In the 15 families we ascertained 638 subjects who were born at a priori 50% risk for 
ARVC. We limited our analysis however to subjects from 'well ascertained ' sibships, 
that is, we knew the disease status of 2: 50% of their siblings (n=496). This strategy was 
designed to minimise the bias present in recognising clinical disease in serious cases, and 
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missing it in less serious cases. Subjects in the unknown group (n=84) were not studied 
further. In this way, 412 (226m, 186f) subjects met the criteria for inclusion in the study. 
3.3.2 Data collection 
All subjects in the family pedigree in the line of descent from a positive subject, born at a 
priori 50% risk of inheriting ARVC, were enrolled in the study. Tills included long 
deceased family members whose only information was dates of birth and death, from 
census records or family bibles on family trees. Following genetic counselling and 
informed consent (obtained from each subject (or surrogate) in compliance with the 
Human Investigation Committee requirements of the Health Care Corporation and 
Memorial University of St. John's, Newfoundland) all available past and present medical 
records were obtained and reviewed from all subjects, alive or dead. Formal clinical 
assessments were conducted as part of a prospective screening regime and for subjects 
presenting with a clinical problem. As occurs in most family studies of inherited disease, 
subjects were ascertained at different stages of their disease process. 
Beginning in 1998, all extant subjects at 50% risk of ARVC were screened at a genetics-
cardiomyopathy clinic at between one and three yearly intervals starting at 10 years of 
age. Subjects ascertained prior to 1998 were seen because of a clinical problem. Subjects 
were offered DNA testing. Trus was initially a DNA haplotype at locus ARVD5 at 3p25 
which segregated with ARVC, done in the research laboratory of Dr. Thierfelder (248). 
Direct mutation analysis was feasible following the definition of the causative gene ( 46)). 
A detailed symptomology and medical history was obtained from all subjects by one of 
two highly trained cardiac nurses, blind to any previous test results (clinical or DNA). 
Page Ill of 292 
Data were included on four male (one positive, three mutation negative) and 10 female 
(eight positive and two negative) subjects who were from other provinces in Canada, or 
the USA. In these cases, with subject consent, we obtained past cardiac records, and 
offered DNA analysis. Follow-up was organized through local genetics and cardiology 
clinical services (276). 
Sudden death at an early age, particularly in males, influenced the non-availability of 
medical records. Among 149 positive males, medical records were available for 87 
(58%), and not available for 62 (42%), of whom 61 (98%) were dead. Notably, however 
the median age to death or last follow-up for positive males with no medical records 
(n=62) was 39 years similar to the 46 years in the group with medical records, (n=87) 
(data not shown). Among 109 positive females, medical records were available for 85 
(78%) and not for 24 (22%), of whom 15 (62%) were dead. Medical records were 
available in 65 of 77 (84%) negative males and 68 of 77 (88%) negative females. The 
negative subjects with no medical records comprised those who had provided DNA, but 
were lost to follow-up. 
We documented age at the first time a subject had palpitations (an awareness of a fast or 
irregular heartbeat), syncope (a sudden brief loss of consciousness from which recovery 
was spontaneous), pre-syncope (a transitory feeling of impending loss of consciousness 
which did not proceed to syncope), chest pain, heart failure, hospitalization secondary to 
a cardiac problem (Table 10 page 113). In addition, age at death or last follow-up was 
obtained. 
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Table 10: Median age to clinical cardiac manifestations in AR VD5 subjects with medical 
records (n=305). 
Cardiac manifestation 
Subject group Palp PS CP s HF Hosp Death 
Positive males n 45 44 29 23 15 39 31 
N=87 % 52 50 33 26 17 45 36 
Median age 39 39 45 61 63 43 45 
(y) to event (35- (33-45) (38-52) (35-86) (46-80) (38-47) (38-52) (95% CI) 44) 
Negative males n 14 20 15 9 0 6 I 
N=65 % 21 31 23 14 0 9 1.5 
Median age 67 64 66 - - - -(y) to event (50- (48-79) (47-85) (95%CI)3 84) 
+ve males c p 0.0001 0.006 0.031 0.04 0.0001 2 0.0001 0.001 
vs. - ve R RR (95% 3.4 2.2 2.0 2.3 - 10.2 31.5 
males C1)3 ( 1.8- (1 .2- ( 1.1- (1.1- (3.9- (4.3-
6.3) 3.8) 3.9) 4.9) 26.4) 231.4) 
Positive n 49 37 26 24 6 21 9 
females % 66 43 30 28 7 24 10 
N=85 Median age 41 49 1 59 66 71 66 -
(y) to event (36- (41-57) (44-74) (52-79) (71-71) (55-76) (95%CI)3 46) 
Negative n 25 18 14 5 0 6 2 
females % 40 39 20 7 0 9 3 
N=68 Median age 62 - 66 - - - -(y) to event (42- (37-95) (95% 
C I)3 82) 
+ve c p 0.02 0.06 0.4 0.006 0.062 0.08 0.4 
females vs. R RR (95% 1.8 ns ns 3.8 ns ns ns 
- ve Cl/ (I. I- ( 1.4-
females 2.9) 10.3) 
+ve males c p 0.8 0.007 0.04 0.45 0.002 0.0001 0.001 
vs. +ve R RR ns 1.9 1.8 ns 5.2 4.4 7.4 
females (95% (1.2- ( 1.1- (1.8- (2.3- (3.3-
CI)3 2.9) 3.1) 14.5) 8.0) 16.2) 
Palp: palpttat10ns, PS: presyncope, CP: chest pam, S: syncope, HF: heart fatlure, Hosp: hospttahzat10n for a 
clinical cardiac event. CR: Cox's proportional regression analysis. 
1
: This analysis was done for females with a formal clinical assessment (see text). The denominators for 
this analysis therefore were 74 positive vs. 63 negative females 
2
• This p value is derived from the log rank assessment of the Kaplan Meier analysis 
3
. Where median ages are· not provided, 50% of the subjects did not reach the end point in the Kaplan Meier 
analysis. 
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We determined whether subjects seen through clinic, who were asked directly about 
symptoms, differed statistically from those who had only a medical record available. 
There were no significant differences in time to various cardiac manifestations comparing 
male subjects with medical records to those with both a medical record and a formal 
clinical assessment. The data for pre-syncope, syncope, chest pain, heart failure and 
palpitations in males is therefore presented here without differentiation by data source. 
Palpitations were three times more likely to occur in clinically affected and/or mutation 
positive females who had a formal clinical assessment (n=74) compared with those with a 
medical record only (n=11) (p=0.01, RR 3.1 (95% CI 1.2-7.6)). Thus data on palpitations 
in females is presented for the group that had clinical assessment only. 
3.3.3 Direct clinical assessment 
In addition to taking a medical history and a physical examination, subjects attending the 
cardiomyopathy /genetics clinic had a 12 lead electrocardiogram (ECG), a signal 
averaged ECG (SAECG), an echocardiogram and a 24 hour Holter monitor test. Serial 
assessments were done at one to three year intervals. The presence of abnormalities on 
each clinical test was assessed. The ECGs were read by two physicians blind to clinical 
status (SC and PP). Poor R wave progression (PR WP) was defined as R wave in V3 of 
less than 3mm (277). QRS was defined as being greater than llOms. Prevalence of 
abnormalities on first ECG was calculated (Table 11 page 115). In positive subjects with 
serial ECGs, the age to onset of de novo PRWP and PVCs was calculated by time to 
event analysis, after excluding those with PRWP and PVCs present at baseline (Table 12 
page 116). 
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Table 11: Anomalies on initia112lead ECG in ARVD5 (n=300). 
Positive group Negative group Analyses 
Male Female Tot. Male Female Tot. ·l l 
N 78 89 167 64 69 133 Positive Positive Females Mean age at 30.0 (12.0) 37.8 (15.8) 33.3 38.2 Males vs. test (SO) (16.1) (12.9) negative vs 
121ead N N Males negative 
ECG n 
0/o n % (%) n % n % (%) Females 
PRWP 23 29 25 28 48 0 0 2 3 2 p:SO.OOOJ p:SO.OOOI (29) (I) 
PVC's 25 32 22 25 47 0 0 I 1 I p:SO.OOOI p:SO.OOOI (28) (<I) 
QRS> 25 32 8 9 33 4 6 2 3 6 p:SO.OOOI p=O. I I9 I 10 ms ( 19.8) (4.6) (ns) 
Septal Q 10 13 14 16 24 0 0 0 0 0 p:50.003 p:SO.OOI 
waves (14) 
Features analysed, but with data not shown due to low prevalence (with most < 5%) 
included ventricular tachycardia, atrial fibrillation, L axis, T wave inv. in V2 V3, R axis, 
1° AV block, Long QT, Short QT, Short PR, Epsilon wave, Tall R in VI , dilated L 
Atrium, dilated R atrium, L ventricular hypertrophy, R ventricular hypertrophy, L bundle 
branch block, R bundle branch block, L anterior hemiblock, L. posterior hemiblock, 
Inferior Q waves, Lateral Q waves, Anterior Q waves, Inferior ST depression, Anterior 
ST depression, Lateral ST depression, Inferior ST elevation, Anterior ST elevation, 
Lateral ST elevation, Flat Inferior T wave, Flat lateral T wave, Inverted lateral T wave. 
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Table 12: Incident events on 12 lead ECG, Holter monitoring and echocardiogram in 
ARVD5. 
s Disease # lE Median Log RR 95% Cox p Positive 
e group without age to rank p CI value males and 
X status anomaly onset of value positive 
on first anomaly • females 
test who compared 
had one 








M Positive 38 II 55 0.001 No No No p:S0.05 
0.. Negative 41 0 - events events events RR=2.3 :s: 
0::: F Positive 64 14 58 0.001 8.4 1.9- 0.005 95% CI (1.01-
f 0.. Negative 43 2 37.4 5.2) -] M Positive 37 II 48 0.001 28.2 3.6- 0.002 p:S0.004 Vl Negative 40 I - 22 1 RR=3.7 
u 95% CI (1.5-~ > F Positive 65 II 77 0.023 4.9 1.1- 0.041 
-
0.. Negative 40 2 70 22.6 9.3) 
M Positive 10 6 25 0.001 48.1 5.3- 0.01 p:S0.02 
0 Vl Negative 3 1 2 72 431 RR=3.6 
.~ 
ou F Positive 21 9 48 0.002 5.6 16- 0.005 95% CI (1 .3-'""> II 0.. Negative 25 4 - 18.8 10.9) 
i M Positive 12 6 26 0.001 No No No p:S0.003 0 Vl Negative 35 0 - events events events RR=5.4 0. oU F Positive 23 8 52 0.009 6.2 1.2- 0.02 95% CI (1.8--> :I II 0.. Negative 30 2 
-
29.8 16.9) 
M Positive 19 10 45 0.006 6.5 1.4- 0.02 p:S0.3 
II Negative 19 2 - 30.2 
i >!.lo F Positive 35 14 51 0.01 4.5 1.3- 0.02 >r:/) ...JN Negative 23 3 60 15.7 
M Positive 22 7 - 0.009 No No No ::;0.5 
II Negative 23 0 
-
events events events 
>!.lo F Positive 38 9 59 0.05 4.0 0.8-1.9 0.07 >r:/) 
' 
...JM Negative 25 2 -
IE: incident events, PRWP: poor R wave progression, PVC: premature ventricular contraction, L VE: left 
ventricular enlargement. * p value from the Kaplan Meier analysis comparing positive and negative 
subjects of the same sex. 
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Left ventricular enlargement (L VE) was defined as left ventricular end diastolic diameter 
(LVEDD)> 112% corresponding to 2 standard deviations (SD) above the predicted mean 
value (Henry's formula) (202). We also assessed LVE > 117% (> 3 SD above the 
predicted mean). Prevalence of abnormalities on first echocardiogram was calculated 
(Table 13 page 118). In positive subjects with serial echocardiograms, the age to onset of 
de novo L VE was calculated by time to event analysis, after excluding those with L VE 
present at baseline (Table 12 page 116). 
Ectopy was determined on Holter monitor testing over 24 hours, and the prevalence of 
number of PVCs, VT, and other forms of ectopy was determined (Table 14 page 118). In 
positive subjects with serial Holter monitors, the age of onset of de novo ~ 200 PVCs or ~ 
1000 PVCs was calculated by time to event analysis after excluding those with ~ 200 or ~ 
1000 PVCs at baseline (Table 12 page 116). This number ofPVCs was chosen because of 
their use within the original and the modified diagnostic criteria for ARVC (25, 142) 
Prevalent late potentials on first SAECG (Table 15 page 119) were classified based on 
recognized criteria: QRS (filtered QRS duration)> 114 ms, LAS (low amplitude 
signals)>38 ms, and RMS (root mean square voltage of the terminal 40ms of filtered 
QRS)<20 ms(260). The SAECG test is considered abnormal when 2/3 of these criteria 
are abnormal. 
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Table 13: Anomalies on initial echocardiogram in ARVD5 (n=248). 
Positive group Negative group Analyses 
Sex Male Female Tot. Male Fema le Tot. r! l 
N 68 76 144 50 54 104 
Mean Age 31.6 39.6 
Positive Positive 
at test 32.6 (15) 38.4 males vs females vs 
(SO) (13.0) (15. 1) (12.1) negative negative 
Echo- N males females 
cardiogram n % n % N (%) n 
0/o n % (%) 
LVE>2SD 35 52 27 20 62 (43) 10 20 4 8 14 p~O.OOl p~O.OOI (14) 
LVE >3SD 24 35 20 26 44 (30) 4 8 2 4 6 (6) p~O.OOt p~O.OOI 
Dyskinesia 19 28 15 20 34 (24) 0 0 0 0 0 p~O.OOJ p~O.OOJ 2loballfocal 
LAE 16 23 8 10 24 (1 7) 5 10 4 7 9 (9) ns ns 
RVD 12 18 6 8 18 (12) 2 4 4 7 6 (6) p~0.05 ns 
FS<25% II 16 8 10 18 (12) 2 4 I 2 3(3) p~0.02 ns 
LVH 7 10 7 9 14 (10) 3 6 3 5 6 (6) ns ns 
PVC: premature ventricular complex, VT: Ventricular tachycardia, LVE: Left ventricular enlargement 
indexed to height and weight, LAE: left atrial enlargement, RVD, right ventricular dilatation, LVH: left 
ventricular hypertrophy, FS: Fractional shortening 
Table 14: Anomalies on initial Holter monitor in ARVD5 (n=239). 
Positive group Negative group Analyses 
Sex Male Female Total Male Female Tot. ·l ·l 
N 67 79 146 49 44 93 
Mean Age 31.1 37.7 33.1 Positive Positive 
at test (13.3) (15.5) (15.9) 38.2 (12.8) males vs females vs (SO) 
Holter 
negative negative 
N N males Fema les Monitor n 0/o n 0/o (%) n % n % (%) 
anomalies 
PVCs 47 70 47 59 94 0 0 I 2 I (I) p~O.OOOl p~0.0001 
>200/24 h (64) 
PVC's:::: 45 67 37 47 82 0 0 I 2 1 (1) p~O.OOOJ p~O.OOOI 1000/24h (56) 
::::I 39 58 43 56 82 0 0 2 4 2 (2) p~O.OOOJ p~O.OOOI 
couplet (56) 
::::I run 24 36 33 42 57 0 0 I 2 1 (1) p~O.OOOI p~O.OOOl bi2eminy (39) 
:::: I run ns 30 45 24 30 54 0 0 0 0 0 p~O.OOOI p~O.OOOI VT (37) 
:::: I triplet 20 30 14 18 34 0 0 0 0 0 p~0.0001 p~O.Ol (23) 
nsVT: non-sustained ventricular tachycardia 
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Table 15: Anomalies on initial SAECG in ARVD5 (n=202). 
Positive group Negative group Analyses 
Sex Male Female Tot. Male Female Tot. l -/ 
N 33 65 98 50 54 104 
Mean Age 31.2 39.8 
Positive Positive 
at test (14.3) (14.5) 36.8 (16.3) 39 (10.8) males vs females vs (SD) negative negative 
SAECG N N males females 
anomalies n % n % (%) n % n o;o (%) 
Total 38 12 QRS 19 58 19 29 10 20 2 4 p:S 0.0001 p:S 0.0001 
>114ms (38) (12) 
RMS<20 15 46 18 28 33 12 24 9 18 21 p:50.041 p=0.2(ns) 
ms (34) (21) 
LAS>38 17 52 21 32 38 15 30 13 25 27 p:50.049 p=0.42 (ns) 
ms (38) (27) 
2/3 16 49 17 26 33 10 14 8 10 18 P:50.041 p:50.041 Abnormal (34) (18) 
3.3.4 Genetic analysis 
Screening for the TMEM43 1073 C>T mutation: 
Venous blood was drawn from 295 subjects and DNA was extracted from peripheral 
lymphocytes (278). Presence or absence of the TMEM43 1073 C>T mutation was 
determined for each subject in each family as described previously ( 46). 
Statistical analysis 
The known sex-differences in survival in ARVC linked to 3p25, (248) determined that 
data for males and females were examined separately. For time to event analysis subjects 
were censored at last follow-up (defined as the age at last clinic visit), death, date of ICD 
surgery or heart transplant. Survival was calculated according to the Kaplan Meier 
product limit method. Relative risk (hazard ratio) was calculated using Cox's 
Proportional Regression model. Version 15 of the SPSS statistics package was used for 
analyses (SPSS, Chicago USA). 
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The diagnostic utility (sensitivity, specificity, positive predictive value, negative 
predictive value) of symptoms and test results present at the first clinic assessment was 
assessed for the identification of those clinically affected and/or mutation positive 
subjects. The likelihood ratio of having, and not having inherited ARVC was calculated 
by sensitivity /!-specificity, and !-sensitivity/specificity respectively. In general, 
likelihood ratios over 10 (for diagnosis), or under 0.1 (for ruling out diagnosis) are 
considered to indicate good diagnostic utility. 
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3.4 RESULTS 
Clinical manifestations of cardiac disease in males 
Table 10 page 113 and Figure 18 page 122 summarize the incidence of cardiac symptoms 
and events in 87 positive and 65 negative males with medical records. Positive males 
were significantly more likely than negative males to develop each of the cardiac 
symptoms and outcomes. Fifty three percent of positive males had presyncope and 
palpitations before age 40 years (Figure 18 page 122) compared with 27% and 17% of 
negative males respectively (data not shown). Heart failure developed in 16% positive 
males before age 40 years, and in 46% before age 60 years, with no events in negative 
· males (p=O.OOO 1 ). Median age at first hospitalisation for a cardiac indication was 43 
years (95% CI 38 years-47 years), with 43% of positive males hospitalised before age 40 
years, compared with 11 % ofnegative males (RR 10.2 (95% CI 3.9-26.4) p=0.0001). Of 
the six negative males hospitalised, three were for investigation of chest pam, one 
following an MI, one with ectopy and one at age 15 years following syncope. 
Median survival in positive males was 45 years (95% CI 38-52), with one death in the 
mutation negative group (p=0.001). Using a strictly conservative ascertainment strategy, 
incorporating those with a medical record, where positive status was defined by genetic 
means only (having the disease mutation or being an obligate carrier), and where all 
subjects in a sibshjp had a known disease status (100% ascertainment), mortality was 
similar (median survival42 years, 95% C I 38-46) (Figure 18 page 122). 
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Figure 18: Cumulative incidence of cardiac symptoms or outcomes in positive males: 
temporal sequence. 
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Table 16: Cumulative percentage with symptom or outcome defined by age group. 
A~ e groups: affected males (percenta~ e) 
0-10 11-20 21-30 31-40 41-50 51-60 61-70 70+ 
Presyncope 2 10 28 53 65 75 81 
Syncope 1 5 15 25 44 44 56 
Palpitations 3 12 29 53 85 80 
Chest Pain 0 6 15 38 61 67 
Heart Failure 0 0 6 16 39 46 46 65 
Hospitalisation 0 0 18 43 79 95 
following a 
clinical event * 
Death 0 1 13 29 54 68 79 100 
* Not shown on graph 
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Clinical manifestations of cardiac disease in females 
Table 10 page 113 and Figure 19 page 124 summarise the incidence of cardiac symptoms 
and events in 85 positive and 68 negative females with medical records. Rates were 
higher for all events in the positive group. Presyncope and heart failure showed a trend 
towards significance but only syncope and palpitations reached statistical significance. 
Positive females were 4 times more likely to have syncope (p=0.006) and 2 times more 
likely to have palpitations (p=0.02) than negative females. A greater proportion of 
positive females (n=21, 24%) were admitted to hospital for cardiac problems than 
negative females (n=6, 9%) (ns). Of the latter, three were for chest pain, one for Wolf-
Parkinson-White syndrome, and one at age 12 years with palpitations. There were more 
deaths in positive females than negative females, but this did not reach significance. 
Comparison of positive males and positive females 
Males were significantly more likely to have had presyncope p=0.007; RR 1.9 (95% CI 
1.2-9), chest pain p=0.04, RR 1.8 (1.03-3.1) and heart failure (p=0.002); RR 5.2 (95% CI 
1.8-14.5) than females (Table 10 page 113). The temporal sequence from cardiac 
symptoms to death was compressed in males but more prolonged in females by 1-2 
decades (Fig. 1 and Fig. 3). Males were 4 times more likely to be hospitalised, p=0.0001 , 
RR = 4.4 (95% CI 2.3-8), and died significantly earlier than females (p=0.001) (RR=7.4, 
95% CI 3.3-16.2). These mortality results were similar using the conservative 
ascertainment strategy, where those analyzed included only those in whom the diagnosis 
was made using genetic data and where all siblings had known disease status (p=0.001) 
(RR=9, 95% CI 2.5-32) (Figure 20 page 125). 
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Figure 19: Cumulative incidence of cardiac symptoms or outcomes in positive females: 
temporal sequence. 
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Table 17: cumulative percentage with symptom or outcome defined by age group. 
Age groups: affected females (percentage) 
0-10 11-20 21-30 31-40 41-50 51-60 61-70 70+ 
Presyncope 0 7 19 38 52 54 69 69 
Syncope 0 8 12 21 31 42 57 88 
Palpitations 0 10 26 49 70 79 93 100 
Chest Pain 0 1 7 19 41 57 71 71 
Heart Failure 0 0 0 2 6 11 20 58 
Hospitalisation 0 0 6 14 25 40 66 82 
secondary to 
clinical event* 
Death 0 0 0 0 6 21 34 100 
* Not shown on graph 
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Figure 20: Cumulative survival in positive males and females, censored at lCD, heart 
transplant or last fo llow-up, in subjects defined by genetic means (mutation analysis or 
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Three hundred subjects (167 positive, 133 negative) had at least one 12-lead surface 
ECG available. The most prevalent features were poor R wave progression (PR WP: also 
septal Q waves; a subset ofPRWP), the presence of PVC's, and extended QRS (Table 11 
page 115). T wave inversion in leads V2-V3, and epsilon waves were noted in :'S 4% of 
positive subjects. Of the positive subjects with no ECG available for analysis, 86% were 
dead. 
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Serial ECGs were available in 84 (50%) positive and 84 (63%) negative subjects and in 
these we assessed the incidence ofPRWP and PVCs (Table 12 page 116). PRWP in the 
anterior chest leads was identified at baseline in 48 (29%) positive subjects (Table 11 
page 115). Twenty-five positive subjects without PRWP at baseline subsequently 
developed de novo PRWP. Two negative females had PRWP at baseline: two negative 
females developed PR WP on a subsequent ECG. The median age to onset of de novo 
PRWP for positive males was 55 years; 16% had PRWP by age 30 years, 30% by age 40 
yrs and 69% by age 60 years (Fig. 4). The median age to onset of de novo PRWP for 
positive females was 58 years; none had PRWP by age 25 years, 9% by age 40 yrs and 
69% by age 60 years (Fig. 5). Positive males were twice as likely to develop PR WP as 
clinically affected and/or mutation positive females (RR 2.3 (95% CI 1.1-5.2) (Table 12 
page 116). 
PVCs in any of the 12 leads on the ECG were identified at baseline in 47 (28%) positive 
subjects. Twenty two positive subjects without PVCs at baseline subsequently developed 
PVCs. One negative female had one PVC at baseline: two negative females and one 
negative male developed PVCs on a subsequent ECG. The median age to onset of de 
novo PVCs for positive males was 48 years; 6% had PVCs by age 30 years, 27% by age 
40 yrs and 100% by age 60 years (Fig. 4). The median age to onset of de novo PVCs for 
positive females was 77 years; none had PVCs by age 25 years, 12% by age 40 yrs and 
25% by age 60 years (Fig. 5). Positive males were four times as likely to develop PVCs 
on 12lead ECG as positive females (RR 3.7 (95% CI 1.5-9.3) (Table 12 page 116). 
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Echocardiography 
Two hundred and forty eight subjects (144 positive and 104 negative) had at least one 2D 
echocardiogram available for analysis. Five reports .without available measurements were 
excluded, four of which (3 males and 1 female, all deceased) were reported to have a 
'massively dilated heart' . Of the positive subjects with no echocardiogram, 85% were 
dead. The most prevalent feature was LYE 112% (2SD above the mean) based on 
LYEDD (Table 13 page 118) (203). 
Fifty-four positive and 42 negative subjects who showed no LYE at baseline had serial 
echocardiograms. Sixty-two of the 144 positive subjects had LYEDD >2SD at baseline 
(LYE). Twenty-four ( 44%) positive subjects without LYE at baseline subsequently 
developed LYE. The median age to onset of de novo LYE for positive males was 45 
years ; 14% had LYE by age 30 years, 42% by age 40 yrs and 52% by age 60 years 
(Figure 21 page 129). The median age to onset of de novo LYE for positive females was 
51 years; none had LYE by age 30 years, 4% by age 40 yrs and 69% by age 60 years 
(Figure 22 page 130). There was no significant difference between positive males and 
positive females for time to development of LYE (Table 12 page 116). 
Seven males (10% of all positive males who had an echocardiogram) and nine females 
(12% of all positive females who had an echocardiogram) fulfilled criteria for DCM 
(279). Six positive male subjects with marked LYE and systolic dysfunction received a 
heart transplant and one died while waiting for a transplant. 
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Although RV echocardiography was not formally assessed, RV thinning/bulges or 
dilatation was reported in 12 of 68 (18%) of positive males, and 6 of 76 (8%) females, as 
well as in six (2 m,4f) of 104 mutation negative subjects (Table 13 page 118). 
Holter Monitor 
Two hundred and forty three subjects (146 positive, 97 negative) had at least one Holter 
monitor available for analysis. Of the positive subjects with no Holter Monitor, 82% were 
dead. The most prevalent feature was 2: 200 PVCs over 24 hours (Table 14 page 118). 
Thirty one positive and 40 negative subjects who did not have 2: 200 PVCs at baseline 
had serial Holter monitors. Ninety four (47 male and 47 female) had 2: 200 PVCs on first 
Holter monitor (Table 14 page 118). Fifteen (48%) positive subjects without 2: 200 
PVC's at baseline subsequently developed 2: 200 PVCs. The median age to onset of de 
novo 2: 200 PVCs for positive males was 25 years; 64% had 2: 200 PVCs by age 30 years 
(Figure 21 page 129). The median age to onset of de novo 2: 200 PVCs for positive 
females was 48 years; 9% had 2: 200 PVCs by age 30 years, 10% by age 40 yrs and 62% 
by age 60 years (Figure 22 page 130). 
Eighty two positive subjects ( 45 m, 37 f) had 2: 1000 PVCs on first Holter monitor (Table 
14 page 118). There were 14 incident cases in the positive group. In the negative group, 2 
females developed 2: 1000 PVCs. There were significant differences between positive and 
negative males (p=0.0001), positive and negative females (p=0.02) and between positive 
males and positive females (p= 0.003, RR 5.4 95% CI 1.8-9.2) (Table 12 page 116). 
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Figure 21: Cumulative incidence of clinical signs on 12 lead ECG, Holter monitor and 
echocardiogram in positive males: temporal sequence. 
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Table 18: cumulative percentage with clinical sign defined by age group. 
Cumulative percentage by age in positive males 
Test Feature <20 <30 <40 <50 <60 <70 <80 <90 
121ead PRWP 0 16 30 38 69 100 
ECG PVC* 2 6 27 100 
>200 5 64 Holter PVCs 
Monitor > 1000 5 60 PVCs * 
>2SD 4 14 42 52 52 68 100 LVE* Echo 
>3SD 3 11 17 39 39 53 100 LVE 
* Not shown on graph 
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Figure 22: Cumulative incidence of clinical signs on 12 lead ECG, Holter monitor and 
echocardiogram in positive females: temporal sequence. 
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Table 19: Cumulative percentage with clinical sign defined by age group. 
Cumulative percentage by age in positive females 
Test Feature <20 <30 <40 <50 <60 <70 <80 <90 
12 lead PRWP 0 4 9 29 66 66 100 
ECG PVC* 0 6 12 15 25 25 66 100 
>200 0 9 10 62 Holter PVCs 
Monitor > 1000 0 3 12 35 51 PVCs* 
Echo >2SD LVE* 0 0 3 33 68 84 p 3SD LVE 0 0 0 13 62 81 
*Not shown on graph 
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SAECG 
Two hundred and two subjects (98 positive, 104 negative) had at least one SAECG 
available for analysis. Extended QRS, and the presence of 2/3 of the SAECG parameters 
abnormal were both significantly different between positive and negative subjects. The 
development of SAECG abnormalities was more common however in negative than 
positive males (Table 12 page 116), and there was no significant difference between the 
positive and negative groups in the Cox regression analysis. 
Diagnostic Utility 
A likelihood ratio of above 10 is considered the level at which a test is diagnostically 
robust. The LR' s of having ARVC are all less than four for all cardiac manifestations 
with the exception of males with heart failure where the LR is 17. For clinical testing 
results, PRWP and PVCs on ECG (in males) and PVC's (>200 and > 1000) on Holter 
monitor for males and females are all well above 10. The likelihood ratios of not having 
inherited ARVC are greater than 0.2 for each manifestation and for each clinical test 
result, suggesting that the absence of clinical symptoms or the absence of the test 
outcomes as presented are inadequate to rule out the diagnosis of ARVC (Data not 
shown). 
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3.5 DISCUSSION 
This paper reports the natural history, and the phenotype of ARVC caused by a founder 
mutation in TMEM43, where clinical manifestations of disease in positive and negative 
family members were compared. 
3.5.1 Natural history 
Results for negative family members helped to determine disease associated cardiac 
symptoms. In positive males, the phenotype was malignant, with early age of onset of 
cardiac symptoms followed soon after by death. A more benign phenotype was observed 
in positive females with a later age of onset of symptoms, less frequent hospitalisations, 
and longer survival. Other than syncope and palpitations, there was no difference in 
symptoms between negative and positive females. The development of cardiac symptoms 
in either sex had no utility in determining those who did, and did not, inherit ARVC. 
Heart failure and chest pain were late manifestations of disease in positive males and 
females, occurring in subjects who did not succumb to malignant arrhythmia. The data 
suggest that heart failure will occur in a majority of male subjects with this TMEM43 
missense mutation whose lives have been prolonged following ICD therapy. 
Despite methodological and sampling differences, our results are similar in magnitude to 
those reported in other studies of ARVC, including 26 subjects with mutations in 
desmoplakin (ARVD8) (280), and within a heterogeneous group of 130 affected 
individuals (281 ). The lack of a comparison group however in these studies make 
comparisons problematic. 
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3.5.2 Clinical features on cardiac testing 
The phenotype of this form of ARVC includes (i) ECG manifestations of arrhythmogenic 
disease (PVCs), ECG features of presumptive conduction disease (PRWP and septal Q 
waves), as well as prolonged QRS, also delineated on SAECG; (ii) echocardiographic 
manifestations of L VE, (iii) frequent early ventricular ectopy on Holter monitor, at an 
early age in males, and (iv) a high risk of SCD at a young age in males. 
This genetic subtype of ARVC has both similarities and differences to more typical 
ARVC. Absent are T wave inversions in the anterior precordial leads, and epsilon waves 
(25), but PR WP in the precordial leads was present in almost half of all positive subjects 
on first ECG. Anterior myocardial infarction can cause PRWP (277), although 
angiography in several subjects was negative. The mechanism by which PR WP occurs is 
unknown but we speculate that fibrous tissue in the septum may produce a pattern similar 
to that following an anteroseptal infarct a suggestion supported by the presence of septal 
Q waves. The presence of PRWP in 2% of negative subjects may reflect the polymorphic 
nature of this finding in the general population, with reports of its presence in up to 10% 
of hospitalised adult patients having a routine ECG (282). 
This genetic subtype of ARVC showed substantial LV involvement. While there is clear 
evidence for L VE in ARVC (266, 267), DCM with L VE and systolic dysfunction 
meeting strict DCM criteria (15) is not often reported. However, a study of a 
heterogeneous group of ARVC patients did note the occurrence of congestive heart 
fai lure (281). In the current study, the LVE was not restricted to a single family or set of 
siblings, reducing the likelihood of familial clustering. Although LVEDD > 2 or 3 SD 
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above the mean is not diagnostic of DCM, L VE may be an early phase of a dilating heart 
as it progresses to depressed ejection fraction in relatives (283, 284). 
Substantial ectopy occurred and was the earliest clinical feature noted on testing on both 
Holter monitoring and 12 lead ECG. As these tachyarrhythmias are considered 
responsible for SCD in young people, it provides clinical evidence supporting ventricular 
arrhythmia as a cause of the early deaths. 
The reduction in survival, particularly in males is a major concern. Previous studies of 
genetically heterogeneous families with ARVC have reported better survival than 
observed in our fami lies (170), although the consensus has been from the earliest reports 
that males have a worse survival than females (12). In this study of ARVC linked to 
3p25, the sex influence on mortality was mirrored in the earlier time to development of 
PR WP, L VE, and ectopy in positive men compared to positive women. 
3.5.3 Limitations of the study 
Describing the natural history of an uncommon inherited disease, which is difficult to 
diagnose and associated with early death, is challenging. Limitations inherent in these 
studies relate to (i) study design, (ii) definition of affected status (iii) ascertainment bias, 
(iv) survivor bias and (v) intervention bias. 
(i) Subjects in this cohort study were assessed in both a retrospective and prospective 
manner. The same consistency of assessment therefore may not have occurred in the 
group studied retrospectively, where data was abstracted from clinical records, and where 
there is almost certainly missing data. Despite this, there were few differences in results 
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between those subjects ascertained in a retrospective manner and those who were also 
assessed in clinic and followed prospectively. The results therefore, for all but one 
symptom (palpitations in females) were analysed together. 
(ii) Defining affected status using the occurrence of a major clinical event (SCD or 
resuscitation for VT before 50 years) could introduce biases particularly through 
identification of those at the more severe end of the disease spectrum. However, 
exclusion of those defined by the clinical event criteria and including only those defined 
by genetic criteria did not alter the conclusions: this form of ARVC is associated with 
early death in males. 
(iii) Ascertainment bias is unavoidable in family studies of inherited disease but we tried 
to limit this by analyzing only subjects in well ascertained sibships, where the disease 
status of at least 50% of siblings was known. The fact that there were more male than 
female subjects in the study may indicate some residual bias in ascertainment where the 
severity of the disease in males may have increased the likelihood of identifying positive 
males. 
(iv) Survivor bias is relevant to this study as a substantial nun1ber of positive males died 
prior to presentation to the health care system and had no clinical record available. 
However, median survival of positive males with no medical records was similar to those 
with medical records supporting the validity of the overall results. It is possible that the 
clinical features observed may relate more to the male survivors in families who may be 
expressing a milder form of the disease. Prospective studies with younger subjects will 
help to address this important issue. 
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(v) We have demonstrated that ICD treatment, as a primary or secondary preventative 
intervention significantly improves survival in males (248).Intervention bias was 
controlled by censoring at the time of ICD implant. We were unable to assess in any 
meaningful way the possible impact of drug treatment on clinical outcomes due to the 
multiplicity of drugs used and the fact that posi6ve subjects were treated over the course 
of several decades, with changing regimes. 
PRWP can occur due to lead misplacement, patient obesity, LV hypertrophy and Wolff 
Parkinson White syndrome (WPW) amongst others, and can also be a normal variant 
(285). In our study, most of the 12-lead ECGs showing PRWP were repeated several 
times, the observed pattern was not restricted to the obese, LV hypertrophy was not 
present on echocardiography and WPW was excluded on ECG. We used the clinical 
criterion of less than 3mm in V3 from ECGs read in a blinded manner as a measure of 
PRWP, which does not take amplitude into account. However, this potential bias would 
be the same across both positive and negative groups. 
Despite ARVC associated pathology and the fulfilment of diagnostic criteria m the 
probands in each family, formal echocardiographic assessment of RV structure was not 
done. Consequently, only limited conclusions can be made on the presence of 
abnormalities in the right ventricle. 
3.5.4 Advantages of the study 
For most subjects we were able to determine the presence of ARVC using genetic data, 
(the TMEM43 1073 C>T mutation, or being an obligate carrier), a diagnostic strategy 
independent of clinical manifestations. This large genetically homogeneous population 
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was a robust resource in which to investigate this form of ARVC, made stronger by the 
use of a negative group of family members, and the presence of medical records from 
extant and deceased subjects from which disease manifestations were carefully and 
consistently classified. We have serial assessments of both positive and negative subjects 
from regular visits to a genetics/cardiomyopathy clinic, where subjects were screened 
prior to a genetic diagnosis. These data provide necessary information for genetic 
counselling and management of the disease in at-risk subjects. The advantage of studying 
large families with a founder haplotype and deep genealogies is offset by the fact that 
these findings may not be generalisable to other forms of inherited ARVC. However, it is 
likely that in the future, ARVC and other cardiomyopathies will be classified by their 
molecular genetic etiology, thus disease specific genotype/phenotype information will 
become the most useful and relevant. It is also likely that mutations in TMEM43 will be 
identified in other populations as a cause of ARVC. 
3.6 CONCLUSIONS 
Disease related symptoms of this genetic subtype ARVD5 caused by a mutation m 
TMEM43 include palpitations, presyncope and syncope which tend to occur at a young 
age, particularly in positive males in whom onset of symptoms is often closely followed 
by death. Hospitalization for cardiac disease, heart failure and SCD were significantly 
more common in positive males than positive females, and occurred at a younger age. 
Heart failure in positive males presented as a late manifestation in survivors. This 
phenotype includes manifestations of both arrhythmogenic and cardiomyopathic disease, 
is more malignant in males than females, frequently exhibits PRWP in the precordial 
leads and ventricular ectopics on ECG, has features of left ventricular disease with L VE 
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which can lead to DCM, and ectopy on Holter monitor at an early age is a reasonably 
sensitive diagnostic test for both sexes. 
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4 THE IMPACT OF IMPLANTABLE CARDIOVERTER 
DEFIBRILLATOR THERAPY ON SURVIVAL IN 
AUTOSOMAL DOMINANT ARRHYTHMOGENIC RIGHT 
VENTRICULAR CARDIOMYOPATHY (ARVDS) 
"Medical science has proven time and again that when the resources are provided, great 
progress in the treatment, cure, and prevention of disease can occur." 
Michael J. Fox 
"Extreme remedies are very appropriate for extreme diseases. " 
Hippocrates of lphicrates 
Kathy A. Hodgkinson, M.Sc, Patrick S. Parfrey, MD, FRCPC, FACP, AnneS. Bassett, 
MD, FRCPC, Christine Kupprion, MD, Jorg Drenckhahn, MD, Mark W. Norman, MD, 
MRCP, Ludwig Thierfe lder, MD, Susan N. Stuckless, M.Sc, Elizabeth L. Dicks, M.Sc, 
William J . McKenna, MD, FRCP, Sean P. Connors, MD, D.Phil, FRCPC. 




To determine the impact of Implantable Cardioverter Defibrillator (lCD) therapy in an 
autosomal dominant form of arrhythmogenic right ventricular cardiomyopathy (ARVC). 
Background 
ARVC is a cause of ventricular arrhythmias causing sudden cardiac death (SCD), which 
may be prevented by lCD. 
Methods 
We studied 11 ARVC families, where a 3p25 DNA haplotype (ARVD5) segregates with 
disease and compared mortality in subjects with an lCD to that in a control group 
matched for age, sex, ARVC risk status, and fam ily. 367 subjects at 50% a-priori risk of 
inheriting ARVC were c lassified as high risk (HR=197), low risk (LR=92) or unknown 
(UK=78) based on clinical events, DNA haplotyping, and/or pedigree position. Forty-
eight HR subjects (30 males, [median age 32 years] and 18 females [median age 41 
years]) were followed after lCD implantation (secondary to documented ventricular 
tachycardia (VT) in 27%). Survival was compared to 58 HR historical control subjects 
who were alive at the same age to-the-day at which the lCD subject received the device. 
Results 
In the HR group (n=197), 50% of males were dead by 39 years, and of females by 71 
years, a relative risk of death of 5. 1 (95% CI 3-8.5) for males. SCD's occurred in 62 
(76%) males and 7 (33%) females. The 5-year mortality rate for males with an lCD was 
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zero compared to 28% in controls (p=0.009). Within 5 years, the lCD fired for VT in 
70%, and for VT >240 beats per minute in 30%. There was no difference in rate of 
discharge when analysed by indication for lCD. 
Conclusions 
The unknown mutation at the ARVD5 locus on chromosome 3 causing ARVC in this 
population results in high mortality. Risk stratification, including genetic haplotyping, led 
to lCD therapy that resulted in substantially improved survival for males. 
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4.2 INTRODUCTION 
Treatment of ventricular tachyarrhythmias, which often cause sudden cardiac death 
(SCD), includes antiarrhythmic drugs and implantable cardioverter defibrillator (ICD) 
therapy. Several randomized control trials have compared these treatment modalities 
(223, 224, 226, 228) and shown that anti-arrhythmic medications have limited 
effectiveness (286). ICD therapy is therefore often now considered the treatment of 
choice for ventricular tachyarrhythmias (222). ICD therapy is safe; rare complications 
include infections (230), surgical complications (231) electrode problems (239) and 
inappropriate shocks (232). 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a cause of SCD, usually 
due to tachyarrhythmias (287), for which lCD therapy may be effective. ARVC may be a 
significant cause of SCD in young adults in the USA (158),and Italy (1 05) although its 
true prevalence is unknown (156). Diagnostic criteria are based on clinical, structural and 
functional features with the gold standard for diagnosis being the presence of fat and 
fibrous tissue on cardiac biopsy or autopsy (19, 25, 173). However, antemortem diagnosis 
is difficult despite investigations including 12-lead electrocardiogram (ECG), signal 
averaged ECG (SAECG), echocardiography, magnetic resonance imaging (MRI), and 
Holter monitoring (HM). These tests are non-specific, particularly as the true penetrance 
of the disease is not clear and variable expression is present both between and within 
families (19). 
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ARVC is recognized to be familial (16-19, 21, 23, 288) in an estimated 30% of cases (24, 
25). However, comprehensive assessments of extended family trees are rarely 
documented (12), and familial cases are likely under recognized (142). Known causes of 
autosomal dominant ARVC include mutations in the cardiac ryanodine receptor (RYR2) 
(36, 83) and desmoplakin (52) genes. Other AD ARVC loci include regions on 
chromosomes 2, (40), 3 (4), 10 (47, 49) and 14 (31, 38). It is clear that ARVC is a 
genetically heterogeneous group of diseases with phenotypic overl,ap (151 ). The number 
of ARVC subjects in previous studies defined by genotype is small (22, 31 , 32, 34-36, 38, 
40, 47, 49, 52, 170). 
A Newfoundland family with autosomal dominant ARVC was reported in 1988 (3). The 
diagnosis of ARVC was made following post mortem documentation of fat and fibre in 
the myocardium, and clinical features fulfilling published criteria (25). ARVC in this 
family was subsequently linked to the short arm of chromosome 3 encompassing a 
critical region of 9.3cM (4) at 3p25 (ARVD5). Subsequently, ten additional ARVC 
families were studied and the critical region was reduced to 2cM, at which locus the 
identical set of DNA markers (haplotype) co-segregates with ARVC. This segregation 
with disease across generations suggests a common founder in these 11 Newfoundland 
families (251) and provides by far the largest group of subjects with ARVC defined by 
genotype. Risk stratification of subjects by ARVC status is therefore feasible in these 
families, based upon family history, clinical history and genetic haplotype (linkage 
analysis) data: a methodology used clinically in several genetic disorders prior to 
determining an underlying causative mutation (289, 290). 
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Previous studies of ICD therapy in ARVC retrospectively assessed efficacy in individual 
patients in the absence of appropriate controls (236-239, 291). We investigated mortality 
after implantation of ICD's in 48 high risk (HR) subjects from 11 families with an 
autosomal dominant homogeneous form of ARVC linked to 3p25, and compared 
mortality to that in HR control subjects, matched for age and sex from the same families. 
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4.3 METHODS 
4.3.1 Sample population 
Thirty-five families were referred to the provincial genetics program because of SCD and 
a family history of cardiomyopathy. Eleven were determined to have autosomal dominant 
ARVC (Figure 23 page 146) based on established histopathological, clinical and genetic 
criteria (25). One of these was the original family in which linkage to 3p was defined 
(4)(0MIM: http://www.ncbi.nlm.nih.gov/omim/), and 10 other families were found to be 
linked to the san1e region. Five hundred and fifty one individuals from extant and 
ancestral generations from these 11 families who were born at ~ 50% pedigree risk 
(ARVC affected individuals and their first degree relatives) were identified. To minimize 
the effects of ascertainment and referral bias 367 subjects (212 male, 155 female) from 
'well-ascertained ' sibships were studied. Well ascertained sibships were defined as those 
where ~ 50% of siblings were known to be at high or low risk of ARVC based on 
clinical, pedigree and/or haplotype data. High-risk (HR) was defined as documented 
sustained ventricular tachycardia (VT) or otherwise unexplained SCD < 50-years, the 
presence of a HR DNA haplotype and/or obligate carrier status (affected offspring and 
parent) by pedigree analysis. Subjects could be defined based on any or all of these 
criteria for HR status. Low-risk (LR) was defined as LR DNA haplotype. Otherwise 
subjects were considered unknown risk status (UK). The terms HR and LR are used 
because the common disease haplotype is assumed to co-segregate with the as yet 
unknown disease-causing mutation. 
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Figure 23 One of 11 autosomal dominant ARVC families linked to 3p25 showing family 
members at high-risk, low-risk, and unknown status 
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Consent for analysis of past and current cardiology records and for DNA analysis was 
obtained from each subject (or surrogate) in compliance with the Human Investigation 
Committee requirements of the Health Care Corporation of St. John ' s. AJJ available 
clinical records and autopsy reports were obtained. 
A cardiomyopathy genetics research clinic was initiated in 1998. Serial data 
(retrospective and prospective) on subjects at 50% risk were collected (including clinical 
events, 12-lead ECG, signal averaged ECG (SAECG), Holter monitor, echocardiography 
and MRI) and subjects were offered genetic haplotype analysis. ICD therapy was offered 
to these subjects foJJowing a HR DNA haplotype and an abnormal clinical test 
compatible with ARVC (n=15 males and 18 females). None of these subjects had 
documented VT. Two more males had an lCD following a HR DNA result alone. Seven 
males prior to 1998, and 6 males implanted in other North American centres had ICD's 
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because of sustained VT requiring cardioversion. No individual to date has declined an 
lCD, although one HR subject refused follow-up and died suddenly aged 31 years. One 
subject died 6 weeks after first attending clinic, during clinical work-up, and prior to 
receipt of a HR haplotype result. Thus we report on the outcome of 30 male and 18 
female subjects with ICD's, 73% for primary prevention ofVT. 
All lCD recipients were followed bi-annually at which time the ICD was interrogated. 
After confirmation of sustained ventricular tachyarrhythmias confirmed by the stored 
electrocardiograms following ICD discharge, time to first appropriate discharge for 
documented VT was recorded, as was time to first VT > 240 bpm. A rate of 240 bpm was 
chosen to delineate potentially fatal arrhythmias (in the absence of the ICD) from 
probable non-fatal arrhythmias (292, 293). ICD discharge was not included if it occurred 
within one week of the implant date. Inappropriate lCD discharge was defined as atrial 
fibrillation, sinus tachycardia or non-sustained VT. 
4.3.2 Haplotype analysis 
Of 367 subjects from well ascertained sibships, 201 (55%) had a venous blood sample 
collected. DNA was extracted from peripheral lymphocytes as previously described 
(294). For each polymorphic short tandem repeat (STR) DNA marker, fluorescent 
labelled primers were used to amplify di-, tri-, or tetra nucleotide repeats by the 
polymerase chain reaction, and fragments were analyzed by capillary gel electrophoresis, 
using an ABI 310 genetic analyzer (Applied Biosystems ). Presence or absence of the 
2cM HR haplotype was determined for each family member assessed. 
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4.3.3 Study design 
Age to death was determined in the initial cohort of 197 HR, 92 LR and 78 UK subjects 
from the 11 ARVC families, with censoring at last follow-up or at time of lCD 
implantation. Survival following ICD was determined, and compared with that of control 
subjects following entry to the study. For each ICD subject, control HR subjects were 
selected who did not receive an ICD, were the same sex, were alive at the age to-the-day 
at which the ICD subject received the ICD, and were I st or 2nd degree relatives of the ICD 
subject. All available 1st and 2nd degree relatives meeting these criteria were used as 
controls (n=40; 69%). If there were no age/sex matched 1st or 2nd degree relatives, one 3rd 
or 4111 degree relative was used (n=ll; 19%). In the absence of any appropriate relatives, 
one age and sex matched control subject from a family in the same geographical region 
was used (n=7; 12%). 
The primary outcome was age at death defined to the day. Secondary outcomes were time 
to initial appropriate ICD device discharge for sustained VT, and time to first VT >240 
bpm. Time to first appropriate discharge was compared in those who had lCD for 
primary versus secondary prophylaxis, and in those with, versus those without left 
ventricular enlargement (L VE) based on the Henry calculations defined as 2 SD above 
the mean for LVE (112%) (202, 203). 
Statistical analysis 
We used version 11.5 of the SPSS statistics package for statistical analyses of clinical 
tests (SPSS, Chicago USA). Categorical data were compared by chi-squared analyses. A 
p-value of <0.05 was considered significant. Survival was calculated according to the 
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Kaplan Meier product limit method. Relative risk was calculated using Cox' s Regression 
model. Follow-up continued until death or June 3 2003. 
4.4 RESULTS 
An affected only linkage analysis was done in the first large Newfoundland fan1ily 
described (3). Of 17 affected individuals who had DNA samples available for molecular 
analysis, 11 manifested symptomatic sustained VT before 50 years of age, one 
demonstrated ARVC pathology at autopsy, and 5 were obligate ARVC disease gene 
caJTiers. Twenty-one deceased family members who transmitted ARVC through five 
generations were also considered obligate carriers. Linkage of disease to 3p25 was 
confirmed with a maximum multi-point LOD score of 9.3 at D3S 1585. Analysis of 8 
markers allowed the construction of a chromosome 3p25 HR haplotype with D3S3610-
Fibulin2-D3S2385-D3S1585-D3S1554-708d1 CA-316A10CA-D3S3613 ordered from 
telomere to centromere shared by all affected family members. The HR haplotype was 
also identified in all affected subjects from ten other families with autosomal dominant 
ARVC. 
As shown in Table 20 page 150, 197 (54 %) of the well ascertained sample was 
designated HR. The method of determining risk-status in men was approximately evenly 
split between pedigree position (33 %), DNA haplotype (31 %) and subjects with SCD or 
VT < 50 years (36 %). Few women were diagnosed as HR because they had SCD or VT. 
Two hundred and seven (56%) of the 367 subjects were born after 1950. Most HR male 
subjects, but only about one quarter of HR female subjects had died. 76% of male and 
39% of female deaths were due to SCD. Only 4 LR subjects died, compatible with 
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survival being necessary to obtain a blood sample for DNA tests (Table 20 page 150). It 
is likely that the majority of those of UK status are in fact LR. 
Table 20 Demographic data, method of risk determination and cause of death in 367 
subjects at an a-priori 50% risk of inheriting ARVC, from 11 families linked to 3p25: 
d fi d b ARV C . k t t e me >y ns sa us 
High Risk Low Risk Unknown 
N = 197 N = 92 N =78 
M F M F M F 
N= 123 N=74 N=46 N=46 N=43 N=35 
N % N % N % N % N % N % 
Born 
< 1950 (n = 160) 61 50 32 43 10 22 13 28 27 63 17 49 
~ 1950 (n = 207) 62 50 42 57 36 78 33 72 16 37 18 51 
Methods of diagnosis 
Obligate carrier (OC) 41 33 30 41 - - - - - - - -
DNA haplotype 38 31 41 55 46 100 46 100 - - - -
Clinical event (SCD or VT) 44 36 3 4 - - - - - - - -
Dead 82 67 18 24 I 2 3 6 19 44 II 31 
SCD 62 50 7 9 - - - - I 2 - -
Overall mortality in the ARVC population. 
Median survival in HR males (n=123) was 39 years (95% CI 36-42), in LR males (n=46) 
76 years (95% CI 76), and in unknown males (n=43) 67 years (95% CI 63-71). Median 
survival for HR females (n=74) was 71 years (95% CI 64-78), for LR females (n= 46), 
median age could not be computed because of the lack of events, and UK females (n=35) 
83 years (95% CI 51-115 years). The mortality rate was significantly greater in HR than 
LR males (p=O.OOOO 1 ), and HR and LR females (p=O.O 1 ). The youngest age at death in 
HR males was 19 years, and the oldest 72 years. In HR females the respective ages were 
37 and 88 years. Female HR subjects survived significantly longer than male HR subjects 
(p=O.OOOO 1) (Figure 24 page 151 ). The RR of death for males compared to females in the 
HR group was 5.1 (95% CI 3-8.5). We also assessed mortality in subjects born before and 
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after 1950 to take into account possible effects of differences in risk status determination: 
results remained the same (data not shown). 
Figure 24 Time to death or last follow-up in high-risk males and females with ARVC 
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4.4.1 Subjects studied 
There were 30 males who received ICD's, at median age of 33 years, [range 15-51years] 
and 18 females at median age of 42 years, [range 22-56 years]. ICD's were implanted in 
17 males and 18 females in the absence of documented VT (primary prophylaxis) and in 
the remaining 13 males following VT (secondary prophylaxis). Fifty eight control 
subjects comprised 36 males whose median age at study entry was 33 years, [15-51 
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years], and 22 female subjects whose median age at study entry was 39 years, [22-56 
years] (Table 21 page below). 
Table 21 Demographic data and method of risk determination of ARVC in 48 subjects at 
high risk who received an lCD and 58 matched controls from 11 families with ARVC 
linked to 3p25 
Demographic lCD Cohort Control Cohort lCD Control p value 
Parameters M+F M+F * 
Males Females Males Females 48 58 
N=30 N= 18 N=36 N=22 
N % N % N % N % P* 
Born < 1950 2 6 I 5 25 69 19 86 3 44 <0.0001 
Born > 1950 28 93 17 95 II 31 3 14 45 14 
Diagnosis 
oc 4 13 4 50 18 5 1 17 49 8 "35 <0.0001 
Haplotype 22 74 14 39 5 50 5 50 36 10 <0.0001 
SCD orYT 4 13 0 0 13 10 0 0 4 13 <0.05 
In years 
Mean AAE 33.3 40.3 32.2 40 ns 
Median AAE 32.9 42 32.7 39.2 ns 
so 9.8 9.0 9.6 9.5 ns 
* P=Cht square wtth 1 dffor lCD M+F vs. Control M+F 
* OC: obligate carrier, SCD: sudden cardiac death, VT: Ventricular tachycardia, AAE: 
age at entry 
The majority of the lCD subjects had risk-status defined by DNA haplotype, and were 
born after 1950. In contrast, 36 of 58 of the controls were born before 1950 and had risk 
status defined by pedigree position. The age at entering the study was the same in the 
control group as the age of receipt of lCD, reflecting the matching strategy. There were 
no statistically significant differences between lCD cases and controls in medication 
profile, presence of syncope or chest pain, or abnormalities on SA ECG, echocardiogram, 
Holter monitoring or MRI. However a significantly higher propot1ion of cases had 
documented palpitation and presyncope than the controls (Table 22 page 153). The 
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abnormalities noted on clinical testing are defined in Table 22 (page I 53). (25, I25, I31 , 
I36, 161 , 202, 295-299). 
Table 22 Clinical manifestations of ARVC in 48 subjects at high risk who received an 
ICD d 58 t h d t I fl II £ T "th ARVC l"nk d t 3 25 an mace con ro s rom amttes WI I e 0 ~p. 
lCD Cohort Control Cohort C hi2 
n = 48 n =58 ldf 
Nwith N with Nwith N with 
manifestation documentation % manifestation documentation % p 
Antiarrhythmics 
Class I 10 44 23 II 42 26 ns 
Sotalol 13 44 33 6 31 13 ns 
Amiodarone II 44 27 5 30 17 ns 
Symptoms 
Palpitations 35 44 79 15 32 47 0.003 
Pre-syncope 29 44 66 12 32 37 0.01 
Syncope 15 44 34 5 33 15 ns 
Chest Pain 14 44 32 18 35 51 ns 
Heart Fai lure 6 47 13 10 3 1 32 0.04 
Abn Tests** 
12-lead ECG ' 33 48 69 32 33 97 0.002 
SA ECG2 17 3 1 55 5 12 42 ns 
Echocard iogram3 24 42 57 20 25 80 ns 
Holter monitor4 33 42 79 20 24 83 ns 
MRI5 4 23 23 0 4 0 ns 
Catheterization6 0 18 0 3 15 20 0.05 
Au tops/ 0 0 16 17 94 
Table 3: Definitions 
*Class 1 medications: Mexilitine, Propafenone, Procainamide, Quinidine and Phenytoin 
The larger denominator for the class 1 medication takes into account those with no 
records because they never visited a doctor. 
** Abnormalities on clinical tests 
1. ECG: T wave inversion, Septal Q waves, poor R wave progression in V 1 V 2 and 
V3, or presence of PVC' s(25, 295) 
2. Signal averaged ECG (SAECG): > 115 ms QRS duration (25) 
3. Echocardiogram: > 112% Left ventricular dilatation(202), any right ventricular 
dilatation, focal or global hypokinesis or akinesis of any cardiac wall (25, 131, 
136, 296) 
4. Holter Monitor,> 1000 PVC's in 24 hours, documented runs ofVT of>4 beats 
(25, 297) 
5. Magnetic Resonance Imaging (MRI): evidence of fatty I fibrous infiltrate or 
ventricular thinning ((161 , 298, 299) 
6. Cardiac catheterization: any critical coronary artery disease 
7. Autopsy: evidence of fat and fibre in the myocardium (25, 125) 
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Mortality following lCD 
The male lCD group was followed for a median of2.6 years (from 3 weeks to 12.8 years) 
and the control group for a median of 9.5 years (from 4.5 months to 31 years). There 
were no deaths in the lCD group. Three subjects went on to successfully receive a heart 
transplant after several (2-1 0) years of lCD therapy. Indications for transplant included 
increasing heart failure as a secondary consequence of cardiomyopathy and intractable 
VT. One subject in the control group received a heart transplant; the remaining 35 
subjects had died. The 5-year mortality rate for males following lCD therapy was zero 
compared to 28% in controls (p=0.009) (Figure 25 page 155). 
The female ICD group (n= 18) was followed for a median of 0.7 years, from 2 weeks to 
3.9 years and the control group (n=22) for a median of28.8 years, from 1.9 years to 37.8 
years. There were no deaths in the ICD group, whereas in the control group, 10 of 22 
(45%) subjects had died. Five year mortality in the control group was 9% not 
significantly different from that in the females who received an ICD (Figure 26 page 
155). 
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Figure 25 Time to death or last follow-up in 30 male subjects at high-risk for ARVC who 
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Figure 26 Time to death or last follow-up in 18 female subjects at high risk for ARVC 
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4.4.2 Time to appropriate first discharge of the lCD 
In the male lCD group (n=30), 14 subjects (47%) had at least one appropriate discharge 
for VT. The median time to first discharge was 2.9 years (95% CI 1.17-4.6years) (range 2 
weeks to 5.1 years). The 5-yr. cumulative frequency for first appropriate ICD discharge 
was 70%, significantly greater than the 5-year mortality rate for the control group 
(p=0.0005). However, the 5 year mortality in the control group was similar to the 5 year 
cumulative rate of 28% for VT >240 bpm in the lCD group (Figure 27 page 156). Two 
(11 %) of 18 female lCD subjects had an appropriate first discharge, both for VT >240 
bpm. 
Figure 27 Time to first appropriate firing or last fo llow-up for VT (lCD 1 ), and for VT 
>220bpm (ICD2), in males who received an lCD and time to death or last follow up in 
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We compared discharge for VT in males based on whether the ICD was for primary or 
secondary indications. There was no signjficant difference between the groups (median 
time 2.5 years, 95% CI 0-5.2 years vs. 2.9 years, 95% CI 0-6 years respectively).A 
similar observation was made when time to first discharge for VT>240bpm was assessed 
(results not shown). No significant difference in discharge in those with or without L VE 
was observed. In 16 subjects with L VE, 45% had fired within 5 year, and in 10 subjects 
without LVE, all had fired. 
With respect to side effects observed, 5 (10%) of the 48 lCD subjects have had single 
inappropriate shocks and 3 have had lead fracture requiring replacement. 
4.5 DISCUSSION 
4.5.1 Mortality 
The results of this study, from a large genetically homogenous population, demonstrate 
that ARVC, caused by an unknown mutation at the ARVD5 locus on chromosome 3, is a 
life-shortening disorder. There is a sigruficantly increased relative risk of earlier death in 
men compared to women, in line with previous studies (12, 167), although the mortality 
rates in the current study are higher than those for other familial forms of ARVC (170). 
Guidelines for the prophylactic use of lCD in ARVC are not established (300). The 
majority of subjects in this study were essentially asymptomatic, presenting a dilemma 
with respect to therapy application. The use of ICD was thus influenced by the fact that 
the presenting symptom was often SCD and the extensive family histories defined a 
malignant natural history. Clirucal testing in subjects from ARVC families in this study 
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who were at an a-priori 50% pedigree risk, and the availability of genetic haplotyping, 
allowed accurate determination of those at greatest risk, permitting prophylactic 
implantation of an lCD. 
Efficacy of lCD 
Few studies have assessed the efficacy of lCD therapy in ARVC (235-239, 291). The 
largest series to date (238), studied a multicentre group of 132 patients: a smaller study 
assessed mainly primary prophylaxis (291), and a single centre study (239) reported on 
60 subjects with advanced disease. These studies of heterogenous ARVC subjects 
estimated lCD mortality benefit based on discharge free survival. In contrast, the 11 large 
ARVC families linked by a founder haplotype in this current study provided the etiologic 
homogeneity that faci litated the identification of a robust control group matched for high 
risk status, age, sex and family. As a result, a closer estimate of the true magnitude of 
lCD therapy could be derived. The results clearly demonstrated that lCD therapy 
significantly reduced mortality in high risk men from the ARVC fan1ilies studied. 
Interestingly, these lCD mortality benefit results (28% 5-year total mortality reduction in 
males compared with familial controls) appear similar to those in previous studies where 
discharge free survival was estimated: 36% 5-year (239) and 28% 3 year (238). Few side 
effects of lCD therapy occurred and all were resolved. It is notable that decreased 
mortality was observed, despite the fact that the majority of men studied received an lCD 
prior to the documented onset of ventricular arrhythmias. The results for women were not 
statistically significant. This was likely attributable to the reduced statistical power due to 
the less malignant course of ARVC in women, the smaller sample size and shorter 
duration of follow-up. 
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Theoretically, first ICD discharge would be analogous to death given certain criteria: that 
the ICD is programmed to fire at only those times when a potentially lethal arrhythmia 
occurs and that the insertion of the ICD is not pro-arrhythmic (30 1 ), the latter being very 
unlikely given previous primary prevention studies (302). By the end of this study about 
half of the male group and 10% of the female group had had an appropriate ICD 
discharge. It was demonstrated however that time to first discharge in the ICD group 
occurred much earlier than death occurred in the control group. There are several 
potential explanations for this finding. Firstly, subjects with ICD's may have progressed 
further in the disease process than the controls, thus were at greater risk of having an 
arrhythmic event. If this were correct then the benefit of ICD may be greater than it 
would appear in this study. Against this possibility however is that the degree of ectopy 
observed on Holter monitoring was similar in the ICD and control groups, and there were 
fewer lCD subjects with an abnormal echocardiogram. The conclusion that lCD and 
control groups were similar should be tempered however by the fact that the course of 
disease in the control group was determined retrospectively, and data on clinical 
manifestations of disease were missing in a substantial minority of controls. Finally, 
individuals in the control group may have survived runs of VT that triggered discharge in 
the lCD group. This explanation seems the most likely, given that we found that time to 
first lCD discharge for sustained VT > 240bpm was similar to time to death in the control 
group. Unlike one recent study of lCD efficacy in ARVC (238), we did not find a 
relationship between L VE and rate of discharge of the lCD. 
There are several limitations to this study. Firstly, it is a cohort study with historic 
matched controls. Secondly, there was selection bias in the choice of cases for the lCD 
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group and to a lesser extent the control group. Thirdly, clinical data from the control 
group and from a minority of the lCD group were collected retrospectively. Finally, only 
families linked to 3p25 were studied and the results may not be generalizable to all 
fan1ilies with ARVC. However, a randomized control trial is not possible in ARVC and 
all previous studies have been descriptive, without an appropriate control group. The 
control group for this study was matched for multiple factors, which may influence 
outcome: ARVC risk status, family, sex, age and survival. Selection bias was limited by 
including all available controls, and by studying only well ascertained sibships in which ~ 
50% of siblings at 50% risk had a known ARVC status. Furthermore, selection bias in the 
cases was likely to limit the effect size of the lCD as some cases had ICD because they 
had already developed VT and may therefore have been more severely affected. 
However, these individuals did not seem to have lCD discharge more often than other 
subjects. The retrospective nature of the study did not influence the determination of the 
primary outcome (mortality) but did limit the conclusions that could be drawn on the 
comparability of the clinical manifestations of disease in the lCD and control groups. 
Although these results may not be generalizable to other causes of ARVC, this ARVD5 
linked population is by far the largest genetically homogeneous group of ARVC subjects 
studied and ARVC caused by this mutation may be prevalent in other populations. 
Careful family history will detect an autosomal dominant mode of inheritance consistent 
with this form of ARVC but positive family histories can be missed if the mutation is 
transmitted through several generations of females. Further studies will be necessary to 
determine the long term clinical course of ARVC following lCD therapy and to assess the 
utility of lCD in females with ARVC. 
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We conclude that this form of ARVC is a malignant disease, particularly in males, who 
frequently die suddenly in early adulthood. The study is unique in that DNA haplotyping 
and extensive family history data are used for risk stratification and subsequent 
prophylactic lCD therapy in a large genetically homogeneous sample. Results 
demonstrate that this genetic risk stratification model for lCD therapy has a beneficial 
impact on survival in males in this population regardless of indication (primary or 
secondary therapy) implying that SCD may be the first symptom in those at high-risk. 
These results support the use of ICD's as a primary prevention therapy in familial ARVC 
linked to 3p25 for individuals at high genetic risk. 
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5 GENETIC KNOWLEDGE AND MORAL 
RESPONSIBILITY: AMBIGUITY AT THE INTERFACE OF 
GENETIC RESEARCH AND CLINICAL PRACTICE 
"Conventionality is not morality. " 
Charlotte Bronte 
Daryl Pullman and Kathy Hodgkinson 
This paper was published in Clinical Genetics 2006 Mar;69(3):199-203. 
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5.1 ABSTRACT 
Despite a rapidly expanding literature on the issue of duty to warn at-risk relatives in the 
context of clinical genetic testing, little has been written on parallel issues with regard to 
the management of genetic research results. Some might view this lack as an indication 
that there is little to discuss in this regard. That is, standard practice is that data obtained 
through medical research should not be treated as though they are clinically relevant, and 
this standard should hold for genetic research as well. This paper challenges this 
conclusion and its underlying assumptions. We argue that the line between genetic 
research and clinical practice is often ambiguous. In some cases research data gathered 
from a very small number of subjects could have immediate clinical implications. Hence 
it is unethical for genetic researchers to absolve themselves of clinical responsibilities for 
research subjects and/or their families, on the grounds that the data were obtained for 
research purposes. Indeed, we argue that it could well be unethical to embark on some 
forms of genetic research unless advance arrangements have been made for genetic 
counselling and clinical follow-up. Furthermore, in some cases it might be unethical to 
enrol subjects in studies if the subjects are unwilling to receive their individual results. 
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5.2 INTRODUCTION 
Despite a rapidly expanding literature on the issue of duty to warn at-risk relatives in the 
context of clinical genetic testing, the situation remains ambiguous. Recent commentary 
tends to favour considerations of individual autonomy, patient confidentiality, and the 
individual's right to control his or her genetic information (303-305). However, there are 
those who argue for an evolving ' duty to warn' which may override considerations of 
patient confidentiality and the right not to know genetic information (306, 307). Some 
have reframed the debate as a matter of fan1ilial obligation with a ' duty to share' 
clinically relevant genetic results with relatives (308), supported by an emerging 
'principle of mutuality' that supersedes individual autonomy in the genetics era (309). 
Emerging case law in the U.S. moves to support this principle, as it extends the 
responsibility of clinicians beyond immediate patients to include family members (31 0, 
311). Meanwhile, broad privacy legislation pushes back in the other direction, as it tends 
to restrict the sharing of genetic information (303, 312, 313). The predictable result is 
moral distress for health care professionals (3 14). 
The current focus on the clinical situation with an emphasis on duty to warn, fails to 
address parallel issues with regard to the management of genetic research results (315). 
On the face of it this lack may appear understandable, as there is a general proscription 
against sharing individual results in medical research. This is because the validity of 
clinical trial information is generally cumulative in nature, such that perceived results 
with a single research subject cannot, and should not be, generalized. For example, a 
clinician/researcher may believe that an individual patient has done well in a clinical trial, 
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ru1d thus might assume he or she has a clinical responsibility to continue the trial 
medication outside the research protocol. However, in the absence of aggregate trial data 
the clinician 's assumption could well be false. While cumulative evidence is necessary in 
some types of genetic research such as those designed to study gene-disease associations 
and gene-environment interactions, there is a broad subset of genetic studies in which this 
is not the case, particularly with serious monogenic disorders for which a tight linkage 
assignment has been established. In such cases the researcher may accrue knowledge 
from a single individual which has immediate clinical relevance not only for that 
individual, but for other members of the pedigree. To argue that there is no obligation to 
share this data with individual subjects and/or with those responsible for their clinical 
follow-up, or to ensure that measures are taken to advise at risk frunily members of their 
status on the grounds that 'these are research results and thus should not be considered 
as clinically relevant, ' is to claim ignorance in the face of knowledge for which the 
researcher is morally, if not legally, responsible. 
5.2.1 Case description 
Here we describe our experience conducting genetic research in Newfoundland, Canada, 
(where it is likely that several serious monogenic diseases remain to be described) on one 
such disease: autosomal dominant arrhythmogenic right ventricular cardiomyopathy 
(ARVC). ARVC is a cause of sudden cardiac death (SCD) in young people.(l05, 158) 
Clinical diagnosis is difficult and is based on observational and descriptive diagnostic 
criteria (25). ARVC is genetically heterogeno'us. It is most often inherited as an 
autosomal dominant disorder, and several genetic loci and cloned genes are known (33, 
86, 316). One locus at 3p25 (4) contains an as yet unidentified gene responsible for one 
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form of ARVC in 16 large families in Newfoundland and Labrador, including up to 1200 
individuals over 9 generations in a single family. Analysis of these families has 
determined the lethal sex-influenced natural history of the disease: 50% of males die in 
the absence of treatment by 40 years and 80% by 50 years, with corresponding risks for 
females of 5% and 20% (248). Our original consent form reflected our ignorance of the 
disease. That document, signed subsequent to genetic counselling, followed common 
practice with genetic research in that it provided assurances that were a genetic location 
found, further counselling would occur after molecular testing. At that point the subject 
would have the option of deciding whether or not to learn his or her DNA results. 
Subsequent determination of a linked locus at 3p25, and the assignment of a founder 
DNA haplotype present in all affected subjects across families, meant that DNA testing 
could define disease status presymptomatically. Effective primary prevention of 
potentially lethal arrhythmias is available with implantable cardioverter defibrillator 
therapy (lCD) (248). Hence, although ARVC in Newfoundland and Labrador is a lethal 
condition with a high recurrence risk and where effective treatment is available, DNA 
testing remains in the research domain. As a result, several cases have occurred where 
concerns have arisen regarding: (i) genetic knowledge and clinical responsibilities on the 
part of genetic researchers; (ii) the rights and responsibilities of research subjects with 
regard to their genetic information; and, (iii) potential responsibilities to other family 
members and the general population. 
5.2.2 Case 1 
A female subject at 50% a priori pedigree risk participated in genetic linkage analysis 
research. The sex-influenced nature of the disease and inheritance through a female 
Page 166 of 292 
family member meant there was no immediate family experience of serious sequalae to 
ARVC, even though multiple SCDs in young people had occurred in the extended 
pedigree. Research revealed a high-risk DNA haplotype. Nevertheless, this subject 
refused to learn her DNA results or to receive further clinical testing. The question was 
raised as to whether we had a duty to warn her eight adult children, including five males 
aged between 20 and 40 years. 
This scenario, although generated through genetic research, could occur following 
clinical testing, as defining affected status of the subject by any method would place the 
subject's offspring at 50% risk of a treatable disease causing SCD. In our opinion, 
clinical testing, regardless of the motivation for the testing (research or clinical), should 
result in disclosure to the individual. Nevertheless, this still leaves open the ethical 
question of duty to warn at-risk relatives. Given the lethal and treatable nature of ARVC, 
even those who support a conservative position with regard to sharing genetic 
information without patient consent, might support doing so in this situation. Indeed, 
emerging case law in the United States has already established that in some instances 
physicians may have a duty to breach the confidentiality of a patient so as to warn family 
members who are not their patients of their risk of genetic disease (311 , 317, 318). 
Similar provisions are available in Canadian law under the provisions of the so-called 
Tarasoff situation named for the landmark decision of the Supreme Court of California. 
That case recognizes that: "at some point the need to protect the public from imminent 
danger becomes paramount, and at that point the doctor's duty of confidentiality ends and 
is replaced by a duty to warn the person[s] at risk." (319) However, all of the cases cited 
occur within the clinical context. If the life saving information is unavailable because 
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genetic researchers have failed to establish working relationships with clinicians, or 
because researchers restrict disclosure of ' research results' , the question of contacting at-
risk family members is moot. 
5.2.3 Case 2 (a and b) 
Two young males at an a priori 50% risk of inheriting ARVC participated in the research. 
Again, both were recruited prior to our understanding of the natural history of the disease, 
and thus before we appreciated the true severity of ARVC linked to 3p25 in 
Newfoundland and Labrador. Both subjects refused to hear their DNA haplotype results. 
This left the research team in the position of knowing that a serious risk of a potentially 
lethal but treatable condition was present, yet due to the subjects' refusal to hear their 
results, the research team was unable to take steps to organize treatment with their 
clinical care givers. 
2a) Despite numerous overtures, the first male steadfastly refused further contact with the 
research team. He died of a SCD due to AR VC prior to his 30th birthday. 
2b) The second male initially refused his haplotype information because he was training 
for a career for which a high-risk result would curtail his ability to continue. Furthermore, 
given the potential for SCD there was a possibility that, due to the nature of the job (in 
transport), members of the public would be put at risk. In this case the individual 
eventually agreed to receive his results and he was treated successfully. His career plans 
were subsequently altered. 
These, and similar cases, contributed to our consternation with regard to our duties to act 
upon genetic information irrespective of how the information was obtained. One result 
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has been a modified consent document so that ARVC study participants are now required 
to accept that they will receive their results if and when these become available through 
the course of the research. If a subject does not want to learn his or her result, then the 
blood sample will simply not be drawn. We are considering a further amendment to the 
effect that if the research subject is either unwilling or otherwise unable to share 
clinically relevant results with at-risk family members, steps may be taken by the 
research/clinical team to ensure that this information is made available to those family 
members. 
5.3 DISCUSSION 
The manner in which we frame the distinction between genetic research and clinical 
genetics will affect our understanding of our duties regarding the management of 
information accrued through genetic research. First, it is important to contrast the nature 
of the relationship between the researcher and the subject in genetic research, with that of 
the clinician and patient in the clinical context. In the clinical context patient autonomy 
and the assurance of confidentiality in the patient-physician relationship, are often 
presented as key considerations in arguing against a generalized duty to warn (312, 320). 
However, insofar as genetic research involves families, the family must remain the 
primary focus of concern with regard to the management of research results. 
The foregoing speaks to the importance of ensuring that genetic research is coordinated 
with local clinical genetics services, ideally through the mechanism of disease based, 
health region coordinated, genetic registers that are sensitive to both clinical and research 
interests. (321-324) Families are the focus of registers, and ongoing clinical care and 
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management, follow-up of those at risk, and appropriate genetic counselling for serious 
diseases with high recurrence risks are their major function. When research results are 
obtained they can be discussed with trained genetic professionals, and issues of potential 
error in research data can be addressed. Thus, in the absence of an established 
relationship between genetic researchers and the clinical genetics team, a research project 
of the nature described above, could well be considered unethical. This last point has 
particular significance when genetic researchers are from outside the jurisdiction in 
which clinical services are provided, a not uncommon scenario for genetic research 
conducted in Newfoundland. 
Newfoundland and Labrador's population is ideal for genetic research because of its 
geographic and genetic isolation, and large family sizes. This has been the impetus for 
numerous successful collaborative relationships with out-of-province genetic research 
teams. However, some out-of-province teams have studied Newfoundland families in the 
absence of local clinical genetics input. In some cases outside researchers have abdicated 
any responsibility for sharing clinically significant results with research subjects or with 
local clinicians responsible for their follow-up, on the grounds that research results 
should not be applied to the clinical context. As a consequence, the province has drafted 
legislation to ensure that all genetic studies conducted here are subject to local ethics 
review. For diseases that fit the risk profile of ARVC, local research ethics board 
approval will occur only when satisfactory arrangements have been made through the 
clinical genetics service to ensure appropriate follow-up, and for the communication of 
relevant results with subject/patients and their families. Clinical geneticists working 
directly with researchers in this manner may be placed under significant burden regarding 
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potential 'duty to warn' issues that might arise. Although professional clinical guidelines 
in the USA, UK and Australia permit breaking of confidentiality in 'exceptional 
circumstances,(325-327) the mechanism by which this would occur remains unclear. One 
suggestion is that health professionals be required to notify a legislated statutory body, 
whose remit would be to warn relatives of their risks without identifying the affected 
proband.(307) Again, however, we note that such guidelines are aimed primarily at the 
clinical context and do not account for research findings. 
The key consideration here is that information obtained through genetic research for 
serious monogenic disorders (where results from a single individual can have immediate 
clinical implications) differs from results generated in the course of a standard clinical 
trial, or in population based, gene association studies. The distinction, therefore, between 
research results and clinical application, so important . in the context of clinical trials, 
cannot be used as the standard for genetic studies of serious diseases with high recurrence 
risks, particularly for those with potential ameliorative interventions. 
Finally, it is important to mention the privacy paradox. This paradox lies in the fact of 
increased legislative emphasis on individual privacy protection, even as the advance of 
genomic medicine necessarily reveals information that is familial in nature. We are 
sensitive to concerns regarding genetic discrimination, and recognize the need to protect 
individual and family privacy when appropriate. However, genetic privacy is a somewhat 
fickle matter, dependent to a large extent on the phenotypic expression of the particular 
genetic condition. Individuals with achondroplasia, for example, may have concerns 
about genetic discrimination, but it has nothing to do with the privacy of their genetic 
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information. Concerns about insurability can also be misleading, as knowledge of serious 
genetic disease in the family has to be disclosed, regardless of individual disease status. 
In the case of ARVC, for example, multiple deaths in young people within the extended 
family will immediately affect insurability. To put it bluntly, individuals at-risk of ARVC 
have to face the choice of dying with an insurance policy of dubious validity because 
they failed to disclose relevant fan1ily history irrespective of genetic testing, or, to be 
alive enjoying their loved ones but without insurance. 
We acknowledge that ARVC in Newfoundland and Labrador is in some respects an 
atypical genetic disease. Hence we do not assume that the manner in which we manage 
research results on this condition is generalizable to all genetic studies. However, the 
lessons learned from ARVC provide another perspective on the nature and extent of our 
obligations with regard to genetic information. This behoves genetic researchers in 
general and research ethics boards in particular, to consider carefully the possible clinical 
ramifications of research data prior to embarking upon or approving a genetics research 
project. 
We are still in the early days of the genomic era in medicine. It remains unclear whether 
the new wine of rapidly expanding genetic information can be contained in the old 
wineskins of principles, policies, and procedures for gathering, storing, and sharing 
medical information. Our suspicion is that one size simply will not fit all. A more 
nuanced understanding of the relationship between genetic research and clinical practice 
is essential as we move forward in this regard. 
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6 THE CASE FOR CLOSER INTEGRATION OF CLINICAL 
AND RESEARCH GENETICS PROGRAMS: LESSONS FOR 
NEWFOUNDLAND AND LABRADOR. 
An idealist believes the short run doesn't count. A cynic believes the long run doesn't 
matter. A realist believes that what is done or left undone in the short run determines the 
long run. 
Sydney J. Harris 
Kathy Hodgkinson and Daryl Pullman 
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6.1 INTRODUCTION 
The fundamental difference between genetics and other branches of medicine, whether 
clinical service or research, is that genetic disease provides medical information pertinent 
to the relatives of the diagnosed patient. This is particularly true for classic Mendelian 
diseases where the risks for relatives are high. Optimal management of patients with 
Mendelian genetic disorders and their at-risk relatives requires both clinical and research 
expertise, and a systematic approach to the collection, storage and sharing of research and 
clinical data. 
This paper discusses our experience in Newfoundland and Labrador in the management 
of autosomal dominant arrhythmogenic right ventricular cardiomyopathy (ARVC). 
Newfoundland and Labrador is the Eastern most province in Canada. It is known for its 
founder population and the genetic diseases that result from its historic settlement 
patterns (250). These diseases provide an excellent resource for research, and a 
concomitant burden for health care provision (251). ARVC is common in Newfow1dland 
and Labrador, with a prevalence of about 113000. We have faced numerous theoretical, 
practical and ethical challenges in managing ARVC patients while conducting research 
on this disease, and we have adjusted our policies and practices in light of our evolving 
knowledge and experience. We believe the lessons learned can inform policy and practice 
for the management of genetic diseases in all Canadian jurisdictions. 
In what follows we begin with some general observations about genetic research with an 
emphasis on ARVC and its phenotype. We define the structural differences between 
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clinical genetics and genetic research on the one hand, and their non-genetic counterparts 
on the other. We then discuss the nebulous distinction between clinical genetics and 
research genetics, and the implications this has for the management of genetic 
information. The points raised are illustrated with reference to our own experience in 
serving patients in our genetic cardiomyopathy clinic even as we conducted research in 
an attempt to discover the causative gene. Our experience has convinced us that it is not 
only more pragmatic but also ethically imperative to create genetic registries in order to 
manage our clinical and research data in a more effective manner. We believe the lessons 
learned have broad implications for the manner in which genetic data are managed in 
both clinical and research settings. 
6.2 GENETIC RESEARCH IN NEWFOUNDLAND AND LABRADOR 
Genetic research has occurred in Newfoundland since the inception of the Faculty of 
Medicine at Memorial University. (328). Such research is funded through research grants 
and is at times curtailed because of insufficient funds. In such cases families may be left 
with no information regarding the research findings despite what could be significant 
risks associated with their disease. In some cases samples taken from families have been 
lost, including samples from ARVC families for whom the disease is lethal (248). Many 
samples taken in the 1970' s and 1980' s were destroyed in the early 1990' s due to a lack 
of storage facilities (45). A significant number of those samples were from individuals 
who subsequently died of ARVC. It is a sobering to think that had those early samples 
been available in the late 1990's, the ARVC gene, found in 2008, (46) might have been 
found earlier. Our experience with ARVC motivated us to rethink many aspects of the 
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manner in which we handle genetic information and the patients and families affected by 
that information. 
ARVC in Newfoundland is caused by a missense mutation in a transmembrane protein 
(TMEM43) of unknown function (46). At least 15 very large ARVC families (up to 1200 
people over 10 generations in one family) have been ascertained. ARVC causes sudden 
cardiac death (SCD) due to tachyarrythrnias. If untreated, 50% of young males will be 
dead by age 40, and 80% by 50 years compared with 5% and 20% of women 
respectively. Those who survive SCD are still susceptible to heart failure (248, 329). 
Implantable cardiodefibrilator (lCD) treatment significantly alters survival for males 
(248). 
Given the significant burden of genetic disease and the relatively small genetics research 
unit at Memorial University, Newfoundland and Labrador, collaboration with external 
teams is required. However in the early days there were no written agreements regarding 
provision of DNA results, and no involvement with clinical genetics services. External 
teams in the past did not require local research ethics board (REB) approval. If 
treatment/diagnostic options became available, or patent and subsequent royalty 
payments resulted, there was no guarantee that these would be made available to 
participating families. As a direct result of the need to protect Newfoundland and 
Labrador families, recent legislation requires external research teams to undergo 
Provincial ethics approval. This has the benefit of allowing ·external collaborators to 
continue working with local families and research teams, provides local clinical care for 
families, and allows for equitable benefit sharing arrangements (330). With regard to 
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ARVC, we were fortunate that one of our external collaborators (Dr. Ludwig 
Thierfelder's team in Berlin, Germany) was able to provide linkage results for 6 years 
prior to our local attempt to find the causative mutation. 
Local capacity to conduct genetic research is much greater now due to the Atlantic 
Medical Genomics Genetics Initiative (AMGGI), a large project funded through Genome 
Canada (331). AMGGI aims to facilitate appropriate local service and support for 
patients and their families within a framework of research to identify novel disease 
causing genes in a wide range of genetic conditions prevalent in Atlantic Canada. This 
ambitious and comprehensive initiative covers the gamut from clinical ascertainment of 
patients, to research in molecular genetics and the provision of clinical genetics services, 
culminating with the development and implementation of health policy to ensure the most 
effective care for our fan1ilies. 
AMGGI provided significant funding for genetic research in Newfoundland and Labrador 
It also however exacerbated already existing problems with regard to data management. 
With multiple genetic research projects occurring both locally and in collaboration with 
external collaborators for many decades, genetic data is often present in various places, 
and pedigrees exist in various forms. Some pedigrees contain large quantities of 
information and in some cases irreplaceable samples have been lost. At times family 
members are seen clinically before a research study is initiated, which means some 
individuals may be approached numerous times to provide the san1e information. This is 
onerous even if there is ongoing clinical management, and an inappropriate burden if 
there has never been feedback and continuity. 
Page 177 of292 
While the double ascertainment of a pedigree is troubling in and of itself, the current 
environment of stricter ethics protocols complicates matters even more when additional 
consent is required in order for the clinical genetics team to access pedigree information 
from the genetics research team or vis-a-versa. We have yet to understand from whom 
permission should be obtained for a pedigree containing 1200 people when there may be 
as many as 20 pro bands. The worst aspect of this system is that data accrued by one set of 
people is not available to another set, when the fan1ilies are the same, the disease is the 
same, and the families themselves perceive that the data is being shared, particularly 
when that data is essential to the ongoing research or clinical care. High risk individuals 
who have given their family details many times understandably assume that their disease 
and risk status is known and being managed appropriately by health care professionals. 
However, when their status is known only to the research group due to technical, 
conceptual or procedural barriers, the prospect of clinical information slipping through 
the cracks is frightening at best. 
6.3 CLINICAL GENETICS: WHO IS THE PATIENT? 
Clinical genetic service in Newfoundland Labrador has been provided at the tertiary 
health care centre in St. John's since 1988, with secondary service available in Central 
and Western health districts. Genetic services provide accurate diagnosis of genetic 
disease and risk assessment to individuals and families and clinical management (in many 
cases). Risk depends on a number of factors. The same disease gene can affect 
individuals differently (variable expression), and the presence of a disease gene may lead 
to a probability, rather than a certainty, of disease manifestation (reduced penetrance). 
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One aim of the clinical genetic service is to reduce disease burden through appropriate 
screening and/or treatment. 
Like all clinical care in a complex health care environment, clinical genetics services are 
provided by a range of medical professionals including physicians, nurses, genetic 
counsellors, social workers, and others as needed. However, a moment's reflection 
reveals that clinical genetics dealing with Mendelian disease is distinct from other clinical 
services in a number of respects. The first key difference is that the primary clinical 
information for genetic services comes not from the individual patient, but rather from 
the family pedigree. Even in the current climate of heightened awareness around privacy 
and confidentiality, genetic health care staff continue to collect and utilize family history 
information without direct permission from everyone on the pedigree. Although access to 
a medical record requires permission from the patient or their next of kin, demographic or 
disease-status information can exist on a pedigree with no permission requested or 
required from the listed individuals, many of whom may be dead. Without this privileged 
access to familial information, risk assessment, genetic counselling and in some cases 
diagnosis would not be possible. This leads to a second key difference between clinical 
genetics and other clinical services. On the basis of pedigree structure alone genetic risk 
figures (based on probability) are often available. Thus it is possible for the genetics 
clinician to provide a probabilistic diagnosis for some family members without even 
seeing them. If a causative gene is known, then risk information is often concrete and 
genetic testing can inform individual patients and/or family members of their disease or 
relative risk status. The familial nature of genetic information thus presents particular 
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ethical challenges with regard to the clinician's duty to warn at risk relatives who may 
not even be their patients (276). 
6.4 RESEARCH GENETICS: WHO IS THE SUBJECT? 
Genetic research is simply an attempt to determine the relationship between genotype and 
phenotype, looking for genes that cause, or contribute to a disease. The aim is to find the 
gene(s) and reveal the pathophysiology. The two main methods are family based linkage 
analysis and population based association studies (332), the latter more usually applied to 
complex disorders where family history does not follow a Mendelian pattern. Once a 
major disease gene is discovered, researchers can determine genotype/phenotype 
associations, genetic and/or environmental modifiers to the expression and penetrance of 
the disease, and disease epidemiology, including the natural history and the efficacy of 
potential treatments. Typically such research takes years. The research questions 
ultimately lead to information that is relevant to the participating individuals, from the 
initial 'do I have the causative gene?' and ' if I do, how will the disease affect me?' to 
'what effective treatments or screening are available?' Such research also informs policy 
and procedure for provision of evidence based health care. 
Newfoundland is known for the willingness of many families with genetic disease to 
participate in long term research projects, with both clinical and ethical implications for 
the individuals concerned. The process starts with an individual presenting with a genetic 
disease and can lead to years of research into the disease and the family. The process of 
constructing a pedigree will include unaffected family members and others who may be 
at significant risk for the condition. Genetic researchers may or may not have direct 
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contact with all of these individuals, but many will be contacted and consented into the 
study for the purpose of providing additional genetic samples as the research proceeds. 
Many at risk individuals may not yet be patients in a clinical genetics service, but 
depending on their risk status it could be imperative that they be referred for clinical 
follow-up. 
While it is standard practice in non-genetic medical research to make a clear distinction 
between research data and clinical information, this standard is often inappropriate in the 
context of genetic research. The difference lies in the fact that clinical trial data is 
aggregate information such that the research result applies not to an individual enrolled in 
the study but rather to a statistically powered group. Thus it is generally only after a 
significant number of individuals have been studied in a clinical trial that a valid research 
result can be generated. For this reason it is inappropriate to make clinical decisions 
based on preliminary research data and hence research data should not be treated as 
clinical information. In genetic studies, on the other hand, information acquired from a 
single individual could have immediate clinical implications for that individual and 
perhaps to other family members as well. Historically, research teams from other 
jurisdictions (usually from the USA or mainland Canada) have recruited 
Newfoundlanders for genetic research of this type, and failed to recognise the clinical 
significance of their findings. This has sometimes led to morbidity and mortality that 
could have been avoided. 
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6.5 GENETIC COUNSELLING AND THE PROVISION OF GENETIC 
INFORMATION: THE IRRELEVANCE OF THE RESEARCH/CLINICAL 
DISTINCTION 
There is significant overlap between a clinical genetic and a research genetic approach to 
fami lies with severe Mendelian disease (Table 23 page 189). A coordinated approach to 
disease management would thus appear sensible. Newfoundland is ideally suited to an 
overlapping approach primarily because the population is clearly demarked in terms of 
history and geography, and is served by a single tertiary centre. 
If a gene is already known, then counselling and screening can be offered to other at-risk 
family members. This extended contact is made through the original proband, and family 
members are asked if they would like an appointment to discuss the issues. If a condition 
is seen for which the genetic defect is unknown, or where the defect is known but further 
epidemiology or research into modifying genes needs to occur, the family can be 
recruited into a genetic research project. Contact with family members occurs the same 
way as for clinical service, from the original proband, who approaches other family 
members asking if they agree to be contacted. With initial permission granted in this 
manner, cons~nt for the research can be obtained from each participant, and information 
regarding the research progress can be returned as appropriate. To facilitate this process, 
it is imperative that research tean1s work in concert with their clinical genetics 
counterparts who can coordinate clinical management of affected and at risk indiv.iduals 
while providing appropriate support to the fan1ily. 
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If through genetic research a genetic linkage or a causative gene is found, then family 
members can be notified, and testing offered exactly as it would under clinical conditions 
where the gene is already known. It matters little to families with an inherited disorder 
whether they were ascertained via a clinical or research route. Either way, genetic 
counselling and the provision of genetic information is required, and/or appropriate 
clinical management instigated at whatever level that information exists. If research 
provides new information, then individuals who were previously at-risk on the basis of 
pedigree status may be provided with test information which will place them in a state of 
near, if not total certainty of whether they have inherited the predisposition. Bear in mind 
that at some point all known genes were unknown and families had to be recruited via 
clinical genetics where clinical management was central to the process. 
Genetic information is disease and gene specific. Individuals make a decision as to 
whether they wish to hear the information which is now available. Implications that 
patients take into consideration include medical matters (the seriousness of the condition, 
the availability of treatment, etc), and social matters (does the individual have life 
insurance/mortgages etc. for which a pre symptomatic diagnosis based on genetic 
information might create difficulties). 
The aim of all genetic research should be to benefit patients, and provide information 
pertinent to their clinical needs. Without research, there would be no progress. For 
families devastated by severe genetic disease, a move towards amelioration of their 
condition through research is often desired. It may be argued that there is an ethical 
imperative to do research into diseases where answers to clinically important questions 
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are unknown. But ethical problems abound when the ambiguous distinction between 
research and clinical genetics is maintained or improperly managed (276), and these 
problems are exacerbated when the genetic condition in question can include early 
mortality and significant morbidity. A centralized register, allowing access to researchers, 
and providing robust research information back to those providing clinical care would 
obviate some of these issues. 
6.5.1 Genetic clinical/research registers: a model for Newfoundland 
Genetic registers take many forms. In some instances they are primarily research 
registers, where data is collected from many jurisdictions, in an attempt to find out more 
about rare disorders than is possible in one locale (333). Other registers collect disease 
information on a population basis. Finland provides an excellent example of this 
approach (334, 335). These registers have enormous potential for research into the 
genetic epidemiology of common, genetically complex conditions such as schizophrenia. 
(336). 
The type of register we advocate for here was recommended already in 1972 by the 
World Health Organisation (WH0)(322). In those early days WHO advised all medical 
genetics centres (i.e., a clinical department within a health care setting) to establish 
registers of high risk genetically determined disease so that genetic counselling could be 
offered to all those who would benefit. Thus all individuals referred to a clinical genetics 
program would be placed on a genetic register following consent. In the early 1970s 
direct mutation testing was not available, yet WHO recognized that with the introduction 
of linked markers gene tracking through families would be facilitated. The WHO had a 
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clear remit in proposing this model. They wished to extend counselling from the proband 
to the at-risk family and maintain long-term contact with the relatives to allow recall for 
those at-risk for counselling and/or testing. They were clear about the importance of 
ensuring that appropriate DNA and/or other samples were stored against future need. 
This was enacted for clinical reasons at a time when few DNA markers were available 
and few gene locations were known. The final aim of genetic registers was to facilitate 
research: the recognition that without research, the scope of genetic services, and thus the 
provision of information to patients would be limited. The total ascertainment of families 
with a given disorder in the population served by the register was recommended, so that 
accurate epidemiological studies could occur. 
One of the first genetic registers was established in Edinburgh (337), followed by several 
more UK centres after the Clinical Genetics Society (now the British Society of Human 
Genetics) working committee report of 1978 (321). In Britain a register covers a Health 
Service Region with a population of up to 5 million. In Newfoundland one genetic 
register would be required to cover the province, located in the tertiary centre of St. 
John's. 
The primary clinical benefit of a genetic register system is the improved management of 
Mendelian genetic disease, with maximum prevention of morbidity and mortality(338). 
Also of benefit, and related to the above is the availability of a single main pedigree, and 
a central repository for demographic and medical information. Changes to a pedigree, 
whether from a researcher or a clinical genetics health care provider, would occur 
centrally, with only one accurate digital copy of the family tree available for clinical and 
Page 185 of 292 
research purposes. A register asks whether clinical patients consent to being on the 
register. If they do, they know they may be called about research. Their consent to 
participate in any research ethics board (REB) approved project would then be decided 
between them and the researcher. 
Researchers apply for REB approval for each project and permission is requested for 
access to either minimal (no identifying information) or maximal (identifying 
information) data. The determination as to whether identifying data is required should be 
based on the clinical significance of the study. In cases where clinical significance is 
high, issues of clinical management must be resolved prior to onset of the research, and 
genetic counsellor support provided. A properly managed registry would assist in 
identifying where on the spectrum of clinical importance a disease lies, and thus what 
information should be available from the research team to the patients at any given time: 
in effect, a triage system. An ongoing challenge in this regard is that research labs 
generally do not operate to the same standards as do clinical labs, and this has 
implications for whether it is appropriate to use research data for clinical purposes. Again 
the triage system that separates diseases on the basis of clinical significance should 
inform laboratory processes as well. That is, the basic molecular work of a disease with 
high clinical signjficance would generally not be entrusted to a junior researcher (e.g. an 
undergraduate or relatively inexperienced graduate student), and would require close 
oversight and validation of results by a senior researcher. As is clear to many working in 
this field, patients often do not make the distinction between researchers and clinical 
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staff. It thus behoves us to make sure that this regular misunderstanding results in no 
harm to the patient population. 
The costs of running a genetic register should be outweighed by the benefits in health 
care to the family members in terms of decreased morbidity and mortality. As those 
deemed not to be at risk are no longer followed and screened, overall health care system 
costs would hopefully be lowered . Preliminary evidence for this approach is available for 
the Von Hippel Lindau hereditary tumour syndrome in Newfoundland (339), and 
elsewhere (340). Appropriate numbers of staff affect the costs required for a register, 
particularly genetic counsellors who are central to this form of clinical management. The 
benefits of genetic counselling cannot be overemphasized (341 ). Staff costs are always 
the most expensive part of any endeavour: in this type of system, funding from research 
projects could offset counsellor salaries, and the monies liberated used to fund other 
counsellors. 
Confidentiality issues are always of concern in the provision of any health care, but 
should be adequately dealt with within a secure computerized network, particularly if 
housed securely within a health care system. The potential for providing unsolicited 
information to unsuspecting people that they are at risk of a devastating disease may be 
exacerbated with a family based register system. This is true of all genetics however, with 
or without a register. In most cases individuals in a family with a devastating genetic 
condition are already aware of their risk, although the perception of risk may be 
overestimated (342) (343). The question has been raised as to whether failure to provide 
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information pertinent to individuals may be unethical (276). Register systems of this 
nature have been used in the UK for over 30 years (323, 324, 344). 
6.6 DISCUSSION 
The boundaries between research and clinical care in genetics are hard to maintain. A 
register approach helps to make the situation clearer as it ensures more effective clinical 
management while potentially expediting related research. Given the nature of genetic 
disease the registry gives priority to clinical care as affected individuals must be managed 
irrespective of whether causative genes have been identified. Nevertheless, the registry 
system does not treat research as separate from and incidental to clinical management, 
but explicitly acknowledges the critical importance of genetic research to that clinical 
care. When functioning properly the process is something of a non-vicious circle in 
which patients are seen clinically, their information is ascertained, they become part of a 
research project, and their research information is fed back to the clinical staff who return 
it to the family members, who may then choose to become part of the next project. 
6.7 SUMMARY 
There are many conditions in Newfoundland and Labrador for which gene mapping has 
yet to be instigated, or is in progress. These include conditions where the clinical picture 
remains unclear, where the mode of inheritance is unknown as well as those where the 
genetic cause is well recognised, and yet research is required to determine the clinical and 
genetic epidemiology and the modifiers of the phenotype. These families sti ll require 
genetic counselling and risk assessment. In order for both of these to be as accurate as 
possible, research has to occur. We advocate therefore for an amalgamation of clinical 
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and research genetics under the remit of a genetic register for Mendelian disease within 
Newfoundland and Labrador. This approach should be considered in all health regions 
where genetic programs exist, particularly those where research and clinical endeavours 
deal with the same individuals. 
Table 23 Inherited diseases with high morbidity and/or mortality and high recurrence risk 
Clinical Genetics Research Genetics 
Ascertainment of 1. Initial referral of 1. Recognition of 
family pro bands pro bands 
2. Draw family tree 2. Draw family tree 
3. Expand contact to 3. Expansion to other 
other family members family members via 
via proband proband 
Maintenance of Ideally, pedigree drawing Ideally, pedigree drawing 
pedigree/pedigree software and appropriate software and appropriate 
data associated database associated database 
Primary reason for 1. Diagnosis 1. Determination of 
ascertainment 2. Mutation screening underlying gene 
3. Risk assessment /mutation(s) 
4. Appropriate clinical 2. Determination of 
follow up modifiers 
3. Determination of 
clinical and genetic 
epidemiology 
Clinical Significant regarding risk Significant re risk from 
importance from pedigree alone. pedigree alone. Potentially 
Significant if gene and or significant if gene and or 
mutation known. Significant mutation found as a result of 
regarding information on research OR research 
prognosis, screening, determines information 
ri1anagement and treatment. regarding disease progression 
and therapeutic outcomes from 
epidemiological studies. 
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7 DISCUSSION/CONCLUSION 
"One never notices what has been done; one can only see what remains to be done. " 
Marie Curie 
This thesis describes novel clinical, and epidemiological information pet1inent to the 
ARVD5 patient population. It also describes the discovery of a hitherto unknown gene 
for ARVD5. This work has provided key evidence for the creation of a 
genetics/cardiomyopathy clinic, has changed perceptions regarding clinical responsibility 
within genetic research and has led to a health care policy for ARVC in Newfoundland 
(345). The discovery of the causative gene was positional cloning at its best, using a well 
ascertained set of families with deep genealogies, with 'across the lifespan' medical 
information, leading to the ability to define the clinical phenotype, penetrance and 
expressivity for ARVD5. In this concluding chapter, I briefly expand and amalgamate the 
multiple conclusions generated throughout the thesis, and discuss some of the pertinent 
findings in greater detail. I also assess the global advantages and limitations of this study 
and assess future directions for research. 
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1. The ARVDS gene was localized to a broad region on the 
short arm of chromosome 3 
Accurate survival statistics determined that 50% 
of untreated males would die before aged 40 
years, and 80% by aged 50 years. The respective 
statistics for women were 5% and 20%. 
2. One family was known (ARl) 
3. Males died suddenly and at young ages Novel clinical findings include the presence of 
poor R wave progression in leads vl, v2 and v3 of 
the 12 lead ECG. 
Post 2001 
Treatment using implantable cardioverter 
defibrillators was shown to significantly 
improve survival in males. As a result of t he body of work in 
this thesis 
The diagnostic criteria for ARVC require 
modification to take into account left 
ventricular disease, and need to be widened 
to accommodate early clinical disease in 
relatives although the use of genetic testing 
obviates the dependence on descriptive 
clinical diagnostic stratagems. 
The natural history of the disorder was 
determined. Palpitations and presyncope 
occurred prior to death in men. Heart failure 
occurred in those who did not die of SCD. 
The natural history for women was spread over the . 
entire lifespan and serious sequelae occurred at 
least 1-2 decades after those in men. 
The gene on chromosome 3 was found to be a 
transmembrane protein: TMEM43. This protein 
was found to be conserved across evolutionary 
time, and had not been previously associated 
with human disease. 
Cardiac symptoms had no significant diagnostk utility. 
Holter Monitoring was the only clinical test with a 
sensitivity sufficient to clinically detect affected status 
prior to death in males. 
This work has challenged the"Huntington's 
paradigm'~ Issues that have arisen include 'duty 
to warn' and the difficulties associated with the 
overlap between clinical genetic practice and 
genetic research. 
7.1 GENETICS 
We knew that ARVC worldwide was a genetically and allelically heterogeneous disorder. 
Our haplotype data however defined ARVC at locus ARVD5 as a founder population. 
Thus we hypothesised that the gene and the underlying mutation in all 15 ascertained 
families would be the same. Following a traditional positional cloning approach (utilising 
linked DNA markers segregating with disease across generations), we identified a 
missense mutation in a conserved region of a transmembrane protein (TMEM43), a 
protein with no previous association with human disease, as the cause of ARVD5 in 
Newfoundland;. Although the positional cloning method generally works efficiently with 
this type of disorder (Mendelian autosomal dominant), in this case it was made more 
difficult by the lack of DNA from those who had died suddenly (who were, by our 
definition, affected, Table 5 page 60), the inherent variable expressivity and reduced 
penetrance associated with dominant disorders, the sex influenced nature of the disorder, 
and the potential for misclassifying subjects based on common, rather than ARVC related 
cardiac anomalies resulting in the inability to unambiguously clinically diagnose subjects. 
This issue of diagnosis made the search for the ARVD5 gene more challenging, but 
speaks to the need for detailed clinical assessment and ascertainment, and the 
requirement for a diagnostic strategy that utilises all available information and is easily 
applied. 
The mutation causing ARVD5 is a mutation at position 358 in TMEM43 (1073 C-T, 
S358L). A protein is produced with a leucine instead of a serine within the third 
transmembrane region of the four transmembrane region protein (Figure 15 page 94). The 
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presence of a missense mutation (rather than a deletion, or a premature stop codon 
resulting in an absent protein) is less definitive for predicting disease causality. 
Indications of causality were thus used to define probably causation. These included i) 
the gene lies within the original ARVD5 chromosome 3 linked haplotype (4, 248), ii) the 
gene is expressed in the heart (although this is not obligatory: the gene may be 
developmentally required for example), iii) the mutation occurs in all affected and 
obligate carrier subjects from whom DNA has been obtained, iv) the an1ino acid is 
conserved throughout evolution (a measure of its biological importance), and v) the 
mutation is absent/rare in matched population controls and clearly unaffected family 
members. In addition, the specific base pair change was predicted (by NCBI Build 36.1 ), 
to be biologically deleterious. All of those criteria were fulfilled in the case of the 1073 
C-T, S358L mutation in TMEM43, confirming this as the cause of ARVD5. The 
production of fat in the myocardium via signalling pathways implicates TMEM43 (MIM 
601487) as a regulator of an adipogenic pathway (263). This might explain fibrofatty 
replacement of the myocardium in ARVC patients if the pathway is deregulated. 
That a mutation in TMEM43 causes of ARVD5 in what is probably the largest population 
of ARVC in the world may change the perception that ARVC is primarily a disease of the 
desmosome (74, 243). 
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7.2 IMPLICATIONS OF THE TMEM43 MUTATION 
7.2.1 ARVC and DCM overlap 
The presence of L VE, although noted in other studies, (132, 135, 140, 266, 267) is 
striking in this cohort and supports placing ARVC within a group called 'arrhythmic 
cardiomyopathies,' which would take into account various presentations of disease (268). 
It also speaks to the way the heart is remodelled in the face of disease and how mutations 
affecting different cardiac proteins and thus different aspects of cardiac morphology work 
in concert. The only previously known gene with mutations shown to cause both a DCM 
and ARVC phenotype is desmoplakin, implicated in both autosomal recessive DCM 
(Carvajal syndrome) and AD ARVC (ARVD9). 
How does TMEM43 fit with the other known proteins implicated in 
ARVC/DCM? 
One can speculate that a 'final common pathway' occurs in the development of the 
cardiomyopathies, with the eventual phenotype influenced by the primary mutation, 
alongside other proteins that determine cardiac myocyte function. DCM may be 
considered a non-specific degenerative response as a result of a genetic mutation, a virus, 
or volume overload, either via several physiological pathways, or combining within one 
main pathway. As many of the proteins causing DCM are cytoskeletal, one can imagine 
that contractile force may be impaired from the sarcomere to the extracellular matrix, a 
mechanism implicated also by the fact that mutations in some sarcomere proteins also 
cause DCM (94). However, DCM is also often caused by defects in the nuclear 
membrane protein Lan1in AC. These mutations may cause dilatation as a result of 
impaired force generation from the connections between the Lamins and the cytoskeletal 
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proteins. Lamin AC is ubiquitous, and is involved in nuclear membrane dissociation 
during mitosis. The variability of human disease caused by Lamin mutations is wide 
(346), and includes muscular dystrophies, with or without cardiac involvement. Mice 
deficient in Lamin AC have problems with formation of the nucleus and their desmin 
cytoskeletal network; their mechano-transduction is deficient and they have problems 
with the activation of transcriptional programs responding to mechanical strain (347). 
However, with the Lamin mutations, it is harder to understand the arrhythmogenic effects 
that may occur earlier than the structurally apparent defects in DCM (94). 
Mutations in phospholamban, the reverse inhibitor of the cardiac sarcomplasmic reticular 
Ca2+ - A TPase that regulates cardiac contractility, also causes DCM, implicating calcium 
metabolism as part of the same pathway (348). TMEM43 may fit into this pathway either 
at the level of the cell membrane or the nuclear membrane, interacting with either the 
desmosomal/dystrophin-associated complexes or the nuclear membrane proteins. 
It is likely that TMEM43 is influenced by regulating factors as yet unknown. It is known 
that only 2% of genomic DNA codes for proteins, yet there are large tracts of the 
remaining 98% of DNA that are highly conserved across evolutionary time. They may 
therefore have a functional role (349). 
As was described in the introduction, the majority of proteins implicated in ARVC prior 
to TMEM43 were the desmosomal proteins. These proteins provide an anchoring and 
signalling function between and within the cardiac myocyte, and have a link to desmin 
and other cytoskeletal structures, linking the arrhythmogenic and structural phenotypes. It · 
is likely therefore that ARVC and DCM are diseases on the same pathophysiological 
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pathway. Emphasising the parallels between these clinical entities are the autosomal 
recessive disorders of Naxos and Carvajal caused by mutations in plakoglobin and 
desmoplakin respectively. Both include causing keratoderma and woolly hair in their 
phenotypes, with an ARVC-like phenotype in the former and a DCM-like phenotype in 
the latter (77). · 
RYR2 mutations cause ARVD and catecholiminergic polymorphic ventricular tachycardia 
(CPVT). Initial reports suggested differences in the positions of these mutations and the 
predominant phenotype expressed. RYR2 mutations in the amino cluster cause CPVT and 
those in the carboxyl cluster cause ARVC. The amino cluster of the RYR2 protein is 
located in the cytoplasm, whereas the carboxyl cluster contains the transmembrane 
domains (350) (36) (83) (84) Mutations in the centre of the gene can lead to both 
phenotypes. It is postulated that all RYR2 mutations produce the tachycardia, but only the 
transmembrane domains cause the structural changes seen in ARVC. Modifier genes or 
environmental influences may also make a difference in the phenotype (94). Functional 
studies are available for the RYR2 mutation Arg176Gln (351) where both hypersensitivity 
and hyperactivation of the RYR2 channel are seen. This leads to excess calcium release 
from the sarcoplasmic reticulum, leading to calcium overload and delayed 
afterpolarisations, producing VT (352). The relationship between RYR2 mutations and 
ARVC structural defects is unclear. 
All the currently separate ARVC/DCM phenotypes will likely be eventually defined by 
their underlying genes and mutations, each against a background of modifying genes and 
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environmental factors. Exactly what part TMEM43 will finally play in this orchestra will 
be the focus of future research. 
7.2.2 Natural history and phenotype 
For the first time, the natural history and phenotype of a genetic subtype of ARVC has 
been delineated using mutation negative family members as controls. Salient conclusions 
are i) that the ARVD5 phenotype is lethal, ii) the disease is sex-influenced affecting 
males significantly more than females, iii) the onset of cardiac symptoms in males is 
often followed by death, iv) hospitalisation for cardiac disease, heart failure and SCD is 
significantly more common in mutation positive males than mutation positive females, 
and occurs at a younger age, v) cardiac symptoms have limited diagnostic utility in 
determining those with and without the mutation, vi) Holter monitoring for signs of 
ectopy is the most sensitive diagnostic test (considered the most sensitive test for 
determining ARVC in Boxer dogs (178)), vii) a late manifestation of the disease in those 
who do not die is heart fai lure. 
Clinical test abnormalities common in ARVD5 include PVCs and PRWP on 12 lead 
ECG, delayed LV conduction on SAECG, L VE on echocardiography (with some subjects 
meeting criteria for DCM) and massive ectopy on Holter monitor at an early age in 
males. Some ARVC features included in the diagnostic criteria, including epsilon waves 
and T wave inversion (25)(Figures 2 and 3 page 46), are rarely seen in ARVD5. This 
must be related to how the underlying mutation affects the myocardium in this genetic 
subtype. The absence of the epsilon wave in our population may mean that the RV is not 
affected to the san1e extent, or that in order to show the epsilon wave properly, a slowed 
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ECG trace may be required. We have never run this modified 12 lead ECG in 
Newfoundland. PR WP on ECG (Figure 28 page 198) resembles the pattern seen after an 
anteroseptal infarct affecting one branch of the left coronary artery. Septal Q waves are a 
subset of PRWP and occur when all the myocardium at that point is scar tissue. The 
pattern therefore relates to disruption within the septal region of the heart, in the absence 
of a significant left axis or LBBB of the heart. As the septum is considered to be spared 
in 80% of ARVC cases (108) this ECG pattern must tell us something about the ' lack of 
sparing' of the septum in ARVD5. The SAECG is less diagnostically useful in ARVD5, 
in contrast to the literature (176). 
Figure 28 PRWP in ARVD5: In leads Vl, V2 and V3, the R wave is almost non-existant. 
(See Appendix C for a normal tracing) 
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Taking all affected subjects alive in 2008 the prevalence of ARVD5 is 113000 (Data not 
included in thesis). This is higher than the oft quoted 115000 (110). It is also likely an 
underestimate. 
Involvement of the right ventricle 
Although in this ARVD5 population the disease appears to affect the LV more than the 
RV, this almost certainly reflects a 'missing data' bias. We have consistent LV data but 
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minimal RV data due to the difficulty visualising the RV compared to the LV on 
transthoracic echocardiography (Appendix C). Like the ECG, echocardiography is 
available in many non-tertiary centres. Unlike the ECG, it is operator and analyser 
dependent. 
We have some clues that the RV is affected in ARVD5, despite the limitations of the 
clinical testing. In one case of SCD in a 31 year old (from family ARl), the 
echocardiogram done 6 months prior to death showed an enlarged LV with a normal RV. 
On autopsy the RV was massively enlarged. The most recent case was that of an affected 
male aged 62, who had been maintained on Amiodarone having refused an ICD. 
Following SCD, his heart was obtained and although his echocardiogram one month 
earlier was described as ' normal ' , his RV on autopsy was not, and included many areas 
of fat (Figure 29 page 200). 
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Figure 29: Heart post mortem: 62 year old affected male 
Other genetic subtypes of ARVC in the literature appear to be restricted to the RV. The 
explanation usually provided is that the RV is more susceptible to dilatation following 
mechanical stress, due to its thinner walls. 
ARVC due to the TMEM43 mutation (ARVD5) is a lethal, sex-influenced, autosomal 
dominant disorder. It is 100% penetrant. The determination of penetrance allows for the 
definition of a residual risk of expressing ARVC for at-risk subjects based on clinical 
testing alone, that is, the remaining likelihood, in the presence of the mutation and the 
absence of clinical features on clinical testing, of still expressing the disease. This may 
seem superfluous in the presence of a known mutation detectable on molecular testing, 
but will be useful for modifying underlying pedigree risk while awaiting molecular test 
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results, or in jurisdictions where these are not available, or in ARVC families which link 
to 3p25, but without a known mutation. 
The dilemma of diagnosis: how the conclusions from this thesis may inform the 
diagnostic criteria. 
Defining the diagnostic criteria for ARVC depends upon biased ascertainment of those 
presenting with severe disease. This however is merely one of the multiple problems 
inherent with the diagnostic criteria for ARVC. Most of the major criteria for ARVC 
(Table 3 page 57) require tertiary centre type testing or invasive testing. This is true for 
516 of the major criteria, and up to 3/9 of the minor criteria. Many of our ARVD5 
affected subjects presented with death. These individuals could not fulfil current ARVC 
criteria, as they would meet only one major criterion (autopsy determining evidence of 
the disease). Even this may not be the case if the pathology was at a unit where little 
more than a gross assessment was done, and the cause of death was recorded as ' likely 
arrhythmia' . Additional problems in Newfoundland relate to the limited availability of 
'newer' clinical testing compared with larger urban centres. In addition, many subjects 
live in remote areas of the province, with less access to medical centres larger than a 
cottage hospital. 
Standard ARVC diagnostic criteria (25) had limited usefulness therefore for clinical 
diagnosis in our Newfoundland families. However, ARVD5 is an autosomal dominant 
genetic disorder and thus unambiguous obligate carrier status could be assigned. After 
sudden death under 50 years, the most likely phenotype was serious arrhythmia requiring 
cardioversion. These three features were used to define affected status in this thesis lised 
even minimal information. 
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Table 5 page 60). For epidemiological studies, diagnosis for large populations has to be 
effective, reproducible, easily defined, and consistent. Our definition fulfilled these 
requirements. 
The issues of clinical diagnosis and presence or absence of symptoms or clinical test 
findings as diagnostic predictors are common to all diseases that have an underlying 
genetic cause. The cases that come to initial attention are the tip of the iceberg: those that 
are serious enough to be recognised or large enough families. The remainder of the 
iceberg is initially invisible. With 22q11.2 deletion syndrome, a multisystem disorder 
caused by a common deletion of 3MB on the long arm of chromosome 22, initial 
ascertainment was through congenital cardiac clinics. The majority of cases thus had 
congenital heart problems and this feature became closely tied to the diagnosis. With the 
recognition of the underlying chromosome 22q deletion, the presence of congenital heart 
defects in those with the deletion is less than 40% (353). 
This is analogous to the situation in ARVD5. Using the TMEM43 mutation to determine 
those with the genetic susceptibility to develop ARVC allowed us to investigate the 
efficacy of the current diagnostic criteria. For males with ARVD5 (i.e., those with major 
clinical sequalea and/or mutation positive and/or obligate carrier status), the diagnostic 
utility of the 1994 criteria (25) showed 13% sensitivity and 100% specificity. When the 
modified ARVC criteria were assessed (142), sensitivity and specificity were 43% and 
96% respectively. For women the situation was similar, with the original ARVC 
diagnostic criteria providing a sensitivity of 5% and a specificity of 100% and the 
modified criteria giving a sensitivity of 60% and a specificity of 97% (data not shown in 
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the thesis). This is consistent with data from Syrris et al. in 2007 (61) who looked at 
family members with DSG2 mutations and showed that the penetrance of the disease was 
58% if the original Task Force criteria were used (25), and 75% using the modified 
criteria (142). Data from this paper, and from this thesis underscores the necessity for the 
ARVC disease diagnostic criteria to be widened. 
7.2.3 Treatment 
We have demonstrated that lCD therapy is life saving in this population with ARVC, 
using an innovative study design to determine a statistically robust result. This study 
design had to account for the fact that subjects were from different generations, at 
different stages in their disease process, some of whom had lived through the application 
of multiple treatment regimes, and had to use a method to compare those who were 
treated with lCD to those who were not. The use of the nested case control within the 
cohort study, with historic controls, was instrumental in obtaining a significant result 
despite low sample size. 
The effectiveness of a cohort study, as in this case, can be enhanced when there is no 
possibility of doing an RCT. "Experiments are ethically permissible only when adherence 
to the scientific protocol does not conflict with the subjects ' best interests" (354). Good 
observational data are essential (355). Our strategy, which worked well, was to maximize 
the similarities between this cohort study and a RCT by: (i) defining eligibility criteria 
analogous to those employed in clinical trials (ii) specifying a zero time (time at which 
the intervention was applied) for eligibility and modification of baseline differences in 
prognostic risk, (iii) using the same analyses as a RCT (355). 
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ARVC in Newfoundland is responsible for many young SCDs and proof of the efficacy 
of lCD therapy is of immense importance. Given the high prevalence of ARVC in 
Newfoundland, treatment and follow-up costs alone made it imperative to show that the 
intervention made a difference. Fwther research is required to assess the economic 
impact of lCD use in this population, taking into account all familial, social and medical 
factors. 
7 .2.4 Ethics 
Another first for this thesis was the definition of the privacy paradox: that an emphasis on 
protecting individual privacy can be harmful when applied to genetic information with 
clinical repercussions for family members, and also, that the privacy of genetic 
information is dependent upon the manifestation of disease: a physically obvious 
phenotype cannot be kept 'private' . ARV C acts in direct contrast to Huntington 's disease, 
which has for many years served as the template against which other genetic disorders are 
compared. Huntington disease is an autosomal dominant lethal neurological disorder, 
with no ameliorative treatment or screening. Affected individuals will die, generally 10-
15 years post diagnosis, usually in the 4th to 6th decades. Huntington' s is however in 
many respects a most unusual genetic disease. It is deterministic: if you have the gene 
mutation you will get the disease. It is a trinucleotide repeat expansion resulting in 
anticipation (the gene size expands during meiosis) when the allele is transmitted from 
father to child. Disease onset is usually late, with no decrease in reproductive fitness and 
many disease free years prior to a clinical diagnosis. For affected individuals the only 
reason for not dying of Huntington' s would be death due to another cause, prior to the 
onset of disease. 
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Historically, the diagnosis of Huntington's was made following a neurological 
assessment when the symptoms of the disease were beginning to manifest. But when the 
Huntington's gene was linked to the short arm of chromosome 4 in 1983 (356) followed a 
decade later by the cloning of the causative gene (357), it became possible to perform 
pre-symptomatic testing of this untreatable disorder. Based on family history, at risk 
individuals could now choose whether they wanted to open 'Pandora's Box' for a look 
into the future, or keep it closed and take their chances. In contrast to a neurological 
clinical test which gives information about the neurological state of the patient 
immediately, getting a DNA result said nothing about the neurological status of the 
individual on the day of the test. 
The advent of the test for Huntington's effected a change in medical practice for this 
disease as it brought into stark relief the possibility that genetic information could be used 
in a more insidious manner (358). It was also recognised that insurance companies could 
use this information to ban someone from coverage based on a disease they would not 
manifest for years. This led to a reassessment as to the best way to deal with the 
information accrued. As a direct result, a genetic counselling protocol was established for 
dealing with the implications (physical, psychological and societal) for each person 
intending to undergo pre-symptomatic testing for Huntington's (289). 
Inasmuch as Huntington's was one of the first genetic tests to become readily available 
for clinical purposes, it set the standard as to when and how genetic information should 
be shared with at risk individuals. However, the vast majority of disease genes are not 
like HD. They are variably expressive and exhibit reduced penetrance, and there is often 
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screening and the possibility of treatment, if not a cure. The Huntington's paradigm may 
therefore be the wrong structure upon which to hang the 'standard of care' for other 
Mendelian disorders. Indeed the question of whether insurance issues should have the 
stature afforded to them in genetics is itself debatable (359). It may be argued therefore 
that for many diseases, DNA testing should be considered in the same light as other 
clinical tests, whether via a research or a clinical route, and the point of consent should 
thus occur when the test is initiated. 
ARVC is almost the opposite end of the spectrum to Huntingtons. Both conditions are 
autosomal dominant, lethal conditions, but the former has amelioration in the form of 
lCD treatment. Thus knowing that one is a gene mutation carrier for ARVC allows for 
the application of prophylactic lCD treatment: considered by most to be a clinical 
imperative. Insurance issues would also be minimised in ARVC, in the same manner as 
any lethal clinical condition (whether genetic or not: e.g. diabetes) that requires life 
saving intervention yet will impact on the ability of the patient to get life insurance. 
That patients/subjects/family members not be harmed is a central issue in research. When 
research has major clinical ramifications (as is the case in many high risk genetic 
disorders), a mechanism for managing the flow of information is imperative. The 
solution, in part, is to amalgamate clinical and research genetics under the remit of a 
genetic register for Mendelian disease within Newfoundland and Labrador. 
"What has been will be again, what has been done will be done again; there is nothing 
new under the sun. " - Ecclesiastes 1:9 
Page 206 of292 
The concept of a genetic register is not a new concept for Newfoundland. During the 
writing of this thesis, I discovered this document, written by Clarke Fraser (McGill 
University, Professor of Medical Genetics) in August 1990, regarding the initial members 
of the ARl family 
"A 30 year old Newfoundlander was diagnosed 6 years ago as having a potentially lethal 
heart condition (arrhythmogenic right ventricular dysplasia ARVD). During the next 
couple of years, four more cases were identified in various parts of the province. A full 
compilation of the family trees of these patients was made because in several cases there 
appeared to be other male family members who had died suddenly while undergoing 
strenuous exercise, often in the woods. This compilation, made the hard way by 
interviewing numerous relatives, by searching parish registers etc. revealed that all jive 
patients were related, being connected to a common ancestor over 100 years ago-
although they did not realize it. They all had an inherited disease that could be 
transmitted by male or female but which in the case of the female might never be 
revealed. Thus to an individual family the condition might not appear inherited and 
would appear as a heart attack coming out of the blue. Some 30 members of this family 
had died in this way in the prime of their lives. Having compiled the pedigree and 
understood the inheritance it is now possible to decide who of the living family members 
is at risk and to give a degree of risk in each case, and to contemplate the possibility of 
providing preventative treatment in the form of a drug to reduce the incidence and 
severity of the arrhythmia. Had there been a familial disease registry with a good 
collection of family tree information, this compilation of the family tree for these jive 
patients could have been achieved more simply and quickly". 
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ARVC continues to support the need for implementation of a genetic registry as the 
responsibility for information to be passed back to subjects in a clinically appropriate 
manner is paramount, regardless as to how that information has been derived. 
7.2.5 Future research directions 
The results presented in this thesis prompt a number of future research directions and 
remaining questions. 
Functional studies 
Functional studies are required to determine the role of TMEM43 in the myocyte, and to 
ascertain how the protein fits into the DCM/ARVC pathways. It will be an interesting 
journey for the protein chemists. TMEM43 may point to a new pathogenesis. An exciting 
possibility is that TMEM43 may turn out to have a target that is amenable to drug therapy 
that could eventually replace or provide key adjunctive support to symptomatic treatment 
with the lCD. 
Modifiers 
"A genetic modifier, when expressed, is able to alter the expression of another gene by 
affecting transcription or by altering the immediate gene transcript or by affecting 
phenotypes at other levels of organization. " (360) 
Penetrance and variable expressivity 
As defined in the introduction, a common (indeed, almost universal) feature of genetic 
disease is the situation when a single mutation is not expressed in all subjects who have 
that mutation, or when it is expressed, it is not always expressed in the san1e way. The 
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former is termed penetrance: the proportion of subjects who carry a mutation and express 
the phenotype. The latter is variable expressivity: the extent to which a mutation shows 
all, or part of its phenotype in those who have the mutation and/or the variable age at 
which symptoms develop. 
Mendelian diseases, although caused by a single gene mutation, are far from simple 
(361). Other factors (modifiers) affect the single gene, and these can be genetic or 
environmental. Genetic factors would include other genes acting as modifiers, either 
directly on the gene product in question, or somewhere in the pathway. An analogy useful 
for patients relates to a hockey team. With the abnormal gene (the hockey player who 
cannot skate or hit the puck), the game would only be salvageable if every other player 
on the team were an NHL hockey star. If however, the team-mates were a mixture of 
those who made the junior levels of the NHL plus high school players, the team would 
struggle. Thus, other genes are the team players, which if strong and protective may have 
a positive impact on the phenotype dictated by the abnormal gene (incompetent player). 
The opposite would be true for the non-supportive genes (weak team mates). 
Environmental issues also may act as phenotypic modifiers. In the hockey analogy these 
would include ice surface, fan support etc. In diseases, these may include viruses, diet, 
smoking, drinking, drugs, exercise, work practices, pregnancy, lactation, and the uterine 
environment affecting early development amongst many others. 
Sex differences 
ARVD5 has a high variability of expression, the most obvious being the difference 
between males and females. One is tempted to implicate hormones as a protective 
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mechanism in females, but there may also be epigenetic changes. Epigenetic changes are 
those that affect a cell, organ or individual without directly affecting the heritable DNA 
sequence. Included would be the process of DNA methylation (including the methylation 
of one of the X chromosomes in females) (362), chromatin remodelling (the structural 
changes occurring throughout cell division for transcriptional regulation and for 
chromosome segregation) (363) and gene silencing (the creation of facultative 
heterochromatin when genes are no longer required in embryogenesis) (364). 
One can imagine that a protein that affects TMEM43 coded by a gene on the X 
chromosome may be more deleterious in a hemizygous male compared with a 
heterozygous female. Alternatively, the mechanism of methylation of the X chromosome 
in the female may affect proteins in the pathway implicated in the cardiomyopathies, by 
affecting the nuclear membrane (the anchor point for the methylated X chromosome). 
Some have suggested that the sex differences in ARVD5 may in part be related to work 
practices. In other forms of ARVC, mechanical stress in athletes on a heart muscle 
already stressed by an underlying biological defect has been described (365). There is 
little evidence in the ARVD5 families for such a mechanism. While many men worked 
physically hard, most of it was not of a cardiovascular nature and appears similar to the 
physical labours performed by women around the house (the children, the garden, the 
animals, the housework), particularly in previous generations prior to labour-saving 
devices. 
There is also a possibility that women with ARVD5 may be more seriously affected now 
than they were in the past. While the data have not been assessed in a systematic manner 
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to address this question, if such a worsening has occurred, this could not be due to genetic 
factors and must be related to ascertainment bias or external environmental factors. 
Exogenous hormones in food, and the introduction 40 years ago of the oral contraceptive 
pill are possible factors that require further research. 
Other variable expression 
Variability in ARVD5 is not restricted to differences between the sexes, variability also 
occurs within each sex. Although few women present early and severely, there are 
individual examples of thjs within the Newfoundland pedigrees. Many women are 
significantly affected with symptoms in their middle years, whjle others have no signs or 
symptoms of disease for several decades. Men can present young with heart failure, with 
SCD or with non-specific symptoms, while still others live well into their middle years 
with no clinical sequalae. These latter individuals will have clinical features recognisable 
on clinical testing but will not have brought themselves to medical attention. The most 
striking example of this is in family AR8 (Figure 8 page 79), where the 19 year old 
proband died suddenly and the grandfather who transmitted the disease, a man who had 
never presented for any cardiac testing or treatment, died suddenly at age 72 years. This 
pedigree pattern might direct us to 'anticipation', a mechanism of variable expression 
with the worsening of disease across generations. In most conditions in which tills occurs, 
the cause is an expanding DNA tri-nucleotide repeat (TNR), where at meiosis, the 
number of TNR' s may change: usually increasing in number. The gene in effect 
' expands' by the addition of copies of the TNR sequence. Diseases exhibiting this ' gross' 
example of variable expression include Huntington' s disease, myotonic dystrophy and 
Fragile X syndrome. We have not systematically examined clinical anticipation in 
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ARVD5, i.e., without bias, assigned disease status to all individuals in at least 3 
generations within each family and investigated severity of disease and age of onset of 
key manifestations of disease. However, with the available pedigree data, there does not 
appear to be consistent worsening of disease across generations, manifested by increasing 
severity or younger age of onset. Also, the TMEM43 gene does not contain a trinucleotide 
repeat sequence, making anticipation an unlikely explanation of variable expression in 
ARVD5. Investigation of other hypothesized mechanisms of anticipation (366), where 
there is no identification to date of a specific molecular mechanism, would remain a 
possible area of future research. 
Remaining questions 
There are many other questions that remain to be answered for ARVD5. For example, the 
determination of the location of the ectopy in these families is possible from the 
morphology of the PVC' s observed on the Holter monitor. We have yet to determine if 
the ectopy is primarily left sided in origin, right sided, or both, or the temporal sequence 
of ectopy during the disease process. The disease course following lCD therapy also 
needs to be assessed. Are there prognostic factors that determine those likely to go on to 
heart transplant after the lCD that are similar to, or different from, the modifiers of the 
natural disease phenotype? Is there a pattern to the frequency and type of shock from the 
lCD across time? How would such functional findings relate to the structural findings? 
These and other clinical questions remain to be answered. 
A genetic question remaining to be answered is how the ARVD5 mutation is maintained 
in the population. The disorder is lethal at early ages in men. Despite the fact that the 
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majority of women are alive through their reproductive lifespan, one would expect that 
the removal of 50% of affected men before age 40 years, and 80% before 50 years might 
have an effect on gene frequency. With a population this large, there is an opportunity to 
look at the possibility of meiotic drive. 
Meiotic drive 
The general features of meiosis were understood by the early 20th century, particularly 
that cell division led to accurate partitioning of nuclear chromosomes with half the 
parental number in each daughter cell: encompassing Mendel's law of segregation: that 
each allele in a pair of alleles has an equal chance of being transmitted to the next 
generation. Meiotic drive is defined as "any meiotic mechanism that results in the 
unequal recovery of the two types of gamete produced by a heterozygote"(367). This was 
initially assessed as unequal segregation of chromosomes in heterozygous Drosophila 
melanogaster males (368), later defined as a dominant segregation distorter allele 
mapping to the centromere of Drosophila chromosome 2. The system is complicated by 
responder genes and enabling genes. In mice, meiotic drive is obvious with the tail-less ' t 
alleles' which are transmitted in a frequency as high as 99% c.f. wild type. The disease 
that has been most associated with the potential for meiotic drive in humans is myotonic 
dystrophy (369-374) although the concept has been dismissed by others (375) (376). 
Meiotic drive in other diseases has also been implicated (3 77). Meiotic drive is postulated 
as a method to maintain disease alleles in a population despite decreased reproductive 
fitness. 
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What is the consequence of meiotic drive? 
"Clearly a higher plant species is at the mercy of its pollen grains. A gene which greatly 
accelerates pollen tube growth will spread through a species even if it causes moderately 
disadvantageous changes in the adult plant" (J.B.S. Haldane, 1932) 
Haldane recognised that the evolutionary consequences of drive (before it was described) 
could be considerable: a mutation leading to almost 50% reduction in the fitness of 
diploid adults could still increase in frequency, or remain the same in the population 
provided it had a compensatory mechanism, e.g. meiotic drive. 
It remains to be seen whether there is any indication that meiotic drive occurs in ARVD5. 
Of immediate interest is that if one asks of the subject population in general, which parent 
passed on the ARVD5 gene, the proportions (not presented in this thesis) are 49.9 % 
fathers and 50.1% mothers. Given the early deaths in males, one might imagine that a 
greater skew would occur towards females. Whether the presence of more affected males 
than affected female' subjects in this population is related to a bias because of the greater 
ease of diagnosing males, or a biological indication of some other mechanism (e.g. foetal 
loss) is unknown. We have an opportunity to further assess this issue in ARVD5. 
7.2.6 Study advantages 
The homogeneous population 
Newfoundland and Labrador is one of the few populations in the world known as a 
founder population, and is thus of enormous interest to geneticists. Although the history 
Page 2 14 of292 
of the region is known to enhance genetic studies of autosomal recessive conditions 
where distant cousins are affected in one geographic area due to consanguinity, 
autosomal dominant conditions also flourish due to founder effects. Newfoundland 
fan1ilies have proved to be an invaluable resource in the mapping and cloning of disease 
causing genes (251 ). The presence of large families in the province facilitates genetic 
research, including the genetic and clinical epidemiology of disease. 
Other advantages 
There are several specific advantages of the studies presented in this thesis, particularly in 
chapters 2-4. In brief therefore, the main advantages are as follows. The homogeneous 
population allowed identification of a novel gene on a single background haplotype. This 
is the largest homogeneous group with ARVC in the world. The ability to define affected 
status using genetic data, i.e., the TMEM43 1073 C>T mutation, or pedigree 
identification of obligate carriers, provided a diagnostic strategy independent of clinical 
manifestations. Mutation negative subjects within the family cohort provided a superior 
control group. The depth and quality of clinical data, including accurate classification of 
all available medical records on each person born at 50% risk, alive or dead and in the 
absence of a medical record, the availability of birth and death data, provided advantages 
for assessment of diagnostic utility and penetrance. The availability of serial testing data 
across time was advantageous for studying the natural history of the disease from medical 
records and visits to an at-risk clinic. All of the clinical and genetic data provided 
essential information for genetic counselling and management of the disease in at-risk 
individuals. 
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7.2.7 Study limitations 
As with any study, there were several limitations, again presented more fully in the thesis 
chapters, but briefly revisited here. With respect to study design, the subjects in this 
cohort study were assessed in both a retrospective and prospective manner. Despite 
having collected available medical records, there are almost certainly missing data. With 
respect to diagnosis, we created our own diagnostic strategy which was easy to apply, and 
straightforward. This was necessary given the inherent limitations in the ARVC task 
force diagnostic criteria (25), and the lack of anything except very simple clinical testing 
in many subjects from past generations. Our strategy took into account both a genetic 
definition, either through the use of a linked haplotype or a mutation, and a clinical 
definition with the presence of early unexplained death, and the use of cardioversion to 
alter a lethal rhythm back to sinus rhythm in those aged under 50 years. Bias may thus be 
present in ascertaining those with more severe disease. However, using only a genetic 
definition did not change the survival statistics. In addition, we used sibships where over 
50% of the sibship had a defined disease status to offset the ascertainment bias inherent 
in studies of inherited disease. The use of sibships where all of the siblings had a known 
disease status did not change the survival statistics. However, there may still be 
ascertainment bias in that there are more male than female affected subjects in the study, 
as has been mentioned, probably due to the greater ease with which males are diagnosed. 
One of the greatest limitations for this study is survivor bias. One had to be alive in order 
for a test to be applied, or to have a medical record other than an autopsy report. 
However, with the continuation of the prospective study, and the follow-up of those at 
risk from age 10 years, the remaining questions relating to survivor bias should be 
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answerable in the future. It is likely that we have failed to ascertain all ARVD5 families 
in Newfoundland. Families with positive family histories of ARVC could be missed for 
example if the TMEM43 mutation is transmitted through several generations of females. 
Also, time trends, particularly the differences in drug usage across time, pose potential 
problems. Data have been collected on the use of medical interventions, but the fluidity 
of drug prescription and the changes in such practices over time make their impact 
difficult to determine accurately. Other possible time trends in tetms of environmental 
modifiers are also challenging to ascertain and assess. The lack of RV data from 
echocardiographic assessment limited any conclusions regarding the structure and 
function of the right ventricle. 
7.2.8 Validity and conclusion 
This study has excellent internal validity due to the relative completeness of the data and 
the homogeneity of the population. Of 11 families with ARVC in Nova Scotia where the 
genetic etiology of their disease is known, nine have the same TMEM43 mutation as the 
Newfoundland families. One of these nine has no apparent Newfoundland roots (378). In 
London, England, we have determined that other mutations within TMEM43 apparently 
segregate with ARVC disease in UK kindreds (data not shown in thesis). There are thus 
likely to be individuals with ARVC due to ARVD5 in Canada and the rest of the world 
for whom the results presented in this thesis are directly applicable. These findings will 
have external validity for families with the same mutation and may help to inform 
families with a different mutation in the same gene. 
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The results from the series of studies presented in this thesis have moved the field of 
ARVC genetics research forward significantly. The clinical and research implications of 
this work include families with ARVC who are receiving improved diagnosis, 
investigation and treatment and researchers with new insights into the variable 
expressively and pathogenesis of this complex disease. Ethical issues have even broader 
implications. The future is bright for answering the many exciting research questions 
arising from this body of work. 
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Ascertainment Status > or = 50% 
Ascertainment status: All of sibship 
Ascertainment > 50% 
MCP 
Gender of trans. parent 
Gender 
Date of Birth 
Accuracy of DOB 
Year of Birth 
Decade of birth 
DOB (before and after 1950) 
DOB (Before and after 1920) 
age at last fo llow-up 
Age at last follow-up natural history: taking into account date of defib and 
date of Ht trans and death 
Year of Death 
Are they dead?. This is censored for date of lCD or trans. If they died after 
this time, they are considered alive for the analysis 





ARVC Clinical Status 
Do they fulfill task force criteria? NB A no SCD answer is ANY SCD at 
ANY age (tells why there are no records) 
Ifyes1 which criteria do they fi ll? 
Using modified criteria as in Hamid paper 2002, with addition of any relative 
not just I st degree 
DNA Obtained 
Linkage Status 
Are they positive for the TM 43 SNP? 
I Year of Death 
Were they alive at the begining of 1996 (when Kathy first started to ascertain 
famil ies) 
Were they alive at the begining of 1998 when the main clinical screening 
started? 
Were they penetrant for any of the features listed? 





















59 1 longstan 
60 vis dr 






















Were they penetrant for any of the features listed (removing those where 
. there was no difference shown between affected and unaffected subjects)? 
km variable for penetrance. Age at which affected individuals (born at an a 
priori 50% risk) manifested a feature (for feature list see ARVC datasets file) 
I 
~·~~~~ f:l~~;e~p 
Which feature (assuming had more than one at the same age)? 
I Which feature (assuming had more than 2 at the same age)? 
Which feature (assuming had more than 3 at the same age)? 
Which feature (assuming had more than 4 at the same age)? 
I Disease Status Method of Diagnosis: Clinical event = SCD, VT, or transplant under 50 





I Mode of presentation 
Have they attended a screening clinic? 
Was there a retrospective chart review? If Yes: we got chart notes. This 
includes autopsy reports only. 
Mode of presentation: chart review only or chart review and interview 
Clinical Problem I Clinical problem type 
Age at first clinical problem 
I Longstanding 
Visit to Doctor 
Age at first visit to Dr. 
Presyncope 
Age @ Presyncope presentation 
Age group at PS 
KM: time toPS, lCD, Ht trans, death or last f/up 
[ Those with clinical event: difference between age at death and age at pre-
syncope 
Syncope 
Age at syncope presentation 
J Age gp at syncope 
j KM: time to S, lCD, Ht trans, death or last f/up 
Palpitations 
Age at palpitation presentation 
Age gp at palpitations 
KM: time to Palp, lCD, Ht.trans, death or last f/tp 
Chest Pain 
I Age at chest pain presentation 
Age group at chest pain 




Age at Heart Failure presentation 












94 j num_hosp 
95 days_ hos 
96 varOOOO I 
97 varOOO 19 
98 var00028 
99 dead 
I 00 I datedead 


























127 varOOO 13 
128 var00025 
129 var00026 
130 de fib 
Age group at heart failure 
Functional assessment of heart failure 
KM : time to HF, lCD, Ht. trans, death or last f/up 
Cardiac Arrest 
Age @ Cardiac Arrest 
KM: time to CA, lCD, Ht. trans, death or last f/up 
Hospitalization 
Reason for hospitalisation I Age at first Hospitalization 
KM: time to Hosp, ICD, Ht.trans,death or last f/up 
KM : time to Hosp for 2nd reasons, lCD, Ht trans, death or last f/up 
r Number of Hospitalizations J Days in Hospital 
ID number I First name 
Last name 
Are they dead? 
l Date of Death Accuracy of DOD Year of Death 
Dead before 1980: Class 3 meds not g iven prior 
Age at Death 
1 Age at Death or Last follow-up 
Was it a SCD? 
I Cause of Death 
Describe (Cause of Death) 
Class I Drugs 
Age at Rx (Class I Drug) 
T Class I drug name 
I Sotolol 
Age at Rx (Sotolol) 
Did they take any antiarrhythmic? 





Age at Rx. (Amiodorone) 
Betablockers 
Age at Rx. (Betablocker) 
Betablockers Name 
[ Cardiac Meds 
Age at Rx. (Cardiac Meds) 
1 




Defibri II a tor 




134 I defiprob 
135 typeprob 
136 age_defi 
137 datI fir 











149 com def 
150 pacemake 
151 age _pace 
152 com _pace 
153 cardvers 
154 age_cv 
155 com cv 
156 heart tx 
157 age_htx 
158 den afib 
159 i agedafib 
160 den atlu 
161 agedatlu 








170 den I ax 
171 aged_ lax 
172 den r ax 
173 aged_rax 
174 den fdav 
175 aged_fav 
176 den mobl 
177 aged_mbl 
178 den mob2 
[ Date of Defib Implant 
Year of Birth 
Was the implant for primary or secondary reasons? 
Has there been a problem with the defib? 
Type of problem with the defibrillator 
Age at Rx. (Defibrillator) 
Date of I st firing of lCD for an appropriate reason 
Age of first appropriate firing ofthe lCD 
l What type of Loss of consciousness was there? 10 number 
First name 
f Last name 
VT rate at time of lCD fire 
J What did it appropriately fire for? 
Cause of I st firing 
1 
Did the lCD detect VT which resolved before a chock was required? 
What level of VT was it? 
Was there L VE ( 11 2%) in the echo closest to the lCD implant date? 
Comments (Defibrillator) 
Pacemaker 
Age at Rx. (Pacemaker) 
Comments - Pacemaker 
Cardioversion 
Age at Rx. (Cardioversion) 
Comment- Cardioversion 
Heart Tx. 
Age at Rx. (Heart Tx.) 
Denovo Atrial Fibrillation 
Age @ Denovo Atrial Fibrillation or Age @ last ECG 
Denovo Atrial Flutter 
Age @ Denovo Atrial Flutter or Age @ last ECG 
Denovo Other Atrial Rhythm 
Age @ Denovo Other Atrial Rhythm @ last ECG 
Denovo WPW 
Age @ Denovo WPW or Age @ last ECG 
J Denovo Ventricular Tachy 
age @ Denovo VT or Age @ last ECG 
Denovo Torsades de Pointes 
age @ Denovo Torsades de Pointes or age @ last ECG 
Denovo Left Axis Deviation 
age @ Denovo Left Axis Deviation or Age @ last ECG 
Denovo Right Axis Deviation 
age @ Denovo Right Axis Deviation or Age @ last ECG 
Denovo First Degree A V block 
age @ denovo First degree A V block or Age @ last ECG 
Denovo Mobitz I 
f age @ denovo Mobitz I or age @ last ECG 
f Denovo Mobitz 2 
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179 aged_mb2 age @ denovo mobitz 2 or age @ last ECG 
180 den_comp Denovo Complete Heart Block 
181 aged_com age @ denovo Complete Heart Block or age @ last ECG 
182 den_qt_s Denovo Short QT interval 
183 aged_qts age @ denovo Short QT interval or age @ last ECG 
184 den_qt_l Denovo Long QT interval 
185 aged_qtl age @ denovo long QT interval or age @ last ECG 
186 den_pr Denovo Short PR interval 
187 age_d_pr age @ denovo short PR interval or age @ last ECG 
188 denqrs_ Denovo long QRS duration 
189 agedqrs_ age @ denovo long QRS duration or age @ last ECG 
190 den_eps Denovo Epsilon Wave 
191 aged_eps age @ denovo Epsilon Wave or age @ last ECG 
192 den_prw Denova Poor R Wave 
193 aged_prw Age @ Denova Poor R Wave or Age @ last ECG 
194 den talr Denovo Tall R in VI 
195 aged_tr Age @ Denovo Tall R in VI or Age @ last ECG 
196 den tinv Denovo T inversion in V2 or V3 
197 aged_tin Age @ denovo T inversion in V2 or V3 
198 den lae Denovo Left Atrial Enlargement 
199 aged_lae Age @ Denovo Left Atrial Enlargement or age @ last ECG 
200 den rae Denovo Right Atrial Enlargement 
20 1 aged_rae Age @ Denovo Right Atrial Enlargement or age @ last ECG 
202 den rvh J Denovo Right Ventricular Hypertrophy 
203 aged_rvh Age @ Denovo Right Ventricular Hypertrophy or age @ last ECG 
204 den lvh Denovo Left Ventricular Hypertrophy 
205 aged_lvh Age @ Denovo left Ventricular hypertrophy or age @ last ECG 
206 denlbbb Denovo Left Bundle Branch Block 
207 aged_lbb Age @ Denovo Left Bundle Branch Block or age @ last ECG 
208 denrbbb Denovo Right Bundle Branch Block 
209 aged_rbb Age @ Denovo Right Bundle Branch Block or age @ last ECG 
2 10 den lahb Denovo Left Anterior Hemi-block 
2 11 aged_lah Age @ Denovo Left Anterior Hemi-Block or age @ last ECG 
2 12 den_lphb Denovo Left Posterior Hemi-block 
2 13 aged_lph Age @ Denovo Left Posterior Hemi-Block or age @ last ECG 
2 14 denpvcs_ Denovo Premature Ventricular Complexes 
2 15 aged _pvc Age @ Denovo Premature Ventricualr Complexes or age @ last ECG 
2 16 den_infq Denovo Inferior Q waves 
2 17 agedinfq Age @ Denovo Inferior Q waves or age @ last ECG 
2 18 den_sepq Denovo Septal Q waves 
2 19 agedsepq Age @ Denovo Septal Q waves or age @ last ECG 
220 den_latq Denovo Lateral Q waves 
22 1 agedlatq Age @ Denovo Lateral Q waves or age @ last ECG 
222 den_antq Denovo Anterior Q waves 
223 agedantq Age @ Denovo Anterior Q waves or age @ last ECG 
224 den _peri Denovo Pericarditis 
225 aged peri Age @ Denovo Pericarditis or age @ last ECG 
226 de std i Denovo ST depression > I mm Inferior 
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227 aged_dpi 
228 de std a 
229 aged_dpa 
230 de std I 
231 aged_dpl 
232 de ste i 
233 aged_eli 
234 de ste a 
235 aged_ela 
236 de ste I 
237 aged_ell 
238 den twii 
239 agedtwii 
240 den twif 
241 agedtwif 
242 den twli 
243 agedtwli 














258 nor abn I 
259 htrate I 
260 rhyth_ l 
261 axis I 
262 hb I 
263 qt_ l 
264 pr_ l 
265 qrs_ l 
266 eps_ l 
267 prwp_ l 
268 tallr I 
269 tinv l 
270 lae I 
271 rae I 
272 lvh I 
273 rvh I 
274 lbbb I 
Age @ De novo ST depression > I mm Inferior or age @ last ECG 
Denovo ST depression > I mm Anterior 
Age @ De novo ST depression > I mm Anterior or age @ last ECG 
Denovo ST depression > I mm Laterally 
Age @ De novo ST depression > I mm Laterally or age @ last ECG 
Denovo ST Elevation <I mm Inferior 
Age @ De novo ST Elevation < I mm Inferior or age @ last ECG 
Denovo ST Elevation <I mm Anterior 
Age @ Denovo ST Elevation <I mm Anterior or age @ last ECG 
Denovo ST Elevation < I mm Laterally 
Age @ De novo ST Elevation < I mm Laterally or age @ last ECG 
Denovo Inferior T wave inversion 
Age @ Denovo Inferior T wave inversion or age at last ECG 
Denovo Inferior T wave flattening 
Age @ Denovo inferior T wave flattening or age at last ECG 
Denovo Lateral T wave inversion 
Age @ Denovo lateral T wave inversion or age at last ECG 
Denovo lateral T wave flattening 
Age @ denovo lateral T wave flattening or age at last ECG 
Denovo any poor R wave progression or septal Q waves 
Age @ Denovo any poor R wave progression or septal Q waves or age at last 
ECG 
Any abnormality at EKG on any EKG (poor R wave, pvc's, VT only) 
Is there PR WP on any ECG? 




Did they have an ECG? 
Is there a trace, or is the report from notes? 
J Age Gp @ I st ecg 
Age @ first ECG 
Was it a Normal ECG? 
Heart rate first ECG 
What is the rhythm on first ECG? 
What is the axis on first ECG? 
Is there Heart Block on first ECG? 
What is the QT interval on first ECG? 
Is the PR interval short on first ECG? 
QRS duration on first ECG 
Was there an Epsilon wave on first ECG? 
Was there a poor R wave progression on first ECG(<3mm in V3)? 
Was there a tall R in VI on first ECG ? 
Was there aT wave inversion in V2 or V3 on first ECG? 
Was there left atrial enlargement on first ECG? 
Was there right atrial enlargement on first ECG? 
Was there Left ventricular hypertrophy on first ECG? 
Was there right ventricular hypertrophy on first ECG? 
Was there left bundle branch block on first ECG? 
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275 rbbb I 
276 r lahb=l 
277 lphb_ l 
278 pvc_ l 
279 pvc3_ 1 
280 infq_l 
28 1 septq_l 
282 latq_l 
283 1 antq_l 
284 peric_ l 
285 st_dp_ i I 
286 st_dp_a l 
287 st_dp_ ll 
288 st el i I 
289 st el a I 
290 st el II 
291 l t;_i~f_l 
292 tw tat I 




297 qrsl_ IIO 
298 comm I 
299 comment) 






306 norabn 2 
307 hr 2 
308 rhyth_2 
309 axis 2 
310 hb 2 
3 11 qt_2 
3 12 pr_2 
3 13 qrs_2 
3 14 eps_2 
315 prwp_2 
316 tallr 2 
3 17 tinv 2 
318 lae 2 
319 I rae_2 
320 lvh 2 
321 rvh 2 
322 lbbb 2 
Was there right bundle branch block on first ECG? 
Was there left anterior hemiblock on first ECG? 
Was there left posterior hemiblock on first ECG? 
ANy PVC's on first ECG? 
3 pvc's in a row (NSVT)on first ECG? 
Inferior Q waves on first ECG? 
Septal Q waves on first ECG? 
Lateral Q waves on first ECG? 
Anterior Q waves on first ECG? 
Any pericarditis on first ECG? 
j ST de_eression > I mm (INFERIOR) on first ECG 
1 ST depression > I mm (ANTERIOR) on first ECG 
ST depression > lmm (LATER.ALL Y) on first ECG 
ST elevation > lmm (INFERIOR) on first ECG 
ST e levation > I mm (ANERIOR) on first ECG l ST elevation > I mm (LATER.ALL Y) on first ECG 
Inferior T wave on first ECG 
I Lateral T wave on first ECG Was there any poor R wave progression or septal Q waves on the first ECG 
I lD number 
l QRS on first ECG 
[ QRS on last ECG 
Is the QRS duratioN on the last ECG > .I I 0 ms 
Comments on first ECG 
Comment on I st ECG 
Age @ last ECG 
How many follow-up ecg's? 
Had a second ECG? 
t is there a trace, or is the report from notes? 1 Age gp @ 2nd ECG 
Age @ 2nd ECG 
Normal second ECG? 
Heart rate second ECG 
What is the rhythm on second ECG? 
What is the axis on second ECG? 
Is there Heart Block on second ECG? t What is the QT interval on second ECG? 
Is the PR interval short on second ECG? 
[ QRS duration on second ECG 
Was there an Epsilon wave on second ECG? 
Was there a poor R wave progression on second ECG(<3mm in V3)? 
Was there a tall R in VI on 2nd ECG? 
Was thereaT wave inversion in V2 or V3 on 2nd ECG? 
Was there left atrial enlargement on 2nd ECG? 
Was there right atrial enlargement on 2nd ECG?' I Was there Left ventricular hypertrophy on 2ndECG? 
Was there right ventricular hypertrophy on 2nd ECG? 
Was there left bundle branch block on 2ndECG? 
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..----------------------------------------------------- -
323 rbbb 2 









333 st_dp_ i2 
334 st_dp_a2 
335 st_dp_ l2 
336 st el i2 
337 st el a2 
338 st el 12 
339 tw inf 2 
340 tw lat 2 
341 pr2sq2_2 






348 l norabn_3 
349 hr 3 
350 rhyth_3 
35 1 axis 3 
352 hb 3 





358 tallr 3 
359 tinv 3 
360 lae 3 
36 1 rae 3 
362 lvh 3 
363 1 rvh_3 
364 lbbb 3 
365 rbbb 3 





Was there right bundle branch block on 2ndECG? 
I Was there left anterior hemiblock on 2nd ECG? 
f Was there left posterior hemiblock on 2nd ECG? 
ANy PVC's on 2nd ECG? 
3 pvc's in a row (NSVT)on 2nd ECG? 
Inferior Q waves on 2nd ECG? 
Septal Q waves on 2nd ECG? 
Lateral Q waves on 2nd ECG? 
Anterior Q waves on 2nd ECG? 
Any pericarditis on 2nd ECG? 
ST depression > I mm (INFERIOR) on second ECG 
ST depression > I mm (ANTERJOR) on second ECG r ST depression > I mm (LATERALLY) on second ECG 
ST elevation > I mm (INFERJOR) on second ECG 
ST e levation > I mm (ANTERIOR) on second ECG 
I ST elevation > I mm (LATERALLY) on second ECG 
T wave inferior on 2nd ECG 
T wave lateral on 2nd ECG 
Was there any poor R wave progression or septal Q waves on the 2nd ECG 
Comments on 2nd ECG 
Comment on 2nd ECG 
Has a 3rd ecg? 
Age gp @ 3rd ECG 
Age@ 3rd ECG 
Is it a trace or a report from the notes? 
Normal 3rd ECG? 
Heart rate 3rd ECG 
What is the rhythm on 3rd ECG? 
What is the axis on 3rd ECG? 
Is there Heart Block on 3rd ECG? 
What is the QT interval on 3rd ECG? 
I Is the PR interval short on 3rd ECG? 
QRS duration on 3rd ECG 
Was there an Epsilon wave on 3rd ECG? 
1 Was there a poor R wave progression on 3rd ECG(<3mm in V3)? 
Was there a tall R in VI on 3rd ECG ? 
Was there aT wave inversion in V2 or V3 on 3rd ECG? 
Was there left atrial enlargement on 3rd ECG? 
Was there right atrial enlargement on 3rd ECG? 
Was there Left ventricular hypertrophy on 3rd ECG? 
Was there right ventricular hypertrophy on 3rd ECG? 
f Was there left bundle branch block on 3rd ECG? 
Was there right bundle branch block on 3rd ECG? 
l Was there left anterior hemiblock on 3rd ECG? 
J Was there left posterior hemiblock on 3rd ECG? 
ANy PVC's on 3rd ECG? 
l 3 pvc's in a row (NSVT)on 3rd ECG? 
Inferior Q waves on 3rd ECG? 
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371 septq_3 Septal Q waves on 3rd ECG? 
372 latq_3 Lateral Q waves on 3rd ECG? 
373 antq_3 Anterior Q waves on 3rd ECG? 
374 peric_3 j Any pericarditis on 3rd ECG? 
375 st_dp_ i3 ST depression > I mm (INFERIOR) on 3rd ECG 
376 st_dp_a3 ST depression > I mm (ANTERIOR) on 3rd ECG 
377 st_dp_ l3 ST depression > I mm (LATERALLY) on 3rd ECG 
378 st el i3 ST elevation > I mm (INFERIOR) on 3rd ECG 
379 st e l a3 ST elevation > I mm (ANTERIOR) on 3rd ECG 
380 st e l 13 ST e levation > I mm (LATER.ALL Y) on 3rd ECG 
381 tw inf 3 T wave inferior on 3rd ECG 
382 tw lat 3 T wave lateral on 3rd ECG 
383 pr3sq3_3 Was there any poor R wave progression or septal Q waves on the third ECG 
384 comm 3 Comments on 3rd ECG 
385 comm3 Comment on 3rd EKG 
386 ecg4 Has a 4th ECG? 
387 agegp4 Age gp @ 4th ECG 
388 age_4 Age @ 4th ECG 
389 ecgtrc_ 4 Is it a trace or a report form the notes? 
390 nrmabn 4 Normal 4th ECG? 
39 1 hr 4 Heart rate 4th ECG 
392 rhyth_ 4 What is the rhythm on 4th ECG? 
393 axis 4 l What is the axis on 4th ECG? 
394 hb 4 Is there Heart Block on 4th ECG? 
395 qt_4 What is the QT interval on 4th ECG? 
396 pr_4 Is the PR interval short on 4th ECG? 
397 qrs_ 4 QRS duration on 4th ECG 
398 eps_4 Was there an Eps ilon wave on 4th ECG? 
399 prwp_4 Was there a poor R wave progression on 4th ECG(<3mm in V3)? 
400 tallr 4 Was there a tall R in VI on 4th ECG ? 
401 tinv 4 Was there aT wave inversion in V2 or V3 on 4th ECG? 
402 lae 4 Was there left atrial enlargement on 4th ECG? 
403 rae 4 / Was there right atrial enlargement on 4th ECG? 
404 lvh 4 Was there Left ventricular hypertrophy on 4th ECG? 
405 rvh 4 Was there right ventricular hypertrophy on 4th ECG? 
406 lbbb 4 Was there left bundle branch block on 4th ECG? 
407 rbbb 4 Was there right bundle branch block on 4th ECG? 
408 lahb 4 Was there left anterior hemiblock on 4th ECG? 
409 lphb_ 4 Was there left posterior hemiblock on 4th ECG? 
4 10 pvc_4 ANy PVC's on 4th ECG? 
411 pvc3_ 4 3 pvc's in a row (NSVT)on 4th ECG? 
412 infq_ 4 Inferior Q waves on 4th ECG? 
413 septq_ 4 Septal Q waves on 4th ECG? 
4 14 latq_ 4 / Lateral Q waves on 4th ECG? 
4 15 antq_ 4 Anterior Q waves on 4th ECG? 
416 peric_4 Any pericarditis on 4th ECG? 
4 17 st_dp_ i4 ST depress ion > I mm (INFERIOR) on 4th ECG 
4 18 st_dp_a4 ST depression > I mm (ANTERIOR) on 4th ECG 
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419 st_dp_14 ST depression > I mm (LATERALLY) on 4th ECG 
420 st el i4 ST elevation > I mm (INFERIOR) on 4th ECG 
421 st el a4 ST elevation > I mm (ANTERIOR) on 4th ECG 
422 st el 14 ST elevation > I mm (LATERALLY) on 4th ECG 
423 tw inf 4 T wave inferior on 4th ECG 
424 tw lat 4 T wave lateral on 4th ECG 
Was there any poor R wave progression or septal Q waves on the fourth 
425 pr4sq4_4 ECG 
426 comm 4 Comments on 4th ECG 
427 ecg5 Has a 5th ecg? 
428 agegp5 Age gp @ 5th ECG 
429 age_5 Age @ 5th ECG 
430 ecgtrc_5 Is it a trace or a report !Tom the notes? 
431 nrmabn 5 J Normal 5th ECG? 
432 hr 5 Heart rate 5th ECG 
433 rhyth_5 What is the rhythm on 5th ECG? 
434 axis 5 What is the axis on 5th ECG? 
435 hb 5 Is there Heart Block on 5th ECG? 
436 qt_5 What is the QT interval on 5th ECG? 
437 pr_5 Is the PR interval short on 5th ECG? 
438 qrs_5 QRS duration on 5th ECG 
439 eps_5 f Was there an Epsilon wave on 5th ECG? 
440 prwp_5 Was there a poor R wave progression on 5th ECG(<3mm in V3)? 
441 tallr 5 Was there a tall R in VI on 5th ECG ? 
442 tinv 5 Was there aT wave inversion in V2 or V3 on 5th ECG? 
443 lae 5 Was there left atrial enlargement on 5th ECG? 
444 rae 5 Was there right atrial enlargement on 5th ECG? 
445 lvh 5 Was there Left ventricular hypertrophy on 5th ECG? 
446 rvh 5 Was there right ventricular hypertrophy on 5th ECG? 
447 lbbb 5 Was there left bundle branch block on 5th ECG? 
448 rbbb 5 Was there right bundle branch block on 5th ECG? 
449 lahb 5 1 Was there left anterior hemiblock on 5th ECG? 
450 lphb_5 
1 
Was th«e left postedo• hem;blook on 5th ECG? 
451 pvc_5 ANy PVC's on 5th ECG? 
452 pvc3_5 3 pvc's in a row (NSVT)on 5th ECG? 
453 infq_5 Inferior Q waves on 5th ECG? 
454 septq_5 Septal Q waves on 5th ECG? 
455 latq_ 5 Lateral Q waves on 5th ECG? 
456 antq_5 Anterior Q waves on 5th ECG? 
457 peric_5 Any pericarditis on 5th ECG? 
458 st_dp_ i5 ST depression > I mm (INFERIOR) on 5th ECG 
459 st_dp_a5 I ST depression > lmm (ANTERIOR) on 5th ECG 
460 st_dp_l5 ST depression > I mm (LATERALLY) on 5th ECG 
461 st el i5 ST elevation > I mm (INFERIOR) on 5th ECG 
462 st el a5 ST elevation > lmm (ANTERIOR) on 5th ECG 
463 st el 15 ST elevation > I mm (LATERALLY) on 5th ECG 
464 tw inf 5 T wave inferior on 5th ECG 
465 tw lat 5 T wave lateral on 5th ECG 
466 pr5sq5_5 Was there any poor R wave progression or septal Q waves on the 5th ECG 
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467 comm5 Comments on 5th ECG 
468 ecg6 Has a 6th ecg? 
469 agegp6 Age gp @ 6th ECG 
470 age_6 Age@ 6th ECG 
471 ecgtrce_ Is it a trace or a report from the notes 
472 nrmabn 6 Normal 6th ECG? 
473 hr 6 Heart rate 6th ECG 
474 rhyth_6 What is the rhythm on 6th ECG? 
475 axis 6 What is the axis on 6th ECG? 
476 hb 6 Is there Heart Block on 6th ECG? 
477 qt_6 What is the QT interval on 6th ECG? 
478 pr_6 Is the PR interval short on 6th ECG? 
479 qrs_6 QRS duration on 6th ECG 
480 eps_6 Was there an Epsilon wave on 6th ECG? 
481 prwp_6 Was there a_poor R wave progression on 6th ECG(<3mm in V3)? 
482 tallr 6 Was there a tall R in VI on 6th ECG ? 
483 tinv 6 Was there aT wave inversion in V2 or V3 on 6th ECG? 
484 lae 6 Was there left atrial enlargement on 6th ECG? 
485 rae 6 Was there right atrial enlargement on 6th ECG? 
486 lvh 6 Was there Left ventricular hypertrophy on 6th ECG? 
487 rvh 6 Was there right ventricular hypertrophy on 6th ECG? 
488 lbbb 6 Was there left bundle branch block on 6th ECG? 
489 rbbb 6 Was there right bundle branch block on 6th ECG? 
490 lahb 6 Was there left anterior hemiblock on 6th ECG? 
491 lphb_6 Was there left posterior hemiblock on 6th ECG? 
492 pvc_6 ANy PVC's on 6th ECG? 
493 pvc3_6 3 pvc's in a row (NSVT)on 6th ECG? 
494 infq_6 Inferior Q waves on 6th ECG? 
495 septq_6 Septal Q waves on 6th ECG? 
496 latq_6 Lateral Q waves on 6th ECG? 
497 antq_6 Anterior Q waves on 6th ECG? 
498 peric_6 Any pericarditis on 6th ECG? 
499 st_dp_ i6 f ST depression > I mm {INFERlOR) on 6th ECG 
500 st_dp_a6 ST depression > I mm (ANTERIOR) on 6th ECG 
501 st_dp_ 16 ST depression > I mm (LATERALLY) on 6th ECG 
502 st e l i6 ST elevation > I mm (INFERIOR) on 6th ECG 
503 st el a6 ST elevation > I mm (ANTERIOR) on 6th ECG 
504 st el 16 ST elevation > I mm (LATERALLY) on 6th ECG 
505 tw inf 6 T wave inferior on 6th ECG 
506 tw !at 6 T wave lateral on 6th ECG 
507 pr6sq6_6 Was there any poor R wave progression or septal Q waves on the 6th ECG 
508 comm 6 f Comments on 6th ECG 
509 var00012 ID number 
510 var00014 First name 
511 varOOO 15 Last name 
512 sa_ecg Signal average ECG? 
513 useinaly Use in analysis? Has an ECG got 888? 
514 age_secg Age at first signal averaged ECG 
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515 sa lagegp Age group first SA ECG 
516 sa lag40 Above or below 40 years age group on first SA ECG 
517 saoldnew Is it the old or the new SAECG machine? 
5 18 abn I sa Is the QRS abnormal on the I st ECG (> I I 0 on old,> 120 on new) 
5 19 totqrs I Total QRS 
520 tqrs Ill 0 Total QRS < or = II 0 and > I I 0 
521 tqrs I I 15 Total QRS < or = 115 and > 115 
522 tqrs 1120 Total QRS < or = 120 and > 120 
523 rms Total rms 
524 rmsl20 Total rms< or = 20 and > 20 
525 las Total las 
526 lasl38 Total LAS > or = 38 and < 38 
527 , sa1 _2pos Any 2 out of three criteria positive on the first SAECG 
528 dn_qrsab Denovo QRS abnormal? 
529 dn rmsab Denovo RMS abnormal? 
530 dn lasab Denovo LAS abnormal 
531 dn 23ab Denovo 2/3 abnormal 
532 agednqrs Age at denovo abnormal QRS or age at last follow-up 
533 agednrms Age at denovo abnormal RMS or age at last follow-up 
534 agednlas Age at denovo abnormal LAS or age at last follow-up 
535 agedn23 Age at denovo 2/3 abnormal or age at last follow-up 
536 numfsaeg Number of follow-up SAECGs 
537 sa_ecg2 Did they have a second SAECG? 
538 saoldne2 Is it the old or the new SAECG machine? 
539 usein 2a Use in analysis? BBB on ECG 
540 saage_2 Age @ 2nd SAECG 
541 sa2agegp Age group second SA ECG 
542 totqrs_2 Total QRS (2nd saecg) 
543 abn 2sa Is the QRS abnormal on the 2nd ECG (> 110 on old, > 120 on new) 
544 rms 2 Total rms (2nd saecg) 
545 rms220 Total rms< or =20 and >20 on 2nd SA ECG 
546 las 2 Total las (2nd ecg) 
547 las238 Total LAS > or = 38 and < 38 on 2nd SAECG 
548 sa2_2pos Any 2 out of three criteria positive on the second SAECG 
549 sa_ecg3 Did they have a third SAECG? 
550 saoldne3 Is it the old or the new SAECG machine? 
551 usein 3a Use in analysis? BBBon ECG 
552 abn 3sa Is the QRS abnormal on the 3rd ECG (> I I 0 on old,> 120 on new) 
553 saage_3 Age @ 3rd SAECG 
554 sa3agegp Age group third SA ECG 
555 totqrs_3 Total QRS (3rd ECG) 
556 rms 3 \ Total nns (3rd ecg) 
557 rms320 Total rms< or =20 and >20 on 3rd SA ECG 
558 las 3 Total las (3rd ecg) 
559 las338 Total LAS > or = 38 and < 38 on Jrd SAECG 
560 sa3_2pos Any 2 out of three criteria positive on the third SAECG 
561 sa_ecg4 Did they have a fourth SAECG? 
562 saoldne4 Is it the old or the new SAECG machine? 
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563 usein 4a Use in analysis? BBBon ECG 
564 abn sa4 Is the QRS abnormal on the 4th ECG (> II 0 on old,> 120 on new) 
565 saage_4 Age @ 4th SAECG 
566 sa4agegp Age group fourth SA ECG 
567 totqrs_ 4 Total QRS (4th saecg) 
568 rms 4 Total rms (4th saecg) 
569 rms420 Total rms< or =20 and >20 on 4th SA ECG 
570 las 4 Total las (4th saecg) 
571 las438 Total LAS > or = 38 and < 38 on 4th SAECG 
572 sa4_2pos Any 2 out of three criteria positive on the fourth SAECG 
573 sa_agel Age @ last saecg (first/last) 
574 sa_totql Total QRS last saecg (first/last) 
575 tqrsll 15 I Total QRS < or = I 15 and > I 15 (last saecg) 
576 sa rmsl 1 Total rms last saecg (first/last) 
577 sa lasl Total las last saecg (first/last) 
578 echo Had a first echo 
579 abnecho Any abnormality on any echo 
580 varOOO 10 10 number 
581 varOOO 16 First name 
582 var00032 Last name 
583 echocomm echo comment 
584 numfecho Number of follow-up echoes 
585 age_echo f Age at first Echo 
586 agegpech Age Group @ first echo 
587 e_age l Age(< or >or= 34 yrs) 
588 height Height ( inches) 
589 height I Height (em) needed for Henry 
590 weight Weight (kg) 
591 bsal BSA ( I st echo) 
592 e rvdil RV dilitation (echo) 
593 e rvabn RV abnormality (echo) 
594 e_lvhyp LV hypertrophy (echo) 
595 e lvdil LV dilitation (echo) 
596 e_ lvsys LV systolic dysfunction (echo) 
597 e laenl LA enlargement (echo) 
598 e rwabn Regional Wall Abnormality (echo) 
599 e lad Left Atrial Diameter (echo) 
600 e_pwtd Posterior Wall Thickness in Diastole (echo) 
601 e swtd Septal Wall Thickness in Diastole (echo) 
602 e lvedd LVEDD (echo) 
603 e lvesd LVESD (echo) 
604 e fs j Fractional Shortening (echo) 
605 FS25 Is fractional shortening less than or equal to 25? 
606 e disk Diskinesia (echo) 
607 e diskc I Diskinesia Combined (I st echo) 
608 explved I Expected LVEDD (I st echo) 
609 henry I Henry % ( I st echo) 
6 10 ventvoll Ventricular Volume ( I st echo) 
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611 e dils l Dilatation by size (I st echo) 
61 2 e dilh 13 Dilatation by Henry 3 SO 117% (I st echo) 
613 e dilh 12 Dilatation by Henry 2 SO 11 2% (1st echo) 
614 dendilh3 Denovo development of LV dilatation 3SD I 17% (Henry %) 
615 dendilh2 Denovo development of LV dilatation 2SD 112% (Henry%) 
616 agdenh3s Age @ denovo development of LV dilatation 3SD I 17% (Henry %) 
617 agdenh2s Age @ denovo development of LV dilatation 2SD 112% (Henry%) 
Age @ denovo development of LV dilatation. by Henry 3SD I 17% (KM) or 
618 agedenh3 age at last follow up 
Age @ denovo development of LV diatation by Henry 2SD 11 2% (KM) or 
619 agedenh2 age at last follow up 
620 e dilvvl Dilatation by ventricular volume (I st echo) 
62 1 echo2 Did they have a second echo? 
622 e_age2 Age @ 2nd echo 
623 e_agegp2 Age Group @ 2nd echo 
624 height2 Height @ 2nd echo 
625 height2e Height @ 2nd echo (em) 
626 weight2 Weight @ 2nd echo 
627 bsa2 BSA (2nd echo) 
628 e rvdil2 RV dilitation (2nd echo) 
629 e rvabn2 RV abnormality (2nd echo) 
630 e_ lvhyp2 LV hypertrophy (2nd echo) 
631 e lvdil2 LV dilitation (2nd echo) 
632 e_lvsys2 LV systolic dysfunction (2nd echo) 
633 e laen12 LA enlargement (2nd echo) 
634 e rwabn2 Regional Wall Abnormality (2nd echo) 
635 e lad2 Left Atrial Diameter (2nd echo) 
636 e_pwtd2 Posterior Wall Thickness in Diastole (2nd echo) 
637 e swtd2 Septal Wall Thickness in Diastole (2nd echo) 
638 e lvedd2 LVEDD (2nd echo) 
639 e lvesd2 LVESD (2nd echo) 
640 e fs2 Fractional Shortening (2nd echo) 
641 FS25 2 Is fractional shortening less than or equal to 25 on second echo? 
642 e disk2 Diskinesia (2nd echo) 
643 e diskc2 Diskinesia combined (2nd echo) 
644 explved2 Expected LVEDD (2nd echo) 
645 henry2 Henry% (2nd echo) 
646 ventvol2 Ventricular Volume (2nd echo) 
647 e dils2 Dilatation by size (2nd echo) 
648 e dilh23 Dilatation by Henry 3SD 11 7% (2nd echo) 
649 e dilh22 Dilatation by Henry 2SD 11 2% (2nd echo) 
650 e dilvv2 Dilatation by ventricular volume (2nd echo) 
651 echo3 Did they have a 3rd echo? 
652 e_age3 Age @ 3rd echo 
653 e_agegp3 Age group @ 3rd echo 
654 height3 Height @ 3rd echo 
655 height3e Height @ 3rd Echo (em) 
656 weight3 Weight @ 3rd echo 
657 bsa3 BSA (3rd echo) 
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658 e rvdil3 RV dilatation (3rd echo) 
659 e rvabn3 RV abnormality (3rd echo) 
660 e_ lvhyp3 f LV hypertrophy (3rd echo) 
661 e lvdil3 LV dilitation (3rd echo) 
662 e_lvsys3 LV systolic dysfunction (3rd echo) 
663 e laenl3 LA enlargement (3rd ech<V 
664 e rwabn3 Regional Wall Abnormality (3rd echo) 
665 e lad3 Left Atrial Diameter (3rd echo) 
666 e_pwtd3 Posterior Wall Thickness in Diastole (3rd echo) 
667 e swtd3 Septal Wall Thickness in Diastole (3rd echo) 
668 e lvedd3 LVEDD (3rd echo) 
669 e lvesd3 LVESD (3rd echo) 
670 e fs3 Fractional Shortening (3rd echo) 
671 FS25 3 Is fractional shortening less than or equal to 25 on third echo? 
672 e disk3 Diskinesia (3rd echo) 
673 e diskc3 Diskinesia Combined (3rd echo) 
674 explved3 Expected LVEDD (3rd echo) 
675 henry3 Henry% (3rd echo) 
676 ventvol3 Ventricular Volume (3rd echo) 
677 e dils3 Dilatation by size (3rd echo) 
678 e dilh33 f Dilatation by Henry 3 SO 117% (3rd echo) 
679 e dilh32 Dilatation by Henry 2 SD 112% (3rd echo) 
680 e dilvv3 Dilatation by ventricular volume (3rd echo) 
681 echo4 Did they have a 4th echo? 
682 e_age4 1 Age @ 4th echo 
683 e_agegp4 Age group @ 4th echo 
684 height4 1 Height @ 4th echo 
685 height4e Height @ 4th echo 
686 weight4 Weight @ 4th echo 
687 bsa4 I BSA (4th echo) 
688 e rvdil4 RV dilatation (4th echo) 
689 e rvabn4 RV abnormality (4th echo) 
690 e_ lvhyp4 LV hypertrophy (4th echo) 
691 e lvdil4 LV dilatation (4th echo) 
692 e_ lvsys4 LV systolic dysfunction (4th echo) 
693 e laen14 LA enlargement (4th echo) 
694 e rwabn4 Regional Wall abnormality (4th echo) 
695 e lad4 Left Atrial Diameter (4th echo) 
696 e_pwtd4 Posterior Wall Thickness in Diastole (4th echo) 
697 e swtd4 Septal Wall thickness in Diastole (4th echo) 
698 e lvedd4 LVEDD (4th echo) 
699 e lvesd4 LVESD (4th echo) 
700 e fs4 Fractional shortening (4th echo) 
701 FS25 4 Is tractional shortening less than or equal to 25 on third echo? 
702 e disk4 Diskinesia (4th echo) 
703 e diskc4 Diskinesia combined (4th echo) 
704 explved4 I Expected LVEDD (4th echo) 
705 henry4 Henry% (4th echo) 
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706 ventvol4 Ventricular Volume (4th echo) 
707 e dils4 Dilatation by size (4th echo) 
708 e dilh43 Dilatation by Henry 3SD 117% (4th echo) 
709 e dilh42 l ·Dilatation by Henry 2SD 112% (4th echo) 
710 e dilvv4 Dilatation by ventricular volume (4th echo) 
711 echo5 Did they have a 5th echo 
712 e_age5 Age @ 5th echo 
713 e_agegp5 I Age group @ 5th echo 
714 heightS J Height @ 5th echo 
715 height5e Height @ 5th echo (em) 
716 weightS 1 Wdght @ 5th e<:ho 
717 bsa5 BSA (5th echo) 
718 e rvdil5 RV dilatation (5th echo) 
719 e rvabn5 RV abnormality (5th echo) 
720 e_ lvhyp5 LV hypertrophy (5th echo) 
721 e lvdil5 f LV dilatation (5th echo) 
722 e_ lvsys5 LV systolic dysfunction (5th echo) 
723 e laenl5 LA enlargement (5th echo) 
724 e rwabn5 Regional Wall Abnormality (5th echo) 
725 e ladS Left Atrial Diameter (5th echo) 
726 e_pwtd5 Posterior wall thickness in diastole (5th echo) 
727 e swtd5 Septal Wall thickness in diastole (5th echo) 
728 e lvedd5 LVEDD (5th echo) 
729 e lvesd5 LVEDD (5th echo) 
730 e fs5 Fractional shortening_(Sth echo) 
731 FS25 5 Is fractional shortening less than or equal to 25 on fifth echo? 
732 e diskS j Diskioosia (5th e<:ho) 
733 e diskc5 Diskinesia combined (5th echo) 
734 explved5 Expected LVED (5th echo) 
735 henryS Henry% (5th echo) 
736 ventvol5 j Ventricular Volume (5th echo) 
737 J e_dils5 Dilatation by size (5th echo) 
738 e dilh53 Dilatation by Henry 3SD 117% (5th echo) 
739 e dilh52 1 Dilatation by Henry 2 SO 112% (5th echo) 
740 e dilvv5 Dilatation by ventricular volume (5th echo) 
741 echo6 Did they have a 6th echo? 
742 e_age6 Age @ 6th echo 
743 e_agegp6 Age grou~@ 6th echo 
744 height6 Height @ 6th echo 
745 height6e I Height @ 6th echo (em) 
746 weight6 l Weight @ 6th echo 
747 bsa6 BSA (6th echo) 
748 e rvdil6 RV dilatation (6th echo) 
749 e rvabn6 RV abnormality (6th echo) 
750 e_ lvhyp6 LV hypertrophy (6th echo) 
751 e lvdil6 LV dilatation (6th echo) 
752 e_ lvsys6 I LV systolic dysfunction (6th echo) 
753 e laen16 LA enlargement (6th echo) 
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754 e rwabn6 
755 e lad6 
756 e_pwtd6 
757 e swtd6 
758 e lvedd6 
759 e lvesd6 
760 e fs6 
761 FS25 6 
762 e disk6 
763 e diskc6 
764 e~lved6 
765 I henry6 
766 ventvol6 
767 e dils6 
768 e dilh63 
769 e dilh62 





775 e rvdill 
776 e rvabnl 
777 I e=lvhypl 
778 e lvdill 
779 e_ lvsysl 
780 e laenll 
781 e rwabnl 
782 e ladl 
783 e_pwtdl 
784 e swtdl 
785 r e=lveddl 
786 e lvesdl 
787 e fsl 




792 e dils l 
793 e dilhl3 
794 e dilhl2 




799 f pvcs200 
800 deno200 
801 aged200 
Regional wall abnormality (6th echo) 
Left atrial diameter (6th echo) 
Posterior wall thickness in diastole (6th echo) 
Septal Wall thickness in diastole (6th echo) 
LVEDD (6th echo) 
LVESD (6th echo) 
Fractional shortening (6th echo) 
------ -----
Is fractional shortening less than or equal to 25 on 6th echo? 
J Diskinesia (6th echo) 
Diskinesia combined (6th echo) 
Expected LVEDD (6th echo) 
Henry% (6th echo) 
Ventricular Volume (6th echo) 
j Dilatation by size (6th echo) 
Dilatation by Henry 3SD 117% (6th echo) J Dilatation by Henry 2 SD 112% (6th echo) 
Dilatation by ventricular volume (6th echo) 
Had a first echo 
Last Echo 
Age @ last echo 
Age group at last echo 
RV dilatation (last echo) 
J RV abnormality (last echo) 
LV hypertrophy (last echo) 
LV d i latation(last echo) 
LV Systolic dysfunction (last echo) 
LA enlargement (last echo) 
Regional Wall Abnormality (last echo) 
Left Atrial Diameter (last echo) 
Posterior wall thickness in diastole (last echo) 
Septal wall thickness in systole (last echo) 
LVEDD (last echo) 
LVESD (last echo) 
Fractional Shortening (last echo) 
Diskinesia (last echo) 
Expected LVED (last echo) 
Henry% (last ceho) 
Ventricular Volume (last echo) 
Dilatation by size (last ceho) I Dilatation by Henry 3SD 117% (last echo) 
Dilatation by Henry 2SD 112% (last echo) 




PVCs > or = 200 on any Holter 
f Denovo PVCs > or = 200 
Age @ Denovo PVCs > or = 200 or age @ last holter 
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802 pvcsiOOO PVCs > or = 1000 on any hotter 
803 denoiOOO Denovo PVCs > or = I 000 
804 agedlOOO Age @ Denovo PYCs > or = I 000 or age @ last Holter 
805 hotter Did they have a Holter? 
806 abnholt Abnormality on any Holter: includes PVC's >200 and VT 
807 age_holt Age at first Holter 
808 hagegpl Age gp @ I st Holter 
809 icu ccu ICU or CCU Monitoring 
810 newpvcl PVCs on I st Holter (recoded) 
811 h_pvcs PVCs (24 hrs) 
812 pvc200 PVCs > or = 200 (I st Holter) 
813 pvciOOO PYCs > or = I 000 (I st Holter) 
814 newcoupl I Couplets on I st Holter (recoded) 
815 h_coup Couplets 
816 newbigl Bigeminy on I st Holter (recoded) 
817 h_bigem Bigeminy 
818 newtrip I Triplets on I st Holter (recoded) 
8J9 1 h_trip( J Triplets 
820 h_trig Trigemeny 
821 newrunl Runs of VT on I st Holter (re·coded) 
822 h runvt Runs ofYT 
823 h sust Sustained 
824 h idiov ldioventricular Rhythm on I st hotter 
825 numfholt Number of follow-up holters 
826 holter2 Has a 2nd hotter 
827 h_age2 Age @ 2nd hotter 
828 hagegp2 Age gp @ 2nd hotter 
829 newpvc2 l PVCs on 2nd hotter (recoded) 
830 h_pvcs2 PVCs (2nd hotter) 
831 pvc2_200 PVCs > or = 200 (2nd Holter) 
832 pv2_ 1000 PVCs > or = I 000 (2nd hotter) 
833 h_coup2 Couplets (2nd hotter) 
834 h_bigem2 Bigeminy (2nd hotter) 
835 h_tripl2 Triplets (2nd hotter) 
836 h_trig2 ( Trigemeny (2nd Holter) 
837 h runvt2 Runs ofVT (2nd hotter) 
838 h sust2 J Sustained (2nd hotter) 
839 h idiov2 ldioventricular Rhythm on 2nd hotter 
840 holter3 Has a 3rd hotter 
841 h_age3 Age @ 3rd hotter 
842 hagegp3 I Age gp @ 3rd hotter 
843 pvc3_200 PVCs> or = 200 (3rd holte£) 
844 pv3_ 1 000 PYCs > or = I 000 (3rd hotter) 
845 newpvc3 PVCs on 3rd hotter (recoded) 
846 h_pvcs3 PVCs (3rd hotter) 
847 pvcgp3 PYCs <or= 120 and > 120 (3rd hotter) 
848 h_coup3 Couplets (3rd hotter) 
849 h_bigem3 Bigeminy (3rd hotter) 
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850 h_tripl3 Triplets (3rd holter) 
851 h runvt3 Runs ofVT (3rd holter) 
852 h sust3 Sustained (3rd holter) 
853 h idiov3 ) ldioventricular Rhythm on 3rd holter 
854 J h~lter4 Has a 4th holter 
855 h_age4 Age @ 4th holter 
856 hagegp4 Age gp @ 4th holter 
857 newpvc4 PVCs on 4th holter (recoded) 
858 h_pvcs4 PVCs (4th holter) 
859 pvc4_200 PVCs > or = 200 (4th holter) 
860 pv4_ 1000 t PVCs > or = 1000 (4th holter) 
861 h_coup4 Couplets (4th holter) 
862 h_bigem4 Bigeminy (4th holter) 
863 h_tripl4 I Triplets (4th holter) 
864 h runvt4 Runs ofVT (4th holter) 
865 h sust4 f Sustained (4th holter) 
866 h idiov4 ldioventricular Rhythm on 4th holter 
867 holter5 I Had a 5th Holter 
868 h_age5 Age @ 5th holter 
869 hagegp5 ] Age gp @ 5th Holter 
870 newpvc5 PVC's on 5th Holter (recoded) 
871 h_pvcs5 PVC's 5th Holter 
872 pvc5_200 PVC's > or = 200 (5th Holter) 
873 pv5_ 1000 PVC's > or = I 000 (5th Holter) 
874 h_coup5 Couplets (5th Holter) 
875 h_bigem5 Bigeminy (5th Holter) 
876 h_tripl5 Triplets (5th Holter) 
877 h runvt5 Runs ofVT (?th Holter) 
878 h sust5 Sustained (5th Holter) . 
879 h idiov5 ldioventricular rhythm (5th Holter) 
880 ageh_ lst Age @ last holter 
881 hagegpl Age grouQ_ @ last holter 
882 newpvcl PVCs on last holter (recoded) 
883 h_pvcl J PVCs (last holter) 
884 pvcgpl PVCs <or= 120 and > 120 (last hotter) 
885 h_coupl Couplets (last holter) 
886 h_bigeml Bigemeny (last holter) 
887 h_tripll I Triplets (last hotter) 
888 h runvtl Runs of VT (last holter) 
889 h sustl Sustained (last holter) 
890 h idiovl Idioventricular Rhythm on last holter 
891 mri MRI 
892 abnmri I Abnormality on first MRI 
893 age_ mri Age at first MRI 
894 m_rvdys R V Dysplasia 
895 m_ lvdys LV Dysplasia 
896 m comm Comment on MRI 
897 numfmri Number of follow-up MRis 
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898 m_age2 Age@ 2nd MRJ 
899 m_rvdys2 RV Dysplasia (2nd MRJ) 
900 m_lvdys2 LV Dysplasia (2nd MRJ) 
901 m comm2 I Comment on 2nd MRJ 
902 var00005 ID number 
903 var00017 First name 
904 varOOO 18 Last name 
905 stress t Stress test 
906 abnstres Abnormality on any stress test 
907 age_st Age a_!_first stress test 
908 st resul Stress Test Result I st test 
909 numfst Number of follow-up stress tests 
910 st_age2 Age @ 2nd stress test 
911 st res2 Stress test result (2nd st) 
912 st_age3 Age @ 3rd stress test 
913 st res3 Stress test result (3rd st) 
914 ht cath Heart Cath. 
915 abcthcad Abnormality (CAD critical) on any heart cath 
916 abncth Abnormality of size of ventricle or global/focal dyskinesia 
917 age_hc Age at first heart cath. 
918 he cad Coronary Artery Disease 
919 hc~edp L VEDP (l:leart cath) 
920 he _paps l Pulmonruy Artecy P"'""e systole 
921 hc_papd Pulmonary Artery Pressure diastole 
922 hc_mpap Mean Pulmonary Artery Pressure 
923 hc_wp Wedge Pressure 
924 hc_rap Right Atrial Pressure 
925 he disk Diskinesia (heart cath) 
926 he comm Comment on cardiac cath 
927 numfhc l Number of follow-up heart caths 
928 hc_age2 Age @ ~nd heart cath 
929 he cad2 Coronary Artery Disease (2nd heart cath) 
930 hclvedp2 LVEDP (2nd heart cath) 
931 hc_paps2 Pulmonary Artery pressure systole (2nd eath) 
932 hc_papd2 Pulmonary Artery pressure diastole (2nd cath) 
933 hc_wp2 Wedge pressure (2nd cath) 
934 he_rap2 [ Right Atrial Pressure (2nd cath) 
935 he disk2 Diskinesia (2nd cath) 
936 hc_age3 Age @ 3rd heart cath 
937 he cad3 [ Coronary Artery Disease (3rd cath) 
938 hclvedp3 LVEDP (3rd cath) 
939 hc_paps3 Pulmonary Artery Pressure systole (3rd cath) 
940 he_papd3 f Pulmonary Artery Pressure diastole (3rd eath) 
941 hc_wp3 Wedge Pressure (3rd cath) 
942 hc_rap3 Right Atrial Pressure (3rd cath) 
943 he disk3 Diskinesia (3rd cath) 
944 hc_age4 t Age @ 4th heart cath 
945 he cad4 Coronary Artery Disease (4th cath) 
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946 hclvedp4 LVEDP (4th cath) 
947 hc_paps4 Pulmonary Artery Pressure Systole (4th cath) 
948 hc_papd4 Pulmonary Artery Pressure Diastole (4th cath) 
949 hc_wp4 / Wedge Pressure (4th cath) 
950 hc_rap4 Right Atrial Pressure (4th cath) 
951 he disk4 Diskinesia 0th cath) 
952 ep_study EP Studies 
953 age_ep Age at first EP study 
954 ep_iva Inducible Ventricular Arrhythmia 
955 ep_comm Comment on EP Study 
956 gated_sc Gated Scan 
957 age_gs Age at first gated scan 
958 gs_vwabn Ventricular Wall Abnormalities 
959 gs_vwa Vent. Wall Abn. Category 
960 gs_ef Ejection fraction 
961 rheartbi Right Heart Biopsy 
962 age_hb Age @ heart biopsy 
963 lm_hyper r Light Microscopy-hypertrophy (hb) 
964 lm fib Light Microscopy-fibrosis (hb) 
965 lm fatin Light Microscopy-fatty infiltration (hb) 
966 em_hyper Electron Microscopy-hypertrophy (hb) 
967 em fib Electron Microscopy-fibrosis (hb) 
968 hb comm Comment on Heart Biopsy 
969 ventric Ventriculotomy 
970 age_vent Age @ ventriculotomy 
971 explanht Explanted Heart 
972 ageexht Age @ Explanted Heart 
973 eh htwt I EH-Heart Weight 
974 eh rvdil EH-RV Dilatation 
975 eh_rvhyp EH-R V Hypertrophy 
976 eh lvdil EH-LV Dilatation 
977 eh_ lvhyp EH-L V Hypertrophy 
978 eh cad EH-Coronary Artery Disease 
979 eh lmlvh EH-Light Microscopy LV Hypertrophy 
980 eh lmlvf EH-Light Microscopy LV Fibrosis 
981 eh lmrvf EH-Light Microscopy RV Fibrosis 
982 var00034 l iD number 
983 var00035 First name 
984 var00036 Last name 
985 eh fatin EH-Fatty Infiltration 
986 autopsy Autopsy 
987 abnaut Abnormality related to ARVC at autopsy 
988 var00021 Case or control 
989 age_aut Age at Autopsy 
990 heartwt Heart Weight (g) 
991 rvdilita 1 RV dilatation 
992 rvhyper RV hypertrophy 
993 lvdilita LV dilatation 








1001 oth ht 
1002 age_oht 
1003 echo nm 
I 004 echo nma 
1005 I lvd_~n 
1006 abn nm 
1007 abn_tpe 
1008 abn nme 
1009 filter_$ 
LV hypertrophy 
Coronary Artery Disease 
Light Microscopy-LV hypertrophy 
Light Microscopy-LV Fibrosis 
Light Microscopy-RV Fibrosis 
Fatty lnfilitration 
Autopsy Comment 
Other heart tissue 
Age at test (other heart tissue) 
I Did they have an echo with no measurements for Henry? 
l What age were they? 
Was there LV dilatation recorded? 
Was any other malformation on echo found? 
What type of problem? 
Any other comment on the echo with no measurements 
( ascert = I) & (arvccs = I I arvccs = 2) & (gender = I )(FILTER) 
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14. Arrhythmogenic Right Ventricular Cardiomyopathy. Newfoundland families share fatal disease. 
MUNMED October 4 200 1. 
Concerts, performances, exhibitions, commissions & creative works 
I. Association of Atlantic Universities, 2008. The Life Changers-Mending Broken Hearts. 
Documentary series featuring cutting edge research undertaken at Atlantic Canada's universities. 
Featuring ARVC. Scheduled to air on October 5, 2008 (interviewee) 
http://www.mun.ca/research/changers.php 
2. Collaborative documentary July 9 2003 I 0-40- 11.25 as part of the 3-part documentary Die Gen-
Jtiger (!'he Gene Hunters). Speaking to the issue of the benefits of genetic research as it pertains to 
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3. The DNA dilemma: Canadian documentary 2003.Featuring ARVC and ethical issues 
http://www. te lefi lm.gc.ca/data/production/prod 23 13 .asp?lang=en&cat=tv&g=doc&y=2003 
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Scholarly lectures and other professional presentation 
Television/Radio 
I. The National, CBC Television, February 29, 2008. ARVC gene discovery. 
2. NTV Evening News, February 29,2008. ARVC gene discovery. 
3. The Current (with Anna Maria Tremonty) Radio: February 6 2006 Genetic testing panel and Town 
Hall. With Daryl Pullman. 
Press conferences and releases 
I. Researchers discover gene responsible for deadly heart condition. Genome Atlantic Press 
Conference, February 27, 2008. 
Relevant community service 
2006 Kathy Hodgkinson. Invited speaker for ' Sundays at the Fluvarium' lecture series. The purpose of 
this group of talks was to showcase research at Memorial University for a lay audience. 
2008 Kathy Hodgkinson. Invited speaker at the Canadian Federation of University Women on Sat 
Sept. 13 2-4, the EB Foran Room, St. John 's City Hall. ARVD: the search for a killer. 
Knowledge transfer activities 
I. Quarterly community newsletter for cardiomyopathies. 
2. ARVC (Arrhy thmogenic Right Ventricular Cardiomyopathy) in Newfoundland and Labrador, 
Patient and family Information Guide. Eastern Health Teplitsky, Y, Young, TL, Hodgkinson 
K.A Patient and Family Information Guide. Eastern Health. 2005. 
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APPENDIX C 
The normal heart beat 
Heart beats start at the sinoatrial node in the right atrium where an electrical stimulus is 
generated by ion transfer (calcium, potassium and sodium) through the myocyte cell 
membranes, stimulating the atria just before stimulating the ventricles. The electrical 
impulse travels from the sinus node to the atrioventricular (A V) node, where its rate is 
regulated, then continues through the conduction pathways via the bundle of His and 
purkinje fibres into the right and left ventricles. This depolarization and repolarisation 
results in a coordinated heartbeat at a rate of between 50 and 100 per minute. 
---RR Interval---
QRSComplex 








'' H1s left 
Purkinjc 
Fibers 
P wave = atrial depolarization, PR interval = from the onset of atrial activation to onset of 
ventricular activation, QRS = ventricular depolarization, S-T segment = the ventricles 
before repolarisation, T-wave = ventricular repolarisation, QT interval = the duration of 
ventricular activation and recovery (polarisation and depolarisation), RR interval = the 
time elapsing between two consecutive R waves in the ECG, U wave = repolarisation of 
the papilliary muscles or Purkinje fibres. 
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Ventricular Tachycardia (VT) 
VT is a complex cardiac rhythm originating in the ventricles and is the presence of 
multiple consecutive premature ventricular contractions (PVCs). PVCs result from a 
short circuit of the electrical system in the ventricles, or from an ectopic (out of place) 
ventricular focus that sends out its own electrical impulse. These beats stimulate the 
ventricles ahead of the atria, and do not transmit across the ventricles normally, 
producing an ineffective contraction. They also interfere with the next 'normal' heart 
beat, often producing the feeling of a 'skipped' beat. The rate is usually between 150 and 
200 beats I minute and regular, although VT can produce much faster rates. The rapid 
rate and the disrupted contraction between the ventricles and the atria may lead to low 
cardiac output, hypotension, and cardiac arrest. VT is classified as non-sustained (three or 
more PVCs terminating under 30 seconds) or sustained (VT > 30 seconds or requiring 
termination in under 30 seconds due to loss of consciousness). The VT is often 
polymorphic in nature, where no 2 sequential PVCs have the same morphology in one 
ECG lead or where no morphology lasts for a minimum of 6 beats when at least 3 ECG 
leads are simultaneously recorded. 
Ventricular Fibrillation (VF) 
VF is a rapid, chaotic, uncoordinated, ineffective series of ventricular contractions with 
no QRS complex visible on 12 lead ECG. It is a fatal arrhythmia due to the inability of 
the heart to perfuse (send blood to oxygenate) body systems. Cardioversion with an 
external electric shock is the treatment for VF. VF can arise from rapid VT. 
The 12 lead Electrocardiogram (ECG) 
The 12 lead ECG assesses the electrical impulse across the heart with 6 chest (precordial) 
leads (VI , V2, V3, V4, V5 and V6) and 6 limb leads (avR, avL, avF, I, II, III) The 
inferior leads (II, III and a VF) look at the under surface of the left ventricle, ·the anterior 
leads (V2, V3, V4) look at the front of the heart viewing the left ventricle and septum the 
latera] leads (V5, V6, I, aVL) look at the left side of the left ventricle and the posterior 
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leads (Vl , V2, V3) look at the back of the heart. The ECG assesses the electrical activity 
of the normal heartbeat. 
Normal12 lead ECG 
The Signal Averaged ECG (SAECG) 
The SAECG 'averages' multiple routine ECGs obtained over a 20-minute period from a 
horizontal patient to obtain information about ventricular late potentials (VLPs). VLPs 
are low amplitude high frequency signals at the end of the QRS complex, and are due to 
the late depolarisation of damaged myocardium. They are known to be present in patients 
with VT, and assess, in effect, the time required for the electrical signal to pass through 
the myocardium. They are difficult to elicit as they may be masked by background 
electromyographic noise, which the SAECG attempts to minimize (379). VLPs on 
SAECG are classified based on QRS length (fi ltered QRS duration) > 114 ms, LAS (low 
amplitude signals) >38 ms, and RMS (root mean square voltage of the terminal 40ms of 
filtered QRS) <20 ms (260). 
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A SAECG from a patient in family ARl (Figure 8 page 79) 
QRS 
Holter monitors 
Holter monitors (invented by the biophysicist, Norman Holter (1914-1983)) record a 
continuous ECG over an extended period oftime (either 24 or 48 hours) from ECG leads 
attached to the chest wall. This test documents all heart rhythms, and relates them to the 
presence or absence of symptoms. The old devices used reel-to-reel tape, or C90 audio 
cassettes. Modern units record digitally and upload to a computer, which counts ECG 
complexes, calculates statistics, and highlights areas requiring further study. 
A Holter monitor trace from a patient in fan1ily ARl (Figure 8 page 79) 
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Echocardiography 
A transthoracic (across the chest wall) echocardiogram is an ultrasound of the heart, with 
a frequency of > 20,000 cycles/sec. The first cardiac ultrasounds were available in the 
mid 1950's, and up until the mid 1970's, M-mode echocardiography was used, where the 
ultrasound beam was aimed manually at cardiac structures. M-mode recordings allowed 
for the measurement of cardiac structures, and an assessment of cardiac motion. ECG and 
pulse tracings were recorded simultaneously allowing an analysis of time relationships 
between the different physiological variables. Since the mid 1970' s, mechanical or 
electrical techniques scan the ultrasound beam rapidly across the heart to produce two-
dimensional images (2D). Echocardiography which uses both M-mode and 2D recordings 
is an effective method to determine cardiac output. A clearer view of the heart is obtained 
by a transoesophageal echo, where the transducer is fed into the oesophagus, and the 
heart viewed through the thin oesophageal wall. This is however an invasive procedure, 
requiring, at a minimum, conscious sedation. 3D echocardiography uses a probe with an 
array of transducers and an analysis system to provide even more detailed views of the 
cardiac anatomy. 
M-mode echocardiography showing thinning and reduced systolic thickening in the right 
ventricular wall. Both the RV and LV are dilated 10. 
10 http://www. ijri .org/article /2006/ 16/ 1 /images/ lndianJRadiollmaging_ 2006_ 16_ 1_ 131_29069 _2.jpg 
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MRI 
Magnetic resonance imaging (MRI) is a technique highly adept at visualising bodily 
structures and fimctions, particularly soft tissues. This makes it a powerful tool for 
looking at neurological and cardiovascular structures, and visualising the extent of 
tumour growth in all body systems. It uses powerful magnetic fields. The magnetic field 
aligns the nuclear magnetisation of hydrogen atoms contained in the large supply of 
water in the human body. Radio frequency fields alter the direction of the magnetism 
which causes the hydrogen nuclei to produce a rotating magnetic field. It is this that the 
scanner detects and utilises to create an image. 
An MRI image of an ARVC subject. Note the white (high contrast) fat in the dilated RV. 
Cardiac biopsy 
Cardiac biopsy uses a bioptome catheter with jaws at its tip, inserted through a vein or 
artery. If not part of a catheterization procedure (which uses veins in the groin area), the 
catheter is usually inserted in the jugular vein. Fluoroscopy (an X-ray that can provide 
moving images) is used to guide the insertion. 
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Statistical analyses 
Survival analysis 
Survival analysis is a time to event (or time to failure) technique. Time is the dependent 
variable. The status variable is whether the individual has reached the end point. This is 
often death (hence 'survival 'analysis), but it can be any end point of choice. Usually the 
subjects enter over time and the object of interest is not seen in all subjects: additionally 
some may just be lost to follow-up. This is known as 'censoring' : when individuals 
within the study do not reach the end point during the time of the study. This is usually 
the date of analysis if individuals are still alive at that time but censoring can occur if a 
subject is lost to follow-up, or is moved from the analysis for other reasons. In both cases, 
the subjects were known to have 'survived ' for some amount of time (up until the time 
they were last seen), but how much longer they might ultimately have survived is 
unknown. The Kaplan Meier method was developed to use the information contained in 
those who have survived in the analysis for ' at least this long' This is ' right' censoring 
which occurs when all subjects in the analysis are accounted for and when the outcome of 
interest has not been observed for a participant. Left censoring occurs when the outcome 
of interest has occurred for a subject before the study begins. 
Survival analysis can address several questions, including: 
or 
or 
1. The amount of time before X displays a change in Y, 
11. Given that a change has not been observed in timet, what chances are there it 
will occur in time tl? 
iii. What is the difference in outcomes between different subject groups? (the 
major analyses in this thesis). 
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Survival analysis is predicated on several assumptions. These are: 
1. An identifiable start point is applied uniformly for all subjects (often birth); 
u. There is an identifiable end point: dichotomous and well defined such as 
death; 
iii. Censoring is not related to outcome and 
tv. Secular trends are not present (e.g. changes in diagnosis and treatment over 
the course of a study). This last is the most difficult to achieve in studies 
which collect information over time. 
For the thesis, the Kaplan Meier non-paran1etric survival model was used. It makes no 
assumption about the shape of the underlying curve, and is based on the product limit 
equation. In all the survival analyses, comparing two groups (in the thesis, affected and 
unaffected: mutation positive, versus mutation negative), the question asked is whether 
the slopes of the curves generated are the same or different. 
Thus the null hypothesis would be H0: '/.._A = A.UA, and the alternate hypothesis HA: A.UA 
< A.A where A. is the slope of the curve in a survival analysis defining time to event. The 
steeper the slope, the higher the rate of the event in a shorter space of time. Thus the null 
hypothesis for Chapters 2, 3 and 4 states that there is no difference between the slope of 
the survival curve for affected individuals compared with unaffected individuals, and the 
alternate hypothesis posits that there is a difference and that the slope of the affected 
group is steeper than that of the unaffected group. 
Sample size/power analysis 
No formal assessment of sample size or a power analysis is provided in this thesis. The 
numbers are defined by the boundaries of the families and the inclusion/exclusion 
criteria. The sample used is a demarcated population from which an answer will either be 
statistically valid or not. 
Chi Square analysis 
Chi square analysis investigates whether distributions of categorical variables (yes/no 
answers) differ from one another, and is used on actual numbers, not proportions or 
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means. Initially one calculates the chi-square statistic by finding the difference between 
each observed and expected frequency (obtained via the null hypothesis) for each 
possible outcome, squaring them, dividing each by the expected frequency, and taking 
the sum of the results. The p value is then calculated by comparing the statistic to a chi-
square distribution with a specific number of degrees of freedom (the number of possible 
outcomes, minus 1 ). Examples of categorical variables used in this thesis include the 
presence or absence of a symptom or clinical abnormality on a cardiac test. 
Cox's proportional regression 
Cox' s Proportional Hazards regression produces a baseline survival curve with covariate 
coefficient estimates with their standard errors, a relative (hazards) risk ratio, 95% (or 
99%) confidence intervals, and a p value (significance level). Cox's analysis provides 
information about whether survival is influenced by one or more, categorical or 
continuous, factors. Cox's analysis allows an assessment of the effect of each factor on 
the shape of the survival curve. The method computes a coefficient for each factor that 
indicates the direction and amount of movement it has on the baseline curve. A 
coefficient of zero indicates that the factor is not a predictor of ' survival' at all compared 
with a positive coefficient. These coefficient values allow for the construction of a 
survival curve based on any combination of values, and provide a measure of the 
san1pling error. This analysis method allows an understanding of which variables are 
significantly related to 'survival '. In this thesis, all Cox ' s regression analyses are based 
on a comparison of two groups only. 
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